Removal of exosomes, ectosomes, mirnas, circulating nucleic acids, and viral particles with transplantation

Abstract

Aspects described herein concern methods for removing subcellular nanoparticles, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, or glycolipids, or fragments thereof from organ, tissue, or cell transplant donors, organ, tissue, or cell transplant recipients, or donor organs before, during and / or after transplantation into the recipient.

Description

AETH.044WO PATENT REMOVAL OF EXOSOMES, ECTOSOMES, MIRNAS, CIRCULATING NUCLEIC ACIDS, AND VIRAL PARTICLES WITH TRANSPLANTATION CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to United States Provisional Patent Application no. 63 / 446, 156, filed February 16, 2023 and United States Provisional Patent Application no.63 / 528, 611, filed July 24, 2023, the entire contents of each of which is incorporated by reference herein. BACKGROUND OF THE INVENTION Field of the Invention

[0002] Aspects of the present invention relate to methods for improving transplantation by removing subcellular nanoparticles, a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, including DNA or RNA, extracellular vesicle associated DNA, circulating extracellular DNA (ceDNA), a biomarker or mediator of tissue damage, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, from donor organs, organ perfusate, a population of cells or a tissue, or from the organ or tissue donor or recipient before, during and / or after transplantation. Description of the Related Art

[0003] Transplantation medicine has been incredibly challenging due to the limited number of healthy, viable organs and transplant rejection, which occurs in many patients. Many in the field attribute transplant rejection to the recipient’s immune response to the transplanted organ and / or unhealthy organs obtained from the donor.

[0004] Extracellular vesicles including exosomes and ectosomes are released by cells, including but not limited to mammalian cells. Methods of removing circulatingextracellular vesicles, virus, and viral fragments from a patient’s blood using extracorporeal devices are well known (see e.g., U.S. Patent Numbers 9,707,333; and 10,022,483, herein expressly incorporated by reference in their entireties). The need for approaches to reduce transplant rejection and provide donor organs, cells or tissues that produce less inflammation in a recipient is manifest. SUMMARY OF THE INVENTION

[0005] Aspects of the present invention described herein include devices and methods for removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ donor, cell or tissue donor, an organ, an organ perfusate, a population of cells or tissue being transplanted and / or the organ, cell, or tissue recipient so as to increase or improve organ, cell, or tissue viability, engraftment, and / or survival of the transplant and / or transplant recipient or to remove molecules or compositions, which are associated with tissue rejection, ischemia-reperfusion injury (IRI), organ failure, necrosis, or poor patient outcome after transplantation. Aspects of the present invention concern more generally the use of lectin (e.g., GNA) and / or antibody-based affinity methods for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, from a transplant donor, transplant recipient, and / or organ, tissue, an organ perfusate, or population of cells selected for transplantation. Additional embodiments concern the reintroduction of the sample obtained after a lectin and / or antibody affinity isolation or capture (e.g., after lectin and / or antibody affinity in an extracorporeal device having a substrate with an immobilized lectin and / or antibody or a column packed with lectin affinity resin (e.g., GNA)) into the subject (e.g., the donor and / or recipient of the organ, anorgan perfusate, cell population, or tissue) or an isolated organ, an organ perfusate, population of cells or tissue selected for transplantation, wherein the sample obtained after the lectin and / or antibody affinity isolation or capture comprises a reduced amount of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof as compared to the sample prior to said lectin and / or antibody affinity isolation or capture. Additional embodiments concern selecting a subject (e.g., a transplant donor or recipient) for receiving a lectin and / or antibody affinity therapy accompanying a transplantation procedure (e.g., extracorporeal therapy), which removes pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. In some embodiments, the sample, such as blood or plasma from the subject (e.g., transplant donor and / or recipient) or an organ perfusate, is screened for the presence of (e.g., detecting or identifying), pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans or fragments thereof, before, during, or after the lectin and / or antibody affinity isolation or capture. In some embodiments, the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from the sample from said donor and / or recipient and / or organ, cell population, or tissue selected for transplantation is analyzed. In some embodiments, the ability of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to a lectin, such as GNA, or an antibody is determined. In some embodiments, performing the method for removing pathogens, viral particles, virus-likeparticles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof accompanying an organ, cell, or tissue transplantation procedure, improves, enhances, or benefits the organ, cell population, or tissue viability, engraftment, and / or survival and / or the survival of the recipient is increased or improved, as compared to the organ, cell population, or tissue viability, engraftment, and / or survival of the transplant or recipient after transplantation in the absence of performing such methods for removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. In some embodiments, performing one or more of the methods disclosed herein for removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof on an organ perfusate obtained from an organ prior to transplantation removes or reduces the presence of molecules or compositions from the organ perfusate and organ, which are associated with tissue rejection, organ failure, necrosis, or poor patient outcome after transplantation, as compared to the organ perfusate and organ prior to performing the one or more removal methods described herein.

[0006] Preferred aspects of the present invention are related to the following numbered alternatives: 1. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator oftissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject, wherein said subject is an organ, cell, or tissue donor, the method comprising: a) introducing a sample from said subject prior to removal of an organ, population of cells, or tissue into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody preferably, the support in the vessel, such as in an extracorporeal device; c) reintroducing the sample obtained after b) into said subject, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, cell, or tissue transplantation, which removes the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / ore) optionally, screening for the presence of, e.g., detecting or identifying, the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood or plasma, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof. 2. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject, wherein said subject is an organ, cell, or tissue transplant recipient, the method comprising: a) introducing a sample from said subject prior to or after organ, cell, or tissue transplantation into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody and, preferably, the support in the vessel, such as in an extracorporeal device;c) reintroducing the sample obtained after b) into said subject, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, cell, or tissue transplantation, which viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood or plasma, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, suchas exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof. 3. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, population of cells, or tissue, the method comprising: a) introducing a sample from said organ, organ perfusate, population of cells, or tissue, preferably, a perfused organ or organ perfusate, isolated from a donor, preferably a deceased donor e.g., a donation after circulatory death (DCD) or a donation after brain death (DBD), into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody and, preferably, the support in the vessel, such as in an extracorporeal device; c) reintroducing the sample obtained after b) into said organ, population of cells, or tissue, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample prior to b); and d) optionally, selecting said organ, organ perfusate, population of cells, or tissue for receiving an extracorporeal therapy, which removes the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes orectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said organ, such as blood, plasma or organ perfusion fluid, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said organ or organ perfusate, prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof. 4. A method of organ, cell, or tissue transplantation comprising performing the method of any one of alternatives 1-3 accompanying an organ, cell, or tissue transplantation procedure, preferably wherein organ, cell, or tissue viability, such as tissue functionality including, e.g., production of urine when the organ is a kidney, engraftment, and / or survival of the transplant and / or recipient is increased or improved as compared to the organ, cell, or tissue viability, engraftment, and / or survival of the transplant or recipient after transplantation in the absence of the methods of any one of alternatives 1-3 or, wherein the presence of molecules or compositions from the organ perfusate and / or organ, which are associated with tissue rejection, organ failure, necrosis, or poor patient outcome after transplantation, are reduced as comparedto the organ perfusate and / or organ prior to performing the method of any one of alternatives 1-3. 5. The method of any one of alternatives 1-4, further comprising repeating steps b) and c) to further reduce the amount of the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in the sample. 6. The method of any one of alternatives 1-5, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV- D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof. 7. The method of any one of alternatives 1-6, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof. 8. The method of any one of alternatives 1-7, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum.9. The method of any of alternatives 1-8, wherein the miRNAs comprise miR23a, miR 374b-5p, miR28-5p and / or miR24-3p. 10. The method of any one of alternatives 1-9, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed. 11. The method of any one of alternatives 1-10, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR-29b- 3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa- miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR- 122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa- miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa-miR-132- 3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa-miR-140- 5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa- miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa- miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR-191- 5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b- 3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa- miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa- miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205-5p, hsa- miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa- miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR- 660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b- 5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa- miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa- miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR- 4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195,hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324- 5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa- miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa- miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa- miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR- 486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa- miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p. 12. The method of any one of alternatives 1-11, wherein the miRNAs comprise any one or more of : hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa- miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa- miR-196a-5p. 13. The method of any one of alternatives 1-12, wherein the miRNAs comprise any one or more of hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p. 14. The method of any one of alternatives 1-13, wherein the biomarker or mediator for tissue damage comprise Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC,MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL- 11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL. 15. The method of any one of alternatives 1-14, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO. 16. The method of any one of alternatives 1-15, wherein the biomarker or mediator of tissue damage comprises any one or more of BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1. 17. The method of any one of alternatives 1 -16, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, cell, or tissue donor before the organ, cell, or tissue is harvested from the donor. 18. The method of any one of alternatives 1 -17, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophilextracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, organ perfusate, population of cells, or tissue after the organ, population of cells, or tissue is harvested from the donor and before the organ, population of cells, or tissue is transplanted into the recipient. 19. The method of any one of alternatives 1-18, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, organ perfusate, population of cells, or tissue after the organ, population of cells, or tissue is harvested from the donor and prior to transplantation into the recipient. 20. The method of any one of alternatives 1-19, wherein the organ is a solid organ or the organ perfusate is from a solid organ. 21. The method of alternative 20, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas. 22. The method of any one of alternatives 1-21, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells. 23. The method of any one of alternatives 1-22, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.24. The method of any one of alternatives 1-23, wherein the sample is selected from peripheral blood, serum, plasma, organ perfusion fluid or organ perfusate, such as near normothermic organ perfusion fluid or near normothermic organ perfusate or hypothermic organ perfusion fluid or hypothermic organ perfusate, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, umbilical cord blood, ascites fluid, cell culture, such as CAR T cell culture, stem cell culture, or pancreatic islet culture. 25. The method of alternative 24, wherein the biological sample is mammalian, such as human or porcine. 26. The method of alternative 25, wherein the biological sample is human. 27. The method of any one of alternatives 1-26, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon. 28. The method of any one of alternatives 1-27, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker. 29. Use of a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support to improve, enhance, or increase organ, cell, or tissue viability, engraftment, and / or survival of a transplant or to remove viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellulartraps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue ex vivo, as compared to organ, cell, or tissue viability, engraftment, and / or survival of the transplant or the organ perfusate in the absence of said lectin and / or antibody affinity isolation or capture. 30. The use of alternative 29, wherein said organ is a solid organ, preferably selected from kidney, liver, intestines, heart, lung, or pancreas or, wherein the cell population is selected from chimeric antigen receptor T cells (CAR T cells), bone marrow cells, stem cells, or pancreatic islet cells. 31. A device for use in removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue ex vivo, wherein said device comprises a support, such as diatomaceous earth or an ion exchange resin, and optionally a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support. 32. The device for use as set forth in alternative 31, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV- D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcinecytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof. 33. The device for use as set forth in alternative 31 or 32, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof. 34. The device for use as set forth in any one of alternatives 31-33, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum. 35. The device for use as set forth in any one of alternatives 31-34, wherein the miRNA comprises any one or more of: hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa- miR-15b-5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR- 1972 and / or hsa-miR-196a-5p. 36. The device for use as set forth in any one of alternatives 31-35, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d- 5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa- miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa- miR-1183, hsa-miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b- 5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa- miR-15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa- miR-140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR- 144-3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150- 5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa- miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR- 190b, hsa-miR-191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa- miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa- miR-205-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR- 146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223- 3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa- miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR- 302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa- miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa- miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR- 362-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR- 376a-3p, hsa-miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa- miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR- 425-5p, hsa-miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa- miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483- 5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa- miR-496, hsa-let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509- 3p, hsa-miR-509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a- 5p, hsa-miR-514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa- miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR- 23a-3p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa- miR-590-5p, hsa-miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888-5p, hsa-miR-93-5p and / or hsa-miR-95-3p.37. The device for use as set forth in any one of alternatives 31-36, wherein the miRNAs comprise any one or more of: hsa-miR1285-5p, hsa-miR-575, hsa-miR-223-3p, hsa- miR-127-3p, hsa-miR-29b-3p, hsa-miR-3144-3p, hsa-miR-28-5p and / or hsa-miR-1286. 38. The device for use as set forth in any one of alternatives 31-37, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p . 39. The device for use as set forth in any one of alternatives 31-38, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2 ,Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL- 34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF- 1, sFas, sFasL, TARC, TPO, and / or TRAIL. 40. The device for use as set forth in any one of alternatives 31-39, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO. 41. The device for use as set forth in any one of alternatives 31-40, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN,IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1.. 42. The device for use as set forth in any one of alternatives 31-41, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed. 43. The device for use as set forth in any one of alternatives 31-42, wherein the organ is a solid organ or the organ perfusate is from a solid organ. 44. The device for use as set forth in alternative 43, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas. 45. The device for use as set forth in any one of alternatives 31-44, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells. 46. The device for use as set forth in any one of alternatives 31-45, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. 47. The device for use as set forth in any one of alternatives 31-46, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon. 48. The device for use as set forth in any one of alternatives 31-47, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker.49. A device comprising a support, such as diatomaceous earth or an ion exchange resin, and optionally a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support, wherein the support, lectin and / or antibody is joined to a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue 50. The device as set forth in alternative 49, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma- associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV-D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof. 51. The device as set forth in alternative 49 or 50, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof. 52. The device as set forth in any one of alternatives 49-51, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum.53. The device as set forth in any one of alternatives 49-52, wherein the miRNA comprises any one or more of: hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b- 5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR-196a-5p. 54. The device as set forth in any one of alternatives 49-53, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa- miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR- 106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR- 1183, hsa-miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa- miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR- 15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR- 140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144- 3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa- miR-361-5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa- miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR- 190b, hsa-miR-191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b- 3p, hsa-miR-193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa- miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa- miR-205-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR- 146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223- 3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa- miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR- 302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa- miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR- 362-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR- 376a-3p, hsa-miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa- miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR- 425-5p, hsa-miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa- miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483- 5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa- miR-496, hsa-let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509- 3p, hsa-miR-509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a- 5p, hsa-miR-514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa- miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR- 23a-3p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa- miR-590-5p, hsa-miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888-5p, hsa-miR-93-5p and / or hsa-miR-95-3p. 55. The device as set forth in any one of alternatives 49-54, wherein the miRNAs comprise any one or more of: hsa-miR1285-5p, hsa-miR-575, hsa-miR-223-3p, hsa-miR-127- 3p, hsa-miR-29b-3p, hsa-miR-3144-3p, hsa-miR-28-5p and / or hsa-miR-1286. 56. The device as set forth in any one of alternatives 49-55, wherein the miRNAs comprise any one or more of hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR- 99a-5p. 57. The device as set forth in any one of alternatives 49-56, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2 ,Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL- 15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B,HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL. 58. The device as set forth in any one of alternatives 49-57, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL- 9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL- 20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO. 59. The device as set forth in any one of alternatives 49-58, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1. 60. The device as set forth in any one of alternatives 49-59, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are joined to the support, lectin and / or antibody. 61. The device as set forth in any one of alternatives 49-60, wherein the organ is a solid organ or the organ perfusate is from a solid organ. 62. The device as set forth in alternative 61, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas. 63. The device as set forth in any one of alternatives 49-62, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells.64. The device as set forth in any one of alternatives 49-63, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. 65. The device as set forth in any one of alternatives 49-64, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon. 66. The device as set forth in any one of alternatives 49-65, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker. 67. A method of preparing a kidney, which has been removed from a donor, for transplantation, preferably a kidney obtained from a deceased donor e.g., a donation after circulatory death (DCD) or a donation after brain death (DBD) , the method comprising: a) collecting a biological sample from the kidney; b) detecting the presence or amount of at least one or more pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof; c) comparing the detected one or more pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof to a reference level; andd) upon determining that the detected one or more pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are present or altered in the sample as compared to the reference level, providing a therapy to the kidney, wherein the therapy comprises: i. introducing perfusate from the kidney into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody preferably, wherein the lectin or antibody or both are immobilized on the support; ii. contacting the perfusate with the support, lectin and / or antibody in the vessel; and iii. reintroducing the perfusate obtained after ii) into the kidney, wherein the perfusate obtained after ii) has a reduced amount of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the perfusate prior to ii). 68. The method of alternative 67, wherein the presence or amount of at least one or more of the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones,neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof is detected using Western blot, enzyme-linked immunosorbent assay (ELISA), Northern blotting, quantitative polymerase chain reaction (qPCR) protein microarray, DNA microarray, gene expression analysis or RNA- seq. 69. A method of any one of alternatives 67-68, wherein kidney viability, engraftment, and / or survival of the transplant and / or recipient is increased or improved as compared to the kidney viability, engraftment, and / or survival of the transplant or recipient after transplantation in the absence of the methods of any one of alternatives 67-68. 70. The method of any one of alternatives 67-69, further comprising repeating steps (i)-(iii) to further reduce the amount of amount of the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. 71. The method of any one of alternatives 67-70, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa- miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR- 122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa- miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa-miR-132- 3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa-miR-140- 5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa- miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR-191- 5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b- 3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa- miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa- miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205-5p, hsa- miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa- miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR- 660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b- 5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa- miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa- miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR- 4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324- 5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa- miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa- miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa- miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR- 486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa- miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p.72. The method of any one of alternatives 67-71, wherein the miRNAs comprise any one or more of; hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR- 548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR- 196a-5p. 73. The method of any one of alternatives 67-72, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p. 74. The method of any one of alternatives 67-73, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL. 75. The method of any one of alternatives 67-74, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO. 76. The method of any one of alternatives 67-75, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1.77. The method of any one of alternatives 67-76, wherein the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. 78. The method of any one of alternatives 67-77, wherein the kidney is mammalian, such as human or porcine. 79. The method of alternative 78, wherein the kidney is human. 80. The method of any one of alternatives 67-79, wherein the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon. 81. The method of any one of alternatives 67-80, wherein the vessel is a plate, such as a multi-well plate, a column, tube, flask, or beaker. 82. A method for connecting an organ to a circuit, configured to remove a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans from said organ comprising: attaching the organ, such as a kidney, liver, intestines, heart, lung, or pancreas to a vessel, such as an extracorporeal column, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody preferably, wherein the lectin or antibody or both are immobilized on the support, such that when the organ is perfused with a perfusion solution, the perfusion solution exits the organ and is passed into the vessel comprising the support and when the perfusion solution exits the vessel comprising the support it is, optionally passed back through the organ, and preferably has areduced amount of pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans than the perfusion solution had after exiting the organ prior to entering the vessel comprising the support. 83. The method of alternative 82, wherein the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. 84. The method of any one of alternatives 82 or 83, wherein the organ is a kidney and the kidney is mammalian, such as human or porcine. 85. The method of alternative 84, wherein the kidney is human. 86. The method of any one of alternatives 82-85, wherein the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon. 87. The method of any one of alternatives 82-86, wherein the vessel is a plate, such as a multi-well plate, a column, tube, flask, or beaker. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] In addition to the features described above, additional features and variations will be readily apparent from the following descriptions of the drawings and exemplary embodiments. It is to be understood that these drawings depict typical embodiments and are not intended to be limiting in scope.

[0008] FIG. 1 is a schematic illustration of a longitudinal cross section of an affinity cartridge.

[0009] FIG.2 is a schematic illustration of a horizontal cross section at plane 2 in FIG.1.

[0010] FIG.3 is an illustration of a channel from FIG.2. A hollow fiber membrane structure 40 is composed of a tubular section comprising a relatively tight ultrafiltration membrane 42 and relatively porous exterior portion 44 in which may be immobilized affinity molecules 46, such as lectins.

[0011] FIG.4 is an illustrative representation of exosomal microRNAs associated with Ischemia-Reperfusion Injury, which are contemplated for removal by the devices described herein.

[0012] FIG.5 is an illustrative representation of perfusate fluid from an explanted kidney passed over a packed column of GNA affinity resin.

[0013] FIG.6 is an illustrative representation of perfusate fluid from an explanted kidney split into a shunted flow rate with a peristaltic pump at 200 ml / min passed over a packed column of GNA affinity resin.

[0014] FIG.7 is an illustrative representation of the flow of fluid through 0.2 μm filter for the removal of particles larger than 200 nm from the perfusate fluid from an explanted kidney.

[0015] FIG. 8 is an illustrative representation of benchtop configuration of the exemplary device depicted in FIGS.1-3 for circulating kidney perfusate over a packed column of GNA affinity resin under normal flow direction.

[0016] FIG. 9 is an illustrative representation of benchtop configuration of the exemplary device depicted in FIGS.1-3 for circulating kidney perfusate over a packed column of GNA affinity resin under reverse flow direction.

[0017] FIG.10 is an illustrative representation of a kidney perfusate passed over a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane.

[0018] FIG.11 is an illustrative representation of a kidney perfusate passed over a packed column of GNA affinity resin under normal flow direction.

[0019] FIG.12 is an illustrative representation of a kidney perfusate passed over a packed column of GNA affinity resin under side port flow direction.

[0020] FIG.13 illustrates the measurement of 4 miRNAs (hsa-miR-let7a-5p, hsa- miR-142-3p, hsa-miR-29b-3p, and hsa-miR-99a-5p) in kidney perfusates following contact with a Hemopurifier®. FIGS.13A, 13B, 13C and 13D illustrate the measurement of 4 miRNAs (hsa-miR-let7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p, and hsa-miR-99a-5p) in kidney perfusates contacted with an exemplary device as shown in FIGS.11-12.

[0021] FIG. 14 illustrates the qPCR measurement of a nucleic DNA marker (RNAseP) (FIG. 14A) and a mitochondrial DNA marker (7s) (FIG. 14B) and the ratio of mitochondrial DNA / nuclear DNA copy number (FIG. 14C) in kidney perfusates following contact with a device comprising a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane as shown in FIG.10.

[0022] FIG.15 illustrates the Sytox green staining of the kidney perfusates passed over a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane as shown in FIG.10 and a benchtop configuration of the exemplary device as shown in FIGS.8-9.

[0023] FIG. 16 illustrates the quantitation of extracellular vesicles (EV) in the kidney perfusates passed over a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane as shown in FIG.10 and a benchtop configuration of the exemplary device as shown in FIG.8-9.

[0024] FIG.17 illustrates the Sytox green staining and extracellular vesicles (EV) staining of the kidney perfusates passed over a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane as shown in FIG.10 and a benchtop configuration of the exemplary device as shown in FIG.8-9. DETAILED DESCRIPTION

[0025] Disclosed herein are methods for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteinsand / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, from an organ, organ perfusate, a population of cells or a tissue or from the organ or tissue donor or recipient prior to, during and / or after transplantation. In some embodiments, the donor is a deceased donor. In some embodiments, the organ is donated by a donor, wherein the donation is after circulatory death (DCD). In some embodiments, the organ is donated by a donor, wherein the donation is after brain death (DBD). Definitions

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are expressly incorporated by reference in their entireties unless stated otherwise. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0027] The articles “a” and “an” are used herein to refer to one or to more than one (for example, at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0028] The terms “about” or “around” as used herein refer to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0029] Throughout this specification, unless the context requires otherwise, the words “comprise,” “comprises,” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.

[0030] By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of” is meant including any elements listed after the phrase and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be presentdepending upon whether or not they materially affect the activity or action of the listed elements.

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. If there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise. The practice of the present disclosure will employ, unless indicated specifically to the contrary, conventional methods of molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration.

[0032] The terms “individual”, “subject”, or “patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. The “individual”, “subject”, or “patient” may mean a human or a non-human mammal that is alive. The “individual”, “subject”, or “patient” may mean a human or a non-human mammal that is deceased.

[0033] The term “mammal” is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rodents, rats, mice, guinea pigs, or the like.

[0034] The terms “function” and “functional” as used herein refer to a biological, enzymatic, or therapeutic function.

[0035] The term “isolated” as used herein refers to material that is substantially or essentially free from components that normally accompany it in its native state. For example, an “isolated cell,” as used herein, includes a cell that has been purified from the milieu or organisms in its naturally occurring state, a cell that has been removed from a subject or from a culture, for example, it is not significantly associated with in vivo or in vitro substances.

[0036] The terms “treat”, “treating”, “treatment”, “therapeutic”, or “therapy” as used herein has its ordinary meaning as understood in light of the specification, and do not necessarily mean total cure or abolition of the disease or condition. The term “treating” or “treatment” as used herein (and as well understood in the art) also means an approach for obtaining beneficial or desired results in a subject's condition, including clinical results.Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delaying or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. “Treating” and “treatment” as used herein also include prophylactic treatment. Treatment methods comprise administering to a subject a therapeutically effective amount of an active agent or use of a therapeutic device. The administering step may consist of a single administration or may comprise a series of administrations. The compositions are administered or applied to the subject in an amount, for a duration, or for a number or repetitions sufficient to treat the patient. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age and genetic profile of the patient. It will also be appreciated that the treatment or prophylaxis may be modified over the course of a particular treatment or prophylaxis regime. In some instances, chronic administration or application may be required. The term “prophylactic treatment” refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term “therapeutic treatment” refers to administering treatment to a subject already suffering from or developing a disease or condition.

[0037] The term “inhibit” as used herein has its ordinary meaning as understood in light of the specification, and may refer to e.g., the reduction of a viral infection or sequela thereof or tissue rejection or the presence of extracellular vesicles or cytokines that mediate an inflammatory response. The reduction can be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or an amount that is within a range defined by any two of the aforementioned values. As used herein, the term “delay” has its ordinary meaning as understood in light of the specification, and refers to a slowing, postponement, or deferment of an event, such as a viral infection, or a symptom or sequela thereof, or an inflammatory event to a time which is later than would otherwise be expected. The delay can be a delay of 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or an amount within a range defined by any two of theaforementioned values. The terms inhibit and delay may not necessarily indicate a 100% inhibition or delay. A partial inhibition or delay may be realized.

[0038] The terms “nucleic acid” or “nucleic acid molecule” as used herein refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), or fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. A nucleic acid or nucleic acid molecule can comprise one or more sequences encoding different peptides, polypeptides, or proteins. These one or more sequences can be joined in the same nucleic acid or nucleic acid molecule adjacently, or with extra nucleic acids in between, e.g. linkers, repeats or restriction enzyme sites, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, or 300 bases long, or any length in a range defined by any two of the aforementioned lengths.

[0039] The terms “peptide”, “polypeptide”, and “protein” as used herein refers to macromolecules comprised of amino acids linked by peptide bonds. The numerous functions of peptides, polypeptides, and proteins are known in the art, and include but are not limited to enzymes, structure, transport, defense, hormones, or signaling. Peptides, polypeptides, and proteins are often, but not always, produced biologically by a ribosomal complex using a nucleic acid template, although chemical syntheses are also available. By manipulating the nucleic acid template, peptide, polypeptide, and protein mutations such as substitutions, deletions, truncations, additions, duplications, or fusions of more than one peptide, polypeptide, or protein can be performed. These fusions of more than one peptide, polypeptide, or protein can be joined in the same molecule adjacently, or with extra amino acids in between, e.g. linkers, repeats, epitopes, or tags, or any other sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, or 300 bases long, or any length in a range defined by any two of the aforementioned lengths.

[0040] As used herein, a “lectin” is a protein that binds selectively to polysaccharides and glycoproteins. Although many are insufficiently specific to be useful,certain lectins are highly selective for enveloped viruses. Among lectins which have this property are those derived from Galanthus nivalis in the form of Galanthus nivalis agglutinin (“GNA”), Narcissus pseudonarcissus in the form of Narcissus pseudonarcissus agglutinin (“NPA”) and a lectin derived from blue green algae Nostoc ellipsosporum called “cyanovirin”. GNA is non-toxic and sufficiently safe that it has been incorporated into genetically engineered rice and potatoes (Bell et al. Transgenic Res 10(1): 35-42, 2001; Rao et al. Plant J 15(4): 469- 477, 1998). These lectins bind to glycoproteins having a high mannose content such as found in HIV surface proteins (Chervenak et al. Biochemistry 34(16): 5685-5695, 1995).

[0041] As used herein, a “mannose glycoprotein” refers to a glycoprotein having mannose-mannose linkages in the form of Į-1ĺ3, Į-1ĺ6 mannose-mannose linkages, such as, high mannose, pauci-mannose, or oligomannose glycoproteins. High-mannose glycans typically contain between five and nine mannose residues attached to the chitobiose (GlcNAc2) core; with some of the mannose being alpha 1-3 or alpha 1-6. Pauci-mannose is an N-glycan moiety containing two core GlcNAc residues and two or three Mannose residues that do not bear oligosaccharide extensions. Oligomannose is a glycan that is an oligomer composed of mannose units.

[0042] As used herein, a "viral load" refers to the amount of viral particles, virus- like particles (VLP), or toxic fragments thereof in a biological fluid, such as blood, plasma or organ perfusion fluid. Viral load is accordingly related to the number of virus particles in the body Viral load can therefore be a measure of any of a variety of indicators of the presence of a virus, such as viral copy number per unit of blood, plasma or organ perfusion fluid or units of viral proteins or fragments thereof per unit of blood, plasma or organ perfusion fluid.

[0043] As used herein, the term “microRNA” or “miRNA” refers to highly conserved non-coding RNA molecules, about 21-25 nucleotides in length that play critical roles in regulating post-transcriptional gene expression by targeting messenger RNA (mRNA) of protein-coding genes. Mature miRNAs exist in the cellular cytoplasm as RNA duplexes to which an argonaute (Ago2) protein and a glycine-tryptophan repeat-containing protein bind, forming the core of a multi-subunit complex called the miRNA-mediating silencing complex (miRISC). The miRNA duplex contains two strands identified with either the suffix “-5p” (from the 5’ arm of pre-miRNA) or “-3p” (from the 3’ arm of the pre-miRNA). One of the strands of the duplex is typically discarded (passenger strand) while the retained strand guidesmRNA target selection (guide strand). However, in some cases, two mature miRNAs excised from the 5’ and 3’ arms of the same stem-loop pre-miRNA have been reported to be functional and target on different mRNA. Once assembled into the miRISC through base-pairing interactions between nucleotides 2 and 8 of the miRNA and complementary nucleotides predominantly in the 3’-untranslated regions (UTR) of mRNAs, miRNAs act as repressors of translation. Each miRNA binds to many specific target mRNAs and often not to those in the same molecular pathway. miRNAs exist as both free-floating entities in plasma and other biofluids and also packaged into exosomes. It is believed that extracellular, non-miRNAs in circulation are by-products of dead cells stably bound to the Ago2 protein. Exosomes, which are produced in large quantities by diseased and activated cells, are packed with a full complement of the parent cell’s cargo, including miRNA.

[0044] Some miRNAs have been identified as ubiquitously associated with various diseases. Specific miRNAs have been described as “fine-tuners” of immune responses that can either promote an inflammatory state or have anti-inflammatory effects by regulating toll-like receptor signaling. miRNAs are also non-antigenic, allowing them to escape immune surveillance, which can be beneficial for the virus. In viral infections, certain miRNAs may serve both as antiviral tools that stimulate the innate and adaptive immune systems while others have roles in viral propagation. Host miRNAs can be regulated by viruses and viruses can also usurp cellular resources to produce their own miRNAs that participate in immune evasion and maintaining infection. The presence of the various viral and host miRNAs may be monitored when evaluating the outcome of a therapeutic strategy.

[0045] As used herein, “ectosomes” are extracellular vesicles assembled at and released from the plasma membrane whereas exosomes are released on the exocytosis of multivesicular bodies (MVBs). Despite their considerable differences, the functions of ectosomes may be largely analogous to those of exosomes. In some contexts, the term ectosome is used interchangeably with extracellular vesicles or other terms known in the field, including, but not limited to microparticles, microvesicles, or shedding vesicles.

[0046] As used herein, “NETs” refer to neutrophil extracellular traps. NETs are released by activated neutrophils in the setting of signals including LPS, HMGB-1, pro- inflammatory cytokines, microorganisms and / or activated platelets, as well as, exosomes. NETs are released by neutrophils and are composed of DNA, histones, neutrophil granulationproteins, including myeloperoxidase and neutrophil elastase, and / or oxidant enzymes. NETs serve as microbial traps but also have been demonstrated to cause direct organ injury in a number of conditions.

[0047] As used herein “ceDNA” refers to circulating extracellular DNA and is produced by neutrophils in response to various stimuli including infections or inflammation. ceDNAs are present as NETs and are known to worsen the prognosis of various diseases. As used herein, “cytokines” refer to proteins or fragments or mutants thereof that modulate the immune system. Some non-limiting examples of cytokines include chemokines, interferons, interleukins, lymphokines and tumor necrosis factors. As used herein, “chemokines” or “chemotactic cytokines” are a family of small cytokines that are involved in cell migration. Biological samples

[0048] Some embodiments provided herein include or utilize or analyze a biological sample, which can be referred to as a “sample.” Biological samples include, for example, cell culture media, organ perfusion fluid or perfusate with or without red blood cells or oxygen carriers, which may be near normothermic or hypothermic, including but not limited to Steen solution and University of Wisconsin solution and samples obtained from a subject. As used herein, the term "subject" includes an animal, a mammal, and a human or porcine. A sample, which may be obtained from a subject, can include any organ, tissue or fluid from the subject that may contain subcellular nanoparticles, a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, miRNAs, extracellular vesicle associated DNA, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), a biomarker or mediator of tissue damage, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. Examples of such samples include cell culture media, organ perfusion fluid or perfusate with or without red blood cells or oxygen carriers, which may be near normothermic or hypothermic, including but not limited to Steen solution and University of Wisconsin solution, peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchioalveolar lavage fluid, semen (including prostaticfluid), Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates or other lavage or perfusion fluids. A biological sample may also include the blastocyl cavity, umbilical cord blood, or maternal circulation, which may be of fetal or maternal origin. In some embodiments, the sample may also include cell culture samples. Some non-limiting examples of cell culture samples include CAR T cell culture, stem cell culture, or pancreatic islet culture samples. The biological sample may also be a tissue sample or biopsy. In some embodiments, the sample comprises ascites fluid from a subject. In some embodiments, the sample comprises plasma from a subject. In some embodiments, the biological sample may be obtained from a subject that is alive. In some embodiments, the biological sample may be obtained from a subject that is deceased. In some embodiments, the biological sample may be obtained from an animal that will have organs harvested for purposes of xenotransplantation. Extracellular vesicles, Exosomes and Ectosomes

[0049] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate to which a lectin, such as Galanthus nivalis (GNA), is attached or a column packed with lectin affinity resin (e.g., GNA)) to remove extracellular vesicles (e.g., exosomes or ectosomes) from an organ donor or organ recipient prior to, during, or after transplantation or the organ itself after removal from the donor, such as during or after perfusion, which can be near normothermic or hypothermic perfusion. Some embodiments provided herein include a sample comprising extracellular vesicles, (e.g., exosomes or ectosomes). Generally, extracellular vesicles, (e.g., exosomes or ectosomes) are small vesicles that are released into the extracellular environment from a variety of different cells, for example, cells that originate from, or are derived from, the ectoderm, endoderm, or mesoderm including any such cells that have undergone genetic, environmental, and / or any other variations or alterations. An exosome, for example, is typically created intracellularly when a segment of the cell membrane spontaneously invaginates and is ultimately exocytosed (see e.g., Keller et al. (2006), Immunol. Lett. 107: 102-8, incorporated by reference herein in its entirety). In some embodiments, the extracellular vesicles (e.g., exosomes) have a diameter ofgreater than about 10 nm, 20 nm, or 30 nm; a diameter that is, or is about, 30-1000 nm, 30-800 nm, 30-200 nm, or 30-100 nm. In some embodiments, extracellular vesicles (e.g., exosomes) have a diameter of less than, or less than about, 10,000 nm, 1000 nm, 800 nm, 500 nm, 200 nm, 100 nm or 50 nm. In some contexts, the term extracellular vesicle is used interchangeably with exosomes or other terms known in the field, including, but not limited to, small extracellular vesicles, oncosomes, CytoVesicles, microvesicles, nanovesicles, vesicles, dexosomes, bleb, blebby, prostasomes, microparticles, intralumenal vesicles, endosomal-like vesicles or exocytosed vehicles. In some embodiments, said extracellular vesicles can comprise cytokines or chemokines as cargo and such extracellular vesicles can be removed using the technology set forth herein. Extracellular vesicles can also include any shed membrane bound particle that is derived from either the plasma membrane or an internal membrane. Extracellular vesicles can also include cell-derived structures bounded by a lipid bilayer membrane arising from both herniated evagination separation and sealing of portions of the plasma membrane or from the export of any intracellular membrane-bounded vesicular structure containing various membrane-associated proteins of tumor origin, including surface- bound molecules derived from the host circulation that bind selectively to the tumor-derived proteins together with molecules contained in the exosome lumen including tumor-derived microRNAs or intracellular proteins. Extracellular vesicles (e.g., exosomes or ectosomes) can also include membrane fragments.

[0050] In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from subjects having transplant or tissue rejection or subjects believed to be at risk for ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or transplant or tissue rejection. In some embodiments, the transplant is a solid organ transplant. Some non- limiting examples of a solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In some embodiments, the transplant is a transplantation of a population of cells. In some embodiments, the transplant is a kidney transplant. Some non-limiting examples of the population of cells transplant include a stem cell or a bone marrow transplant, pancreatic islet cells transplant, or chimeric antigen receptor T (CAR T) cells transplant. In some embodiments, the transplant rejection in a subject is hyperacute rejection. In some embodiments, the transplant rejection in a subject is acute rejection. In some embodiments, the transplant rejection in a subject is chronic rejection. In some embodiments, the transplantrejection is cell- mediated while in some embodiments the transplant rejection is antibody- mediated. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples having a delayed graft function (DGF) in kidney transplantation. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples having a transplant of normothermic machine perfused organs. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples having a transplant of hypothermic machine perfused organs. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples subjected to static cold storage. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples that have an Ischemia- reperfusion injury. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from samples having at least one or more of a delayed graft function (DGF), a transplant of normothermic machine perfused organs, transplanted with organs subjected to static cold storage and having an Ischemia-reperfusion injury.

[0051] In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from an organ, a cell or a tissue donor. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from an organ, a population of cells or a tissue that has been removed from a donor. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from an organ, a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from an organ perfusate. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from a kidney perfusate. In some embodiments, the extracellular vesicles (e.g., exosomes or ectosomes) are from a recipient after an organ, a population of cells or a tissue has been transplanted. miRNAs

[0052] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column comprising a lectin affinity resin (e.g., GNA)) to remove miRNAs from an organ, an organ perfusate, a population of cells or a tissue donor or an organ, a population of cells or a tissue recipient prior to, during, or after transplantation or the organ itself after removal from the donor such as during or after perfusion, which can benear normothermic or hypothermic perfusion. Some non-limiting examples of miRNAs include miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p, miR-223, let-7e-5p, and / or miR- 486-3p. Generally, delayed graft function (DGF) is defined as failure of the renal transplant to function immediately with a need for dialysis during the first week after transplantation. DGF affects approximately 30% of cases of renal transplantation. Ischemia-Reperfusion Injury is implicated in the development of DGF and exosomes containing miR 23a and / or miR 374b- 5p are released in kidneys with ischemia-reperfusion injury as illustrated in FIG.4. In some embodiments, the release of exosomes containing miR 23a and / or miR 374b-5p result in decreased regulation of NF-^B. In some embodiments, the release of exosomes containing miR 23a and / or miR 374b-5p result in suppression of Suppressor Of Cytokine Signaling 1 (SOCS1). In some embodiments, the release of exosomes containing miR 23a and / or miR 374b-5p results in conversion of macrophages to a pro-inflammatory M1 macrophages. In some embodiments, the conversion of macrophages results in release of pro-inflammatory cytokines, which cause tubulointerstitial inflammation in the kidneys. Accordingly, some embodiments concern methods of increasing the regulation of NF-^B, decreasing SOCS1 suppression, decreasing the conversion of macrophages to a pro-inflammatory M1 macrophages, or decreasing the release of pro-inflammatory cytokines in a subject having exosomes containing miR 23a and / or miR 374b-5p, wherein said subject receives an extracorporeal therapy, which utilizes any one or more of the lectin affinity devices described herein, such as a device comprising a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column packed with lectin affinity resin (e.g., GNA)). Such extracorporeal therapies and methods can include contacting blood and / or plasma or organ perfusion solution from said subject or harvested organ having exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached or a column packed with lectin affinity resin (e.g., GNA)) for a time sufficient to bind said exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p to said diatomaceous earth and / or lectin or a column packed with lectin affinity resin (e.g., GNA)) and reintroducing the blood and / or plasma or organ perfusion solution from said subject back into said subject or harvested organ, wherein the blood, plasma or organ perfusion fluid that is reintroduced, i.e., after contact with the column, has less exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3pthan the blood or plasma or organ perfusion solution from said subject or organ prior to contact with the column. In some embodiments, the subject is identified or selected as one having exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p prior to and / or after receiving the aforementioned extracorporeal therapy e.g., a sample of said subject’s blood or plasma or organ perfusion solution is analyzed for the presence of exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p before, during, and / or after receiving the aforementioned extracorporeal therapy. Such analysis can be performed by isolating exosomes from said subject or organ and analyzing the RNA present in said exosomes utilizing standard techniques in RNA analysis, such as sequencing or primer extension, or selective amplification after reverse transcription of the RNAs into cDNAs. In some embodiments the donor organ is placed on a perfusion circuit including the Hemopurifier®. Perfusate microRNAs are preferably measured before and during the procedure for a decline over time.

[0053] In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from subjects having transplant or tissue rejection or subjects believed to be at risk for ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or a transplant or tissue rejection. In some embodiments, the transplant is a solid organ transplant. Some non- limiting examples of the solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In some embodiments, the transplant is a transplantation of a population of cells. In some embodiments, the transplant is a kidney transplant. Some non-limiting examples of the population of cells transplant include a stem cell or a bone marrow transplant, pancreatic islet cells transplant, or chimeric antigen receptor T (CAR T) cells transplant. In some embodiments, the transplant rejection in a subject is hyperacute rejection. In some embodiments, the transplant rejection in a subject is acute rejection. In some embodiments, the transplant rejection in a subject is chronic rejection. In some embodiments, the transplant rejection is cell- mediated while in some embodiments the transplant rejection is antibody- mediated. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are from samples having a delayed graft function (DGF) in kidney transplantation. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28- 5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from samples having a transplant of normothermic machine perfused organs. In someembodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are from samples having a transplant of hypothermic machine perfused organs. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from samples subjected to static cold storage. In some embodiments, exosomes containing miR 23a and / or miR 374b-5p are from samples that have an Ischemia-reperfusion injury. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from samples having at least one or more of a delayed graft function (DGF), a transplant of normothermic machine perfused organs, transplanted with organs subjected to static cold storage or having an Ischemia-reperfusion injury.

[0054] In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from an organ, an organ perfusate, a cell or a tissue donor. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from an organ, an organ perfusate, a population of cells or a tissue that has been removed from a donor. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24-3p are obtained utilizing one or more of the devices and methods set forth herein from an organ, an organ perfusate, or a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, exosomes containing miR 23a, miR 374b-5p, miR28-5p and / or miR24- 3p are obtained utilizing one or more of the devices and methods set forth herein from a recipient after an organ, an organ perfusate, a population of cells or a tissue has been transplanted.

[0055] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column comprising a lectin affinity resin (e.g., GNA) to remove miRNAs from an organ, an organ perfusate, a population of cells or a tissue donor or an organ donor, or a tissue recipient prior to, during, or after transplantation or the organ itself after removal from the donor such as during or after perfusion, which can be near normothermic or hypothermic perfusion. Some non-limiting examples of miRNAs that areremoved include hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa- miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR- 122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa- miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa-miR-132- 3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa-miR-140- 5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa- miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa- miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR-191- 5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b- 3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa- miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa- miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205-5p, hsa- miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa- miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR- 660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b- 5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa- miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa- miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR- 4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324- 5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa- miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa- miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa- miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa- miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p. In some embodiments, the miRNAs that are removed include hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p. In some embodiments, hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p, and / or hsa-miR-99a-5p play a role post renal transplantation in recipients. In some embodiments, hsa-let-7a-5p and / or hsa-miR-29b-3p are involved in development of fibrosis in ureteropelvic junction (UPJ) obstruction. In some embodiments, high levels of hsa-miR-142-3p are associated with impaired graft function (see e.g., Vahed et al. (2017), Int. Urol. Nephrol. 49: 1681–1689, incorporated by reference herein in its entirety). In some embodiments, hsa-miR-99a-5p is upregulated in subjects with acute rejection (see e.g., Tao et al. (2015), Transplantation Proceedings. 47 (6):1683-1687, incorporated by reference herein in its entirety). In some embodiments, hsa-miR-29b-3p is associated with chronic allograft dysfunction (see e.g., Chen et al. (2022), Int. J. Mol. Sci.23(20): 12253, incorporated by reference herein in its entirety). In some embodiments, the miRNAs that are removed include hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa- miR-126-3p, hsa-miR-1972, and / or hsa-miR-196a-5p.

[0056] Accordingly, some embodiments concern methods of depleting miRNAs from an organ, an organ perfusate, a population of cells or a tissue donor or an organ donor, or a tissue recipient such as hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR- 29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa- miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR- 100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa- miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa- miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR- 126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR- 151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361- 5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR- 191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR- 193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR- 1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b- 3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205- 5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa- miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR- 26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa- miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR- 4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324- 5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa- miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa- miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa- miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR- 486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p, wherein said organ, organ perfusate, population of cells or tissue donor or organ donor, or a tissue recipient receives a therapy, which utilizes any one or more of the lectin affinity devices described herein, such as a device comprising a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column packed with lectin affinity resin (e.g., GNA). Such therapies and methods can include contacting blood and / or plasma organ or organ perfusion solution from said subject or harvested organ having miRNAs disclosed herein with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached or a column packed with lectin affinity resin (e.g., GNA)) for a time sufficient to bind said miRNAs disclosed herein to said diatomaceous earth and / or lectin or a column packed with lectin affinity resin (e.g., GNA) and reintroducing the blood and / or plasma or organ perfusion solution from said subject back into said subject or harvested organ, wherein the blood, plasma or organ perfusion fluid that is reintroduced, i.e., after contact with the column, has less miRNAs disclosed herein than the blood or plasma or organ perfusion solution from said subject or organ prior to contact with the column. In some embodiments, the subject is identified or selected as one having miRNAs disclosed herein prior to and / or after receiving the aforementioned extracorporeal therapy e.g., a sample of said subject’s blood or plasma or organ perfusion solution is analyzed for the presence miRNAs disclosed herein before, during, and / or after receiving the aforementioned extracorporeal therapy. Such analysis can be performed by isolating RNA from said subject or organ or organ perfusate utilizing standard techniques in RNA analysis, such as sequencing or primer extension, or selective amplification after reverse transcription of the RNAs into cDNAs. In some embodiments the donor organ is placed on a perfusion circuit including the Hemopurifier®. Perfusate microRNAs are preferably measured before and during the procedure for a decline over time. In some embodiments, the organ is a kidney.

[0057] In some embodiments, hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let- 7d-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa,hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR- 125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128- 3p, hsa-miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa- miR-15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa- miR-140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR- 144-3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150- 5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa- miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR- 190b, hsa-miR-191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b- 3p, hsa-miR-193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa- miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa- miR-205-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR- 146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223- 3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa- miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR- 302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa- miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa- miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR- 362-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR- 376a-3p, hsa-miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa- miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR- 425-5p, hsa-miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa- miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483- 5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa- miR-496, hsa-let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR-509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a- 5p, hsa-miR-514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa- miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR- 23a-3p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa- miR-590-5p, hsa-miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888-5p, hsa-miR-93-5p and / or hsa-miR-95-3p are obtained utilizing one or more of the devices and methods set forth herein from subjects having transplant or tissue rejection or subjects believed to be at risk for ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or a transplant or tissue rejection or from the organ or organ perfusate. In some embodiments, the transplant is a solid organ transplant. Some non-limiting examples of the solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In some embodiments, the transplant is a transplantation of a population of cells. In some embodiments, the transplant is a kidney transplant. Some non-limiting examples of the population of cells transplant include a stem cell or a bone marrow transplant, pancreatic islet cells transplant, or chimeric antigen receptor T (CAR T) cells transplant. In some embodiments, the transplant rejection in a subject is hyperacute rejection. In some embodiments, the transplant rejection in a subject is acute rejection. In some embodiments, the transplant rejection in a subject is chronic rejection. In some embodiments, the transplant rejection is cell- mediated while in some embodiments the transplant rejection is antibody-mediated. In some embodiments, miRNAs disclosed herein are from samples having a delayed graft function (DGF) in kidney transplantation. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples having a transplant of normothermic machine perfused organs. In some embodiments, miRNAs disclosed herein are from samples having a transplant of hypothermic machine perfused organs. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples subjected to static cold storage. In some embodiments, miRNAs disclosed herein are from samples that have an Ischemia-reperfusion injury. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples having at least one or more of a delayed graft function(DGF), a transplant of normothermic machine perfused organs, transplanted with organs subjected to static cold storage or having an Ischemia-reperfusion injury. In some embodiments, the organ is a kidney.

[0058] In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from an organ, organ perfusate, a cell or a tissue donor. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from an organ, organ perfusate, a population of cells or a tissue that has been removed from a donor. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from an organ, or a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, miRNAs disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from a recipient after an organ, a population of cells or a tissue has been transplanted. In some embodiments, the organ is a kidney. Chemokines, Cytokines and biomarkers or mediators of tissue damage

[0059] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column comprising a lectin affinity resin (e.g., GNA) to remove chemokines, cytokines and biomarkers or mediators of tissue damage from an organ, an organ perfusate, a population of cells or a tissue donor or an organ donor, a population of cells or a tissue recipient prior to, during, or after transplantation or the organ itself after removal from the donor such as during or after perfusion, which can be near normothermic or hypothermic perfusion. Some non-limiting examples of chemokines, cytokines and biomarkers or mediators of tissue damage that are removed include Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL- 15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^, IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL,TARC, TPO and / or TRAIL. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage that are removed include Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO.

[0060] Accordingly, some embodiments concern methods of depleting chemokines, cytokines and biomarkers or mediators of tissue damage from an organ, an organ perfusate, a population of cells or a tissue donor or an organ donor, or a tissue recipient, such as Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL- 4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL, wherein said organ, organ perfusate, population of cells or tissue donor or organ donor, or tissue recipient receives an therapy, which utilizes any one or more of the lectin affinity devices described herein, such as a device comprising a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column packed with lectin affinity resin (e.g., GNA). Such extracorporeal therapies and methods can include contacting blood and / or plasma or organ perfusion solution from said subject or harvested organ having chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached or a column packed with lectin affinity resin (e.g., GNA) for a time sufficient to bind said chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein to said diatomaceous earth and / or lectin or a column packed with lectin affinity resin (e.g., GNA) and reintroducing the blood and / or plasma or organ perfusion solution from said subject back into said subject or harvested organ, wherein the blood, plasma or organ perfusion fluid that is reintroduced, i.e., after contact with the column, has less chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein than the blood or plasma or organ perfusion solution from saidsubject or organ prior to contact with the column. In some embodiments, the organ, organ perfusate, population of cells or tissue donor or organ donor, or tissue recipient is identified or selected as having chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein prior to and / or after receiving the aforementioned extracorporeal therapy e.g., a sample of said subject’s blood or plasma or organ perfusion solution is analyzed for the presence of chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein before, during, and / or after receiving the aforementioned extracorporeal therapy. Such analysis can be performed by isolating proteins from said subject or organ or organ perfusate utilizing standard techniques and performing ELISA (Enzyme-linked immunosorbent assay), bead-based multiplex Luminex assays, aptamer-based assays, mass spectrometry or high throughput proteomics analysis. In some embodiments the donor organ is placed on a perfusion circuit allowing for contact with the lectin bound resin contained in for example an extracorporeal device. Perfusate chemokines, cytokines and biomarkers or mediators of tissue damage are preferably measured before and during the procedure for a decline over time. In some embodiments, the organ is a kidney.

[0061] In some embodiments, Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL are obtained utilizing one or more of the devices and methods set forth herein from subjects having transplant or tissue rejection or subjects believed to be at risk for ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or a transplant or tissue rejection or from an organ, organ perfusate, population of cells or tissue donor or organ donor, or tissue recipient. In some embodiments, the transplant is a solid organ transplant. Some non-limiting examples of the solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In some embodiments, the transplant is a transplantation of a population of cells. In some embodiments, the transplant is a kidney transplant. Some non-limiting examples of the population of cellstransplant include a stem cell or a bone marrow transplant, pancreatic islet cells transplant, or chimeric antigen receptor T (CAR T) cells transplant. In some embodiments, the transplant rejection in a subject is hyperacute rejection. In some embodiments, the transplant rejection in a subject is acute rejection. In some embodiments, the transplant rejection in a subject is chronic rejection. In some embodiments, the transplant rejection is cell- mediated while in some embodiments the transplant rejection is antibody-mediated. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are from samples having a delayed graft function (DGF) in kidney transplantation. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples having a transplant of normothermic machine perfused organs. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are from samples having a transplant of hypothermic machine perfused organs. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples subjected to static cold storage. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are from samples that have an Ischemia- reperfusion injury. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from samples having at least one or more of a delayed graft function (DGF), a transplant of normothermic machine perfused organs, transplanted with organs subjected to static cold storage or having an Ischemia-reperfusion injury. In some embodiments, the organ is a kidney.

[0062] In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from an organ, organ perfusate, a cell or a tissue donor. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from an organ, organ perfusate, a population of cells or a tissue that has been removed from a donor. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from anorgan, or a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, chemokines, cytokines and biomarkers or mediators of tissue damage disclosed herein are obtained utilizing one or more of the devices and methods set forth herein from a recipient after an organ, a population of cells or a tissue has been transplanted. In some embodiments, the organ is a kidney. Neutrophil Extracellular Traps (NETs) and their Components, DNA, extracellular vesicle associated DNA, histones, neutrophil granule proteins and oxidant enzymes

[0063] Aspects of the invention also concern the use of lectin affinity (e.g., employing a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA, NPA, SNA, and / or MAL is attached or a column comprising a lectin affinity resin (e.g., GNA)) to remove nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, from an organ, a population of cells or a tissue donor or an organ, a population of cells or a tissue recipient prior to, during, or after transplantation or the organ itself after removal from the donor such as during or after perfusion, which can be near normothermic or hypothermic perfusion. NETS and circulating extracellular DNA (ceDNA) are released from activated neutrophils in response to stimuli including LPS, microorganisms, pro-inflammatory cytokines, activated platelets, exosomes and immune complexes. NETS are networks of extracellular fibers containing DNA, histones, the neutrophil granule proteins myeloperoxidase and neutrophil elastase, and / or oxidant enzymes. NETs serve as microbial traps but in excess are injurious to organs. Tissue injury is mediated, for example, through complement activation, exposed histone cytotoxicity, coagulation activation and / or propagation of neutrophil recruitment and activation. NETs have been implicated in acute lung injury and primary graft dysfunction. NETs have been detected in the perfusates of donor lungs undergoing ex vivo lung perfusion (EVLP) and was associated with worse recipient outcomes. NETs have further been implicated in ischemia-reperfusion injury and antibody medicated rejection in kidney transplants. In some embodiments, a donor organ is placed on a machine perfusion circuit containing the lectin affinity device (e.g., a Hemopurifier®) and NETs are measured over time in the perfusate to demonstrate a reduction over time. In other embodiments, the donor and / or the organ recipient will have their blood,plasma or organ perfusion fluid passed over the lectin affinity device (e.g., Hemopurifier®) to reduce the presence of NETs.

[0064] In some embodiments, the circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and / or their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes are isolated, using one or more of the lectin affinity devices set forth herein, from an organ, an organ perfusate, a cell or a tissue donor. In some embodiments, the circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and / or their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes are obtained utilizing one or more of the devices and methods set forth herein from an organ, an organ perfusate, a population of cells or a tissue that has been removed from a donor. In some embodiments, the circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and / or their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes are obtained utilizing one or more of the devices and methods set forth herein from an organ, an organ perfusate, a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, the circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and / or their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes are obtained utilizing one or more of the devices and methods set forth herein from a recipient after an organ, an organ perfusate, a population of cells or a tissue has been transplanted.

[0065] Such extracorporeal therapies and methods can include contacting blood, plasma or organ perfusion solution from said subject or harvested organ having nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached, or to a column comprising a lectin affinity resin (e.g., GNA) for a time sufficient to bind said nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes to said diatomaceous earth and / or lectin or to a column comprising a lectin affinity resin (e.g., GNA) and reintroducing the blood, plasma or organ perfusion solution from said subject backinto said subject or harvested organ, wherein the blood or plasma that is reintroduced, i.e., after contact with the column, has less nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes than the blood or plasma or organ perfusion solution from said subject or organ prior to contact with the column. In some embodiments, the subject is identified or selected as one having nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes prior to and / or after receiving the aforementioned extracorporeal therapy e.g., a sample of said subject’s blood or plasma or organ perfusion solution is analyzed for the presence of nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, NETs and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes before, during, and / or after receiving the aforementioned extracorporeal therapy. Pathogens, Viral Particles, Virus-Like Particles (VLPs) and Fragments thereof

[0066] Aspects of the invention concern the use of lectin affinity (e.g., employing a column having a substrate to which a lectin such as GNA is attached) to remove pathogens, viral particles, VLPs or fragments thereof from an organ, an organ perfusate, a population of cells or a tissue donor or an organ, an organ perfusate, a population of cells or a tissue recipient prior to, during, or after transplantation or the organ itself after removal from the donor such as during or after perfusion, which can be near normothermic or hypothermic perfusion. Some embodiments concern the use of lectin affinity (e.g., employing a column having a substrate to which a lectin such as GNA is attached or a column comprising a lectin affinity resin (e.g., GNA)) to remove pathogens, viral particles, VLPs or fragments thereof from an organ, an organ perfusate, cell population or a tissue to be transplanted. Some embodiments provided herein include a sample comprising pathogens, viral particles, virus-like particles (VLP), or fragments thereof. In some embodiments, the pathogens, viral particles, VLP or fragments thereof are from subjects having ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or a tissue or transplant rejection. In some embodiments, the transplant rejection is a solid organ transplant rejection. In some embodiments, the transplant rejection is a kidneytransplant rejection. Some non-limiting examples of the solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In other embodiments, the transplant rejection relates to a stem cell or a bone marrow transplant. In some embodiments, the transplant is a CAR T cell or pancreatic islet transplant. In some embodiments, the transplant rejection in the subject is a hyperacute rejection. In some embodiments, the transplant rejection in the subject is an acute rejection. In some embodiments, the transplant rejection in the subject is a chronic rejection.

[0067] In some embodiments, the pathogens, viral particles or fragments thereof are from an organ, an organ perfusate, a population of cells or a tissue donor. In some embodiments, the pathogens, viral particles are from an organ, an organ perfusate, a population of cells or a tissue that has been removed from a donor. In some embodiments, the pathogens, viral particles or fragments thereof are from an organ, an organ perfusate, a population of cells or a tissue that has been transplanted into a recipient. In some embodiments, the pathogens, viral particles or fragments thereof are from a recipient after an organ, an organ perfusate, a population of cells or a tissue has been transplanted.

[0068] Such extracorporeal therapies and methods can include contacting blood and / or plasma or organ perfusion solution from said subject or harvested organ having the pathogens, viral particles or fragments thereof with a column having a substrate, such as diatomaceous earth, to which a lectin such as GNA is attached, or to a column comprising a lectin affinity resin (e.g., GNA) for a time sufficient to bind said pathogens, viral particles or fragments thereof to said diatomaceous earth and / or lectin or to a column comprising a lectin affinity resin (e.g., GNA) and reintroducing the blood and / or plasma or organ perfusion solution from said subject back into said subject or harvested organ, wherein the blood, plasma or organ perfusion fluid that is reintroduced, i.e., after contact with the column, has less pathogens, viral particles or fragments thereof than the blood or plasma or organ perfusion solution from said subject or organ prior to contact with the column. In some embodiments, the subject is identified or selected as one having the pathogens, viral particles or fragments thereof prior to and / or after receiving the aforementioned extracorporeal therapy e.g., a sample of said subject’s blood or plasma or organ perfusion solution is analyzed for the presence of the pathogens, viral particles or fragments thereof before, during, and / or after receiving the aforementioned extracorporeal therapy.Removal of Pathogens, Viral Particles, VLPs and / or Extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof

[0069] Some embodiments provided herein include removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from a biological sample obtained from an organ, an organ perfusate, cell population, or tissue from a donor or an organ, cell population, or tissue from a recipient, or from an organ, a population of cells or tissue itself prior to transplantation, such as during or after perfusion of the organ or tissue, which may be near normothermic or hypothermic. In some embodiments, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are isolated by contacting a sample with lectin immobilized on a substrate (e.g., a dish, microtiter plate, resin, fibers, membrane, or bead) for a time sufficient to allow the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof to bind to said lectin. In some embodiments, the lectin binds to a viral coat or envelope protein, or a fragment thereof. In some embodiments, the lectin binds to a bacterial protein, or a fragment thereof. In some embodiments, the lectin binds to Extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof. Examples of lectins useful with embodiments provided herein include, but not limited to, mannose-binding lectins. In some embodiments, the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A. In some embodiments, the lectin is GNA, NPA, SNA, or MAL. In particular embodiments, the lectin is GNA.

[0070] In some embodiments, the lectins bind to the pathogens, viruses or VLPs in the organs, cells or tissues procured from porcine sources for xenotransplantation that include, but are not limited to, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcineRetroviruses, porcine endogenous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus.

[0071] In some embodiments, the lectins bind to the pathogens, viruses or VLPs to be removed in the organs, cells or tissues procured from human sources that include, but are not limited to Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV), Hepatitis B virus (HBV), Hepatitis D Virus (HDV); herpes family viruses such as, HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), and Cytomegalovirus (CMV), Human papilloma virus (HPV), Herpes Simplex Virus (HSV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike Protein, SARS, MERS, OC43, 229E, NL63 and HKU1, porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses such as EV-D68, A71, CoxsackieA / B, echoviruses, polioviruses, rhinoviruses or noroviruses.

[0072] In some embodiments, the lectins bind to inflammatory or immunomodulatory glycoproteins, or glycolipids or lipoglycans, such as LPS. In some embodiments, the lectins bind Mycoplasma or Ureaplasma. Some non-limiting examples of Mycoplasma include M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium , M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum or Ureaplasma urealyticum..

[0073] In some embodiments, the exosomes and exosomal micro RNAs generated in Donors after circulatory death (DCD) and Donors after brain death (DBD) may be removed from the explanted organ or organ perfusate based on their binding affinity to lectin.

[0074] In some embodiments, the lectins or support (e.g., diatomaceous earth) on which the lectins are affixed or both or a column packed with lectin affinity resin (e.g., GNA)) in one or more of the affinity devices described herein bind to the extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof produced in transplants with ischemia-reperfusion injury. In some embodiments, the lectins or support (e.g., diatomaceous earth) on which the lectins are affixed or both in one or more of the affinity devices described herein bind to the extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof produced in transplants subjected to coldstorage. In some embodiments, the lectins or support (e.g., diatomaceous earth) on which the lectins are affixed or both in one or more of the affinity devices described herein bind to the extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof produced in transplants subjected to static cold storage. In some embodiments, the lectins or support (e.g., diatomaceous earth) on which the lectins are affixed or both or a column packed with lectin affinity resin (e.g., GNA)) in one or more of the affinity devices described herein bind to the extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof produced in transplants subjected to normothermic machine perfusion. In some embodiments, the lectins or support (e.g., diatomaceous earth) on which the lectins are affixed or both or a column packed with lectin affinity resin (e.g., GNA)) in one or more of the affinity devices described herein bind to the extracellular vesicles (e.g., Exosomes or Ectosomes), Inflammatory or Immunomodulatory Glycoproteins, Glycolipids or Lipoglycans, or fragments thereof produced in transplants subjected to static cold storage and normothermic machine perfusion. Substrates

[0075] Some embodiments herein include a substrate also referred to as a support herein, which may be present or comprised in a vessel. In some embodiments, the substrate or support comprises a surface to which an extracellular vesicle binding material (e.g., exosome binding material, such as an antibody, lectin, ionic or non-ionic or ionic coating) or viral particle or viral particle fragment binding material (e.g., an antibody, lectin, ionic or non-ionic or ionic coating) is bound or immobilized. Substrates can include but are not limited to, for example, a surface, which may be in a vessel (e.g., a plate or microtiter well), beads, membranes, or fibers. A substrate can comprise appropriately functionalized matrices (e.g., ionic or non-ionic resins, Sepharose, latex, glass, polyethylene beads, polystyrene, polyvinyl, polyacrylamide, nitrocellulose, diatomaceous earth, zeolites or silicon). Therapy

[0076] In some embodiments described herein, methods of treatment or inhibition of organ or tissue transplant rejection are provided utilizing any one or more of the lectinaffinity devices set forth herein. The methods can include removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, extracellular vesicle associated DNA, circulating extracellular DNA (ceDNA),Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof, from an organ, an organ perfusate, cell population, or tissue prior to, during and / or after transplantation into a recipient utilizing any one or more of the lectin affinity devices set forth herein. Following removal of pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof, utilizing any one or more of the lectin affinity devices set forth herein, the transplant rejection or inflammatory response of the subject is reduced or inhibited. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein, the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from subjects that have experienced ischemia-reperfusion injury (IRI), delayed graft function (DGF) and / or organ, cell or tissue transplant rejection. In some embodiments, the transplant is a solid organ transplant. Some non-limiting examples of the solid organ transplant include kidney, liver, intestines, heart, lung, or pancreas. In some embodiments, the transplant is a transplantation of a population of cells. In some embodiments, the transplant is a kidney transplant. Some non-limiting examples of the population of cells transplant include a stem cell or a bone marrow transplant, pancreatic islet cells transplant, and chimeric antigen receptor T (CAR T) cells transplant. In some embodiments, the transplant rejection in a subject is ahyperacute rejection. In some embodiments, the transplant rejection in a subject is an acute rejection. In some embodiments, the transplant rejection in a subject is a chronic rejection. In some embodiments, the transplant rejection is cell- mediated while in some embodiments the transplant rejection is antibody-mediated. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein, the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from subjects having a delayed graft function (DGF) in kidney transplantation. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein, the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from samples having a transplant of normothermic machine perfused organs. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein, the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from samples subjected to static cold storage. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein, the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and theircomponents including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from samples that have an Ischemia-reperfusion injury. In some embodiments, utilizing any one or more of the lectin affinity devices set forth herein the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are obtained from samples having at least one or more of a delayed graft function (DGF), a transplant of normothermic machine perfused organs, subjected to static cold storage and having an Ischemia-reperfusion injury. Exemplary Lectin-based Extracorporeal Devices

[0077] Disclosed herein are extracorporeal devices and methods of use for removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, l miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject, wherein said subject is an organ, an organ perfusate, cell, or tissue donor. The extracorporeal devices comprise a lectin that binds to various glycoprotein-containing biological components, such as exosomes. When used for hemofiltration, the extracorporeal device with the lectin is able to filter, for example, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof.

[0078] Once identified or selected as an organ, an organ perfusate, cell population, tissue, or subject (e.g., an organ, cell population, or tissue donor or recipient or isolated organ, cell population, or tissue) that would benefit from a lectin and / or antibody affinity therapy (e.g., Hemopurifier®therapy) utilizing the methods described herein, one can provide a lectin and / or antibody affinity therapy, such as Hemopurifier®therapy, to said identified or selected subjects. Such methods of selection or identification can be made by clinical evaluation or analysis of samples from said cell population, tissue, organ or subject (e.g., analysis of samples from said subject for the presence of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof). Disclosed herein are extracorporeal devices and methods for the treatment or inhibition of organ, cell or tissue transplant rejection. Extracorporeal devices, such as the Hemopurifier®, comprise a lectin (e.g., GNA) and support (e.g., diatomaceous earth) that binds to various glycoprotein-containing biological components, such as pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. In some embodiments, the extracorporeal devices comprise a packed column of lectin affinity resin (e.g., GNA) that binds to various glycoprotein- containing biological components, such as pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. When used for hemofiltration, the extracorporeal device with the lectin andsupport (e.g., diatomaceous earth) or a packed column of lectin affinity resin (e.g., GNA) is able to filter and remove pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof and transplant rejection mediating nanoparticles.

[0079] For example, in some embodiments, the extracorporeal devices disclosed herein are useful in removing viral particles or fragments thereof that can lead to organ injury and death. In some embodiments, the extracorporeal devices disclosed herein are useful in removing extracellular vesicles (e.g., exosomes or ectosomes) from the organ, an organ perfusate, cell population, or tissue donor and / or the donor organ, cell population or tissue to be transplanted, resulting in reduced transplant rejections. This therapy may also or alternatively involve the depletion of extracellular vesicles (e.g., exosomes or ectosomes) from the transplant recipient after transplantation even if the recipient no longer rejects the transplanted cell(s), organ(s) or tissue(s).

[0080] In some embodiments, the extracorporeal devices disclosed herein comprising a lectin and support or a packed column of lectin affinity resin (e.g., GNA) are used for removing pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject may include the following steps: a) introducing a sample obtained from the subject prior to removal of an organ, an organ perfusate, population of cells, or tissue into a vessel, such as an extracorporeal device, comprising a lectin, such as GNA, NPA, SNA, and / or MAL, or an antibody or both immobilized therein on a support (e.g., diatomaceous earth) or into a packed column of lectin affinity resin (e.g., GNA); b) contacting the sample with the lectin or antibody or both and the support or a packed column of lectin affinity resin (e.g., GNA) in the vessel,such as an extracorporeal device; c) obtaining the sample obtained after b) for re-introduction into said subject or harvested organ, wherein the sample obtained after b) has a reduced amount of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, cell, or tissue transplantation, which removes pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood, plasma, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, NPA, SNA, and / or MAL, or said antibody and / or support (e.g., diatomaceous earth).

[0081] In some embodiments, the devices, systems and methods described herein comprise one or more hollow fiber cartridges containing an affinity agent that is a lectin, whichpreferably is GNA. Other lectins include NPA, Concanavalin A and cyanovirin. Examples of extracorporeal devices comprising lectins that can be used in the methods disclosed herein may be found in WO 2007 / 103572, WO 2009 / 023332, and WO 2010 / 065765, each of which is hereby expressly incorporated by reference in its entirety.

[0082] Accordingly, some embodiments relate to the use of extracorporeal devices comprising a lectin and a support such as diatomaceous earth (e.g., Hemopurifier®therapy), for removing viral particles or fragments thereof ,extracellular vesicles (e.g., exosomes from blood or plasma or organ perfusion fluid from a subject or an organ to be transplanted), miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. In some embodiments, the extracorporeal device comprises one or more hollow fiber cartridges comprising the lectin e.g., GNA. In accordance with hollow fiber membrane technology provided herein or otherwise known in the art, embodiments of the invention can involve a size exclusion mechanism for extracellular subcellular nanoparticles (including but not limited to viral particles, or fragments thereof, inflammatory mediating nanoparticles, extracellular vesicles, e.g., exosomes) to contact the affinity matrix, wherein larger blood components (including cells) are restricted from passing through the pores of the hollow fibers into the extra-capillary space of the device where the affinity agent resides. In some embodiments, the pore sizes range from 20-200 nanometers or 20-700 nanometers (e.g., 20nm, 30nm, 50 nm, 100 nm, 200 nm, 300nm, 400nm, 500nm, 600nm, or 700nm). In some embodiments, the pore sizes are 200 nm or about 200 nm.

[0083] By way of example, blood, plasma, or the organ perfusion fluid is run through an extracorporeal circulation circuit that uses a hollow fiber cartridge with the membranes of said hollow fibers having sufficient permeability for the subcellular nanoparticles found in the blood, plasma or the organ perfusion fluid to be removed through the membrane of the hollow fibers and into an area outside of the fibers containing a substrate that is bound to a single or plurality of agents (e.g. lectins) capable of adhering to said viral particles or fragments thereof, subcellular nanoparticles or extracellular vesicles, (e.g., exosomes) in a manner such that said viral particles, subcellular nanoparticles extracellular vesicles (e.g., exosomes) are attached to said agent and do not substantially re-enter the hollowfibers. Within the knowledge of one skilled in the art are available numerous types of hollow fiber systems. Selection of said hollow fiber system is dependent on the desired blood, plasma or organ perfusion fluid volume and rate of passage of said blood, plasma or organ perfusion fluid volume through the hollow fiber system.

[0084] Regardless of the hollow fiber system used, the desirable approach is that said hollow fiber filters are required to allow passage of blood cells through the interior of said hollow fiber and allow diffusion of subcellular nanoparticles to the exterior. In order to allow such diffusion, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow extracellular vesicles (e.g., exosomes ranging from the size of 20 nanometers to 700 nanometers in diameter), depending on the particles of interest. In some embodiments, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow particles ranging from the size of 50 nanometers to 300 nanometers in diameter. In some embodiments, the pores on the membrane of the hollow fiber need to be of a diameter sufficient to allow particles ranging from the size of 80 nanometers to 700 nanometers in diameter.

[0085] The substrate, support, or matrix to be used with devices described herein preferably allows sufficient permeation of flow so that non-cellular blood components that enter the space exterior to the hollow fiber are distributed throughout the substrate or matrix material, so that substantial contact is made between the viral particles and / or extracellular vesicles (e.g., exosomes or ectosomes) permeating the hollow fiber filter and the binding agent that is attached to the substrate, support, or matrix. Suitable substrates, supports, or matrices are known to one skilled in the art. Said substrates, supports, or matrices include silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, co-polymers of ethylene and maleic acid anhydride, aminopropylsilica, aminocelite, polyethylene or glass beads, zeolite, diatomaceous earth, silicate containing diatomaceous earth or other substrates or matrices known in the art. Examples of such are described in the following patents, each of which are incorporated by reference herein in their entirety: Lentz U.S. Pat. No. 4,708,713, Motomura U.S. Pat. No.5,667,684, Takashima et al U.S. Pat. No.5,041,079, and Porath and Janson U.S. Pat. No. 3,925,152. The agents that are attached to said substrate may be chosen based on known affinity to viral particles and / or extracellular vesicles (e.g., exosomes or ectosomes).

[0086] In some embodiments, the methods described herein are carried out by using an affinity cartridge using the device illustrated in FIG.1. In this device, blood , plasma, or organ perfusate is passed through the lumen of a hollow fiber ultrafiltration membrane that is in intimate contact, on the non-blood wetted side of the membrane, with immobilized lectins, which accept and immobilize viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. Thus, the device retains intact glycoproteins (which may be a part of a larger structure) bound by lectin while allowing other components to pass through the lumen.

[0087] An exemplary device, described in detail in FIGS. 1-3, includes multiple channels of hollow fiber ultrafiltration membrane that forms a filtration chamber. An inlet port and an effluent port are in communication with the filtration chamber. The ultrafiltration membrane is preferably an anisotropic membrane with the tight or retention side facing the bloodstream. The membrane is conveniently formed of any number of polymers known to the art, for example, polysulfone, polyethersulfone, polyamides, polyimides, cellulose acetate, or polyacrylamide. Preferably, the membrane has pores 200-700 nm in diameter, which will allow passage of subcellular nanoparticles but not platelets or most blood cells (red blood cells, 2,000 nm diameter; lymphocytes, 7,000-12,000 nm diameter; macrophages, 10,000-18,000 nm diameter). A diagram of an exemplary device is shown in FIG. 1. The device comprises a cartridge 10 comprising a blood-processing chamber 12 formed of suitable material such as polycarbonate 14. Around chamber 12 is an optional exterior chamber 16. A temperature controlling fluid can be circulated into chamber 16 through port 18 and out of port 20. The device includes an inlet port 32 for the blood and an outlet port 34 for the effluent. The device also provides one or more ports 48 and 50, for accessing the extra-channel space in the cartridge. As shown in FIGS. 1 and 2, chamber 12 contains a plurality of ultrafiltration membranes 22. These membranes preferably have a 0.3 mm inside diameter and 0.5 mm outside diameter. FIG. 3 is a cross sectional representation of a channel 22 and shows the anisotropic nature of the membrane. As shown in FIG.3, a hollow fiber membrane structure 40 is composed of a single polymeric material which is formed into a tubular sectioncomprising a relatively tight ultrafiltration membrane 42 and relatively porous exterior portion 44 in which may be immobilized lectins 46. During the operation of the device, a solution containing the lectins is loaded on to the device through port 48. The lectins are allowed to immobilize to the exterior 22 of the membrane in FIG. 2. Unbound lectins can be collected from port 50 by washing with saline or other solutions. The cartridge housing is made of polycarbonate and the fibers are held in place with polyurethane potting material. The lectins are found in the extra-lumen (or extra-capillary or extra-channel) covalently bound to a solid material 10-200 microns (or wider) in diameter. The substrate material is made of a porous silicon dioxide material (SiO2), preferably diatomaceous earth. Approximately 35-45 grams of lectin bound substrate is loaded into the extra-lumen space around the fibers through the polycarbonate side ports of the cartridge. During operation, blood runs along the length of the fibers and the plasma exits the pores and comes into contact with the lectin that is bound to the solid substrate.

[0088] For binding of lectins to the ultrafiltration membrane, the polymers of the ultrafiltration membrane are first activated (e.g., made susceptible for combining chemically with proteins) by using processes known in the art. Any number of different polymers and copolymers can be used. To obtain a reactive polyacrylic acid polymer, for example, carbodiimides can be used (Valuev et al., 1998, Biomaterials, 19:41-3). Once the polymer has been activated, the lectins can be attached directly or via a linker to form in either case an affinity matrix. Suitable linkers include, but are not limited to, avidin, strepavidin, biotin, protein A, or protein G. The lectins may also be directly bound to the polymer of the ultrafiltration membrane using coupling agents such as bifunctional reagents, or may be indirectly bound. In some embodiments, GNA covalently coupled to agarose can be used to form an affinity matrix.

[0089] Accordingly, in some of the methods described herein a lectin affinity device is used and said device comprises a filtration chamber configured to receive blood, plasma or organ perfusion fluid; a lectin, optionally coupled to agarose, diatomaceous earth, or aminocelite disposed within said filtration chamber; and a porous hollow fiber membrane, wherein said membrane has pores of 200-700 nm in diameter; wherein the lectin is selected from the group consisting of: Galanthus nivalis agglutinin (GNA), Narcissus pseudonarcissus agglutinin (NPA), cyanovirin, and Concanavalin A, and mixtures thereof wherein the cartridgeis configured to remove viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof from a sample (e.g., blood, plasma or organ perfusion fluid).

[0090] Processes that can be used to isolate lectins such as GNA are generally known in the art. For example, Van Damme et al. demonstrate isolating the lectin from Galanthus nivalis (snowdrop) bulbs by affinity purification with mannose or other sugars (Van Damme et al. FEBS Letters (1987) 215(1):140-144). Use of purified GNA for affinity purification purposes have been previously demonstrated, such as for isolating glycoproteins like immunoglobulins (Shibuya et al. Archives Biochem. Biophys. (1988) 267(2):676-680). Each of the references above are hereby expressly incorporated by reference in its entirety.

[0091] Aspects of the present invention also provide a device with a filtration chamber further comprises an inlet port and an outlet port; wherein a channel of said hollow fiber membrane is in fluidic communication with said inlet and said outlet ports; said cartridge having an extra-channel space within said chamber which surrounds said hollow fiber membrane; and wherein said lectin is, optionally, covalently coupled to agarose, diatomaceous earth or aminocelite that is disposed within said extra-channel space proximate to an exterior surface of said membrane.

[0092] Aspects of the present invention also provide a device comprising a column packed with a lectin affinity resin (e.g., GNA). A diagram of an exemplary device comprising a packed column of lectin affinity resin is shown in FIG.5. The device comprises an explanted kidney 100 placed in a basin 102. The basin comprises a chamber 118 that contains a reservoir from renal vein 108 and ureter 104. The explanted kidney 100 is connected directly to a packed column containing GNA affinity resin 110 followed by a 0.2 μm filter 120. An illustrative representation of the flow of fluid through the 0.2 μm filter 120 is shown in FIG.7. A roller pump 116 supplies perfusion fluid 114 via the renal artery 106 to the kidney 100. The perfusion fluid will then exit the kidney 100 via the renal vein 108 and the ureter 104 and then enter the packed column containing GNA affinity resin 110 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellulartraps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof, then pass the 0.2 μm filter 120 for the removal of particles larger than 200 nm such as, microvesicles, apoptotic bodies, oncosomes, and microorganisms before being returned to the renal artery 106 supplying the kidney 100. Perfusion fluid will be collected for pre-treatment and post-treatment assessment of pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof using a sample collection port 112.

[0093] Aspects of the present invention also provide a device having the fluid path from the explanted device split into a shunted flow rate with a peristaltic pump at 200 ml / min with a column packed with a lectin affinity resin (e.g., GNA). A diagram of an exemplary device with a shunted flow and a packed column of lectin affinity resin is shown in FIG. 6. The device comprises an explanted kidney 100 placed in a basin 102. The basin comprises a chamber 118 that contains a reservoir from renal vein 108 and ureter 104. The explanted kidney 100 is connected directly to a packed column containing GNA affinity resin 110 followed by a 0.2 μm filter 120. A roller pump 116 supplies perfusion fluid 114 via the renal artery 106 to the kidney 100. The perfusion fluid will then exit the kidney 100 via the renal vein 108 and the ureter 104 and then fluid path will split into a shunted flow rate with a peristaltic pump at 200 ml / min 122 to a packed column containing GNA affinity resin 110 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof, then pass the 0.2 μm filter 120 for the removal of particles larger than 200 nm such as, microvesicles, apoptotic bodies, oncosomes, and microorganisms before rejoining the fluid path to the renal artery 106supplying the kidney 100. Perfusion fluid will be collected for pre-treatment and post- treatment assessment of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof using a sample collection port 112.

[0094] Aspects of the present invention also provide a benchtop configuration of the exemplary device depicted in FIGS.1-3. A diagram of the benchtop configuration or down- scaled version or a mini-version of the exemplary device depicted in FIGS. 1-3 is shown in FIGS.8 and 9. As shown in FIGS.8 and 9, mini version of the device contains the same fiber material and filter pore size but representing about a 1 / 16th of the surface area of the exemplary device depicted in FIGS.1-3. The device comprises a kidney perfusate 124 placed in a basin. The kidney perfusate 124 is circulated directly to a mini-Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126. In some embodiments, 23.6 ml of kidney perfusate 124 is circulated directly to a mini-Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126. A peristaltic pump at 19 ml / min 128 supplies perfusion fluid 124 to the mini-Hemopurifier®cartridge circuit 126 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. The perfusion fluid will then exit the mini-Hemopurifier®cartridge circuit 126 before being returned to the kidney perfusate 124 placed in a basin. In some embodiments, the kidney perfusate 124 is circulated directly to a mini-Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of 24 volume passes. In some embodiments, the kidney perfusate 124 is circulated directly to a mini-Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of about 2,about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 18, about 20, about 22, about 24, about 26, about 28, about 30, about 40, about 50, about 70, about 100 or any number of volume passes between these values. FIG.8 represents a normal flow of the perfusate into the mini- Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 while FIG. 9 represents a reverse flow of the perfusate into the mini- Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126. Aspects of the present invention also provide a device comprising a column packed with a lectin affinity resin (e.g., GNA) followed by filtration through a 0.2 μm membrane. A diagram of an exemplary device comprising a packed column of lectin affinity resin is shown in FIG.10. The device comprising a packed column of lectin affinity resin as shown in FIG. 10 does not place any size restriction on the components reaching the lectin affinity resin (e.g., GNA) as the components are filtered following their encounter with lectin affinity resin (e.g., GNA). The device comprises a kidney perfusate 124 placed in a basin. The kidney perfusate 124 is circulated directly to an affinity-resin packed column (e.g., GNA affinity resin) 126, which is a borosilicate 4 mL column 130 with a 20 ^m polyethylene disc (DWK Life Sciences 4204001005) 132. In some embodiments, 23.6 ml of kidney perfusate 124 is circulated directly to an affinity-resin packed column (e.g., GNA affinity resin) 126. A peristaltic pump at 18 ml / min 128 supplies perfusion fluid 124 to the affinity-resin packed column (e.g., GNA affinity resin) 126 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. The perfusion fluid 124 will then exit the affinity-resin packed column (e.g., GNA affinity resin) 126 before being externally filtered using a 0.2 μm PES membrane filter to mimic the filtration effect of the exemplary devices of FIGS. 1-3 and 8-9 fibers. The perfusate 124 will then be returned to the kidney perfusate 124 placed in a basin. In some embodiments, the kidney perfusate 124 is circulated directly to an affinity-resin packed column (e.g., GNA affinity resin) 126126 for a total of 24 volume passes. In some embodiments, the kidney perfusate 124 is circulated directly to an affinity-resin packed column (e.g., GNA affinity resin) 126 for a totalof about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 18, about 20, about 22, about 24, about 26, about 28, about 30, about 40, about 50, about 70, about 100 or any number of volume passes between these values.

[0095] Aspects of the present invention also provide a device comprising a column packed with a lectin affinity resin (e.g., GNA). A diagram of an exemplary device comprising a packed column of lectin affinity resin is shown in FIG.11. The device comprises a kidney perfusate 124 placed in a basin. The kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126. In some embodiments, 250 ml of kidney perfusate 124 is circulated directly to an affinity- resin packed column (e.g., GNA affinity resin) 126. A peristaltic pump at 200 ml / min 128 supplies perfusion fluid 124 to the affinity-resin packed column (e.g., GNA affinity resin) 126 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. The perfusion fluid will then exit the Hemopurifier®cartridge circuit 126 before being returned to the kidney perfusate 124 placed in a basin. In some embodiments, the kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of 24 volume passes. In some embodiments, the kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 18, about 20, about 22, about 24, about 26, about 28, about 30, about 40, about 50, about 70, about 100 or any number of volume passes between these values. In some embodiments, the Hemopurifier®cartridge circuit comprises about 40 grams of GNA affinity resin. In some embodiments, the Hemopurifier®cartridge circuit comprises about 10 grams, about 20 grams, about 30 grams, about 40 grams, about 50 grams, about 60 grams, about 70 grams, about 80 grams, about 90 grams, about 100 grams of GNA affinity resin or any amount between these values. FIG.11 represents a normal flow directionof the perfusate into the Hemopurifier®cartridge circuit 126 comprising a packed column containing GNA affinity resin 126.

[0096] Aspects of the present invention also provide a device comprising a column packed with a lectin affinity resin (e.g., GNA). A diagram of an exemplary device comprising a packed column of lectin affinity resin with a side port flow direction is shown in FIG. 12. The device comprises a kidney perfusate 124 placed in a basin. The kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126. In some embodiments, 250 ml of kidney perfusate 124 is circulated directly to an affinity-resin packed column (e.g., GNA affinity resin) 126. A peristaltic pump at 200 ml / min 128 supplies perfusion fluid 124 to the affinity-resin packed column (e.g., GNA affinity resin) 126 for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. The perfusion fluid will then exit the Hemopurifier®cartridge circuit 126 before being returned to the kidney perfusate 124 placed in a basin. In some embodiments, the kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of 24 volume passes. In some embodiments, the kidney perfusate 124 is circulated directly to a Hemopurifier®cartridge circuit comprising a packed column containing GNA affinity resin 126 for a total of about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 18, about 20, about 22, about 24, about 26, about 28, about 30, about 40, about 50, about 70, about 100 or any number of volume passes between these values. In some embodiments, the Hemopurifier®cartridge circuit comprises about 40 grams of GNA affinity resin. In some embodiments, the Hemopurifier®cartridge circuit comprises about 10 grams, about 20 grams, about 30 grams, about 40 grams, about 50 grams, about 60 grams, about 70 grams, about 80 grams, about 90 grams, about 100 grams of GNA affinity resin or any amount between these values. FIG.12 represents a side port flow direction of the perfusate into the Hemopurifier®cartridge circuit 126 comprising a packed column containing GNA affinity resin 126.

[0097] For some methods described herein, blood, plasma, or organ perfusate from a subject or harvested organ having pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof is withdrawn from the subject and contacted with the device mentioned herein. In some embodiments, the blood is first separated into its plasma and cellular components. The blood, plasma or organ perfusion fluid is then contacted with the lectins to remove the viral particles and / or subcellular nanoparticles by binding between glycoproteins and lectins. The plasma can then be recombined with the cellular components and returned to the subject. Alternatively, the cellular components may be returned to the subject separately. In some embodiments, the time required to remove 50% of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof is 5minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours, or any amount of time within a range defined by any two of the aforementioned times. In some embodiments, the percentage of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof are removed in 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours or any amount of time within a range defined by any two of the aforementioned times is 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% or any percentage within a range defined by any two of the aforementioned values. The therapy canbe repeated periodically until a desired response has been achieved. In some embodiments, the therapy can be carried out for 0.1,0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours within a 24 hour period, or any amount of time within a range defined by any two of the aforementioned times. In some embodiments, the therapy can be repeated every day for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days.

[0098] For some methods described herein, blood, plasma, or organ perfusion fluid, or organ perfusate (which can be near normothermic or hypothermic) having pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof is withdrawn from an organ and contacted with the device mentioned herein. In some embodiments, the blood, plasma, or organ perfusion fluid, or organ perfusate (which can be near normothermic or hypothermic) is first separated into its components. The blood, plasma, or organ perfusion fluid, or organ perfusate (which can be near normothermic or hypothermic) is then contacted with the lectin support or the column packed with a lectin affinity resin(e.g., GNA) to remove the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof by binding to the lectin on the support. The blood, plasma, or organ perfusion fluid, or organ perfusate (which can be near normothermic or hypothermic) can then be recombined with the earlier isolated cellular components and returned to the organ. Alternatively, the cellular components may be returned to the organ separately. The therapy can be repeated periodically until a desired response has been achieved. In some embodiments, the therapy can be carried out for 0.1,0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours within a 24 hour period, orany amount of time within a range defined by any two of the aforementioned times. In some embodiments, the therapy can be repeated every day for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days.

[0099] In some embodiments, the methods and devices described herein additionally comprise affinity agents that are antibodies (e.g., monoclonal antibodies) that bind to pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof. In certain embodiments, the methods and devices utilized comprise a GNA or other lectin affinity agent and a monoclonal antibody affinity agent.

[0100] In some embodiments, the removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof using a lectin affinity device as described herein (e.g., Hemopurifier®therapy) may include the following steps: a) providing a hollow fiber cartridge comprising a lectin or other affinity binding agent on a support (e.g., diatomaceous earth) or a column packed with a lectin affinity resin (e.g., GNA) that selectively binds to the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans,or glycolipids, or fragments thereof; b) removing a biological sample (e.g., blood or plasma or perfusate) from a subject or an organ using the system, the biological sample having a concentration of the pathogens, viral particles, virus-like particles (VLPs), extracellularvesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof; c) processing the biological sample using the hollow fiber cartridge or a column packed with a lectin affinity resin (e.g., GNA) such that the affinity agents are in contact with the biological sample; d) capturing at least a portion of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof from the biological sample such that said portion of the pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof is retained in the hollow fiber cartridge; and e) reintroducing the biological sample without said portion of captured pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof to the subject or an organ without removing the biological sample from the system before the biological sample is ready to be administered to the subject or the organ. Optionally, a biological sample from said subject or an organ, such as blood or plasma or perfusate, from said subject or organ is obtained before or after the therapy or both and said biological sample is analyzed for the level or amount of the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof.

[0101] In some embodiments, a lectin and support (e.g., diatomaceous earth), comprised in an extracorporeal device or a column packed with a lectin affinity resin (e.g., GNA), is used to remove pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof in accordance with the following steps: a)introducing a sample obtained from the subject prior to removal of an organ, an organ perfusate, population of cells, or tissue into a vessel, such as an extracorporeal device, comprising a lectin, such as GNA, NPA, SNA, and / or MAL, or an antibody or both immobilized therein on a support (e.g., diatomaceous earth) or a column packed with a lectin affinity resin (e.g., GNA); b)contacting the sample with the lectin or antibody or both on the support or a column packed with a lectin affinity resin (e.g., GNA) in the vessel, such as in an extracorporeal device (e.g., a Hemopurifier®); c) obtaining the sample obtained after b) for re-introduction into said subject, wherein the sample obtained after b) has a reduced amount of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, an organ perfusate, cell, or tissue transplantation, which removes pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of e.g., detecting oridentifying, pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood or plasma or organ perfusion fluid, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, NPA, SNA, and / or MAL, or said antibody or said support or all three.

[0102] One skilled in the art will recognize that a biological sample can be taken from, but not limited to the following fluids: organ perfusion fluid or organ perfusate (which can be near normothermic or hypothermic), peripheral blood, plasma, serum, ascites, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen (including prostatic fluid), Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, nasal fluid (e.g., a nasal swab isolate) stool water, urine, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates or other lavage fluids. A biological sample may also include the blastocyst cavity, umbilical cord blood, or maternal circulation that may be of fetal or maternal origin. The biological sample may also be a tissue sample or biopsy or a cell population (e.g., a sample from a cell culture, such as a CAR T cell culture, pancreatic islet cell population, or stem cell population). Preparation of the Device for Hemopurification

[0103] The extracorporeal circuit is to be connected;

[0104] The extracorporeal circuit is primed and rinsed with a minimum of two liters of priming solution;

[0105] An anticoagulant such as heparin will be added per liter of priming solution if needed to prevent clotting of the blood circuit;

[0106] The initial flow rate for priming will be 200-250 mL / min and up to 400-500 ml / min for several minutes, while using a priming solution not blood, to increase the shear forces inside the fibers to encourage the dislodgement of microbubbles. During this procedure, all bubbles are removed from the tubing and the cartridge by gentle tapping. Therapy

[0107] For use on a subject with established vascular access, the subject will be connected to the dialysis machine, which pumps blood from the subject through the cartridge and returns the purified blood to the subject. Alternatively, an organ will be connected to a pump which will pump perfusate solution with or without red blood cells through the organ. Alternatively, an organ perfusate will be connected to a pump which will pump perfusate solution through the cartridge. Blood flow rates are typically maintained at up to 200 ml / min. In some embodiments, the flow rate of the blood or organ perfusate is 18 ml / min. In some embodiments, the flow rate of the blood or organ perfusate is 19 ml / min. Heparin injections are most often used to prevent blood clotting when the procedure is performed on a human. Typical treatment times are up to 4 hours. Longer times may be used to increase the effectiveness of the treatment. At the end of the treatment, the blood in the tubing and cartridge is washed back into the subject in the case of a treatment done on a human. The machine is then disconnected from the subject or the organ and the contaminated cartridge and blood tubing properly disposed.

[0108] During the therapy on person with the device, testing will be performed to measure the activated clotting times (ACT) for monitoring anticoagulation. Results

[0109] Pre-and post-treatment samples from a subject or an organ that will receive the therapy above will have a significantly reduced pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs)and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof in the blood post-therapy. When an organ, an organ perfusate, cell, or tissue transplantation procedure is accompanied by the therapy above, the organ, cell, or tissue viability, engraftment, and / or survival of the transplant and / or recipient is increased or improved as compared to the organ, cell, or tissue viability, engraftment, and / or survival of the transplant or recipient after transplantation in the absence of the therapy.

[0110] Samples collected from the subject at various intervals after therapy with a lectin affinity hemofiltration device will show reduced levels of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, inflammatory or immunomodulatory glycoproteins, lipoglycans, or glycolipids, or fragments thereof after treatment with the device vs. pre-treatment. EXAMPLES

[0111] Some aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the present disclosure. Those in the art will appreciate that many other embodiments also fall within the scope of the invention, as it is described herein above and in the claims. Example 1-Preparation of GNA Covalently Coupled to Agarose Using Cyanogen Bromide.

[0112] Cyanogen bromide (CNBr) activated agarose was used for direct coupling essentially according to Cuatrecasas, et al (Cuatracasas, Wilchek and Anfinsen. Proc Natl Acad Sci USA 61(2): 636-643, 1968). In brief, 1 ml of GNA at a concentration of 10 mg / ml in 0.1M NaHCO3 pH 9.5 is added to 1 ml CNBr activated agarose (Sigma, St. Louis, Mo.) and allowed to react overnight in the cold. Care must be taken to maintain alkaline pH to prevent the potential release of HCN gas. When the reaction is complete, unreacted materials are aspirated and the lectin coupled agarose washed extensively with sterile cold PBS. The lectin agarose affinity matrix is then stored cold until ready for use. Alternatively, GNA agarose is available commercially from Vector Labs (Burlingame, Calif.).Example 2 - Preparation of an Exosome Specific Antibody or lectin Covalently Coupled to Chromosorb (Diatomaceous Earth) Using Glutaraldehyde.

[0113] Preparation of aminated diatomaceous earth is accomplished using Ȗ- aminopropyl triethoxysilane (GAPS or APTES) (Sigma Chemical, St. Louis, Mo.) and Chromosorb 60 / 80 mesh. Although other grades of diatomaceous earth may be used, Chromosorb of this mesh size (200-300 microns in diameter) is often used to prevent small particulates from entering the sample through the largest available pore sizes found in hollow- fiber cartridges used for plasma separation (˜0.5 micron). Amino Chromosorb was prepared by suspension in an excess of 5% aqueous solution of GAPS in an overnight reaction. Aminated- Chromosorb was washed free of excess reagent with water and ethanol and dried overnight in a drying oven to yield an off white powder. One gram of the powder was then suspended in 5 ml 5% glutaraldehyde (Sigma) for 30 minutes. Excess glutaraldehyde was then removed by filtration and washing with water until no detectable aldehyde remained in the wash using Schiff's reagent (Sigma Chemical). The filter cake was then resuspended in 5 ml of Sigma borohydride coupling buffer containing 2-3 mg / ml of the antibody or lectin and the reaction allowed to proceed overnight at 4 degrees C. At the end of the reaction, excess antibody or lectin is washed off and the remaining aldehyde reacted with ethanolamine as described. After final washing in sterile PBS, the material was stored cold until ready for use. Example 3 – Removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in an organ, cell or a tissue donor prior to removal of the organ, cell or a tissue

[0114] This example pertains to methods of removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory orimmunomodulatory glycoproteins, glycolipids or lipoglycansor fragments thereof from an organ, cell or a tissue donor prior to removal of the organ, a population of cells or a tissue from the donor. This example can be used in addition to performing examples 4 and 5 or individually.

[0115] Procedures for organ, cell or tissue donors prior to treatment with the lectin affinity hemofiltration device: Blood and / or plasma or organ perfusion solution or perfusate will be collected for pre-treatment assessment of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. The results of the pre-treatment can be used for later comparison of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof present in the patient’s circulatory system prior to treatment and in the post-treatment sample. Also, a pre-treatment blood and / or plasma or organ perfusion solution or perfusate sample may be used for detection of cytokines / inflammatory and other blood biomarkers of organ damage. In preparation for therapy, a hemodialysis catheter will be placed into the donor. Example 4 – Removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a perfused organ

[0116] This example pertains to methods of removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleicacids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from a perfused organ and can be used in addition to performing examples 3 and 5 or individually.

[0117] Procedures for perfused organ prior to treatment with the lectin affinity hemofiltration device: The explanted donor organ will be connected directly to the Hemopurifier®filter. Typically, a pump will supply perfusion fluid via the artery supplying the organ. The perfusion fluid will then exit the organ via the vein and then enter the Hemopurifier®for removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof before being returned the artery supplying the organ. Perfusion buffer will be collected for pre-treatment assessment of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. The results of the pre-treatment can be used for later comparison of pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof present in the patient’s circulatory system prior to treatment and in the post-treatment sample. Also, a pre-treatment perfusion buffer sample may be used for detection of cytokines / inflammatory and other blood biomarkers of organ damage.Example 5 – Removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a transplant recipient

[0118] This example pertains to methods of removal of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a transplant recipient. This example can be used in addition to performing examples 3 and 4 or individually.

[0119] Procedures for transplant recipient prior to treatment with the lectin affinity hemofiltration device: plasma or perfusate samples will be collected for pre-treatment assessment of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof. The results of the pre-treatment can be used for later comparison of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof present in the patient’s circulatory system prior to treatment and in the post-treatment sample. Also, a pre-treatment blood and / or plasma sample may be used for detection of cytokines / inflammatory and other blood biomarkers of organ damage. In preparation for treatment, a hemodialysis catheter will be placed into the recipient.Examples 6: Removal of miRNAs from kidney perfusate

[0120] This example describes methods of removal of miRNAs or fragments thereof from a kidney perfusate and can be used in addition to performing examples disclosed herein or individually.

[0121] For this example, discarded kidneys were perfused using normothermic ex vivo machine perfusion. Following this, 250 milliliters of kidney perfusate was put into a circuit (FIG.11 or FIG. 12) containing a full-scale Hemopurifier®, filled with 40 grams of GNA affinity resin. The perfusate was circulated at 200 milliliters per minute for a total of 24 total volume passes. RNA was then isolated using a Plasma / Serum RNA purification Mini Kit (Norgen Biotek Corp, Thorold, Canada) following the manufacturers protocol. In brief, 200 microliters of kidney perfusate samples were loaded onto spin columns with lysis buffer and ethanol. Samples were vortexed and mixed well. After vortexing, 650 μl of mixture was loaded onto a spin column and centrifuged at 400 x g to 13,000 x g based on the protocol. Retained RNA was washed to remove impurities. RNA was eluted with 20 μl of elution buffer. RNA was quantified using the Nanodrop One Spectrophotometer. At least 100 nanograms of total RNA from each sample was provided to either the Proof of Principle (PoP) Laboratory at NanoString (NanoString, Seattle, WA) or NanoString Services Laboratory at Canopy Biosciences (Canopy Biosciences, Hayward, CA). The samples were prepared for nCounter miRNA expression profiling according to the manufacturer’s protocol. Before data normalization, Background Thresholding was performed. The threshold count value was set to 25 reads. Data normalization was performed using the geometric mean of the positive controls for code count normalization. Sample input amounts were normalized to the geometric mean of the positive ligation controls. The data was loaded into the R statistical environment (v4.3.1). Statistical analysis of experimental data was performed using R programing language (v4.3.2) and the integrated development environment RStudio. R and RStudio were used for data preprocessing, exploratory data analysis, hypothesis testing, and data visualization. A list of miRNAs depleted using devices as depicted in FIG.11 or FIG.12 are shown in Tables 1-4. Table 1 shows a list of miRNAs depleted using a normal flow device as depicted in FIG. 11. Table 2 shows a list of miRNAs depleted using a normal flow device as depicted in FIG.11 with a p <0.1. Table 3 shows a list of miRNAs depleted using a side port flow device asdepicted in FIG.11. Table 4 shows a list of miRNAs depleted using a side port flow device as depicted in FIG.11 with p <0.1. Table 1. miRNAs Depleted using GNA Resin Normal Flow. GNA Resin - Normal Flow miRNA Name Accession # Fold Change Log2 FC Percent Change p-value hsa-let-7a-5p MIMAT0000062 0.02 -5.55 -97.87 4.22E-03 hsa-let-7b-5p MIMAT0000063 0.44 -1.18 -55.86 0.20 hsa-let-7c-5p MIMAT0000064 0.28 -1.86 -72.45 0.12 hsa-let-7d-5p MIMAT0000065 0.35 -1.51 -64.89 0.15 hsa-miR-29b-3p MIMAT0000100 0.06 -4.04 -93.92 1.89E-02 hsa-miR-99a-5p MIMAT0000097 0.08 -3.66 -92.09 9.39E-03 hsa-miR-15b-5p MIMAT0000417 0.11 -3.15 -88.73 2.47E-02 hsa-miR-1-3p MIMAT0000416 0.35 -1.52 -65.13 0.57 hsa-miR-548aa MIMAT0018447 0.10 -3.32 -89.99 9.74E-03 hsa-miR-106a-5p MIMAT0000103 0.47 -1.08 -52.70 0.52 hsa-miR-106b-5p MIMAT0000680 0.56 -0.84 -44.14 0.44 hsa-miR-10a-5p MIMAT0000253 0.40 -1.32 -59.95 0.23 hsa-miR-10b-5p MIMAT0000254 0.32 -1.63 -67.69 0.14 hsa-miR-1180-3p MIMAT0005825 0.30 -1.75 -70.27 0.12 hsa-miR-1183 MIMAT0005828 0.57 -0.81 -42.96 0.43 hsa-miR-122-5p MIMAT0000421 0.93 -0.11 -7.34 0.92 hsa-miR-1224-5p MIMAT0005458 0.90 -0.15 -9.87 0.91 hsa-miR-1246 MIMAT0005898 0.66 -0.61 -34.48 0.60 hsa-miR-1253 MIMAT0005904 0.41 -1.27 -58.53 0.13 hsa-miR-1258 MIMAT0005909 0.95 -0.07 -4.74 0.90 hsa-miR-125a-5p MIMAT0000443 0.76 -0.39 -23.69 0.72 hsa-miR-125b-5p MIMAT0000423 0.40 -1.32 -59.95 0.15 hsa-miR-100-5p MIMAT0000098 0.24 -2.04 -75.68 0.10 hsa-miR-548ah-5p MIMAT0018972 0.81 -0.3 -18.77 0.65 hsa-miR-98-5p MIMAT0000096 0.68 -0.56 -32.17 0.66 hsa-miR-4454 MIMAT0018976 0.10 -3.35 -90.19 4.07E-02 hsa-miR-128-3p MIMAT0000424 0.66 -0.61 -34.48 0.56hsa-miR-1285-3p MIMAT0005876 0.73 -0.46 -27.30 0.53 hsa-miR-1285-5p MIMAT0022719 0.59 -0.76 -40.95 0.12 hsa-miR-1286 MIMAT0005877 0.90 -0.16 -10.50 0.86 hsa-miR-1268a MIMAT0005922 0.85 -0.23 -14.74 0.88 hsa-miR-1299 MIMAT0005887 0.38 -1.4 -62.11 0.18 hsa-miR-1306-5p MIMAT0022726 0.87 -0.2 -12.94 0.70 hsa-miR-1290 MIMAT0005880 0.72 -0.48 -28.30 0.63 hsa-miR-15a-5p MIMAT0000068 0.12 -3.05 -87.93 3.33E-02 hsa-miR-132-3p MIMAT0000426 0.24 -2.07 -76.18 0.14 hsa-miR-323a-3p MIMAT0000755 0.77 -0.37 -22.62 0.53 hsa-miR-133a-3p MIMAT0000427 0.66 -0.6 -34.02 0.77 hsa-miR-135a-5p MIMAT0000428 0.46 -1.12 -53.99 0.44 hsa-miR-135b-5p MIMAT0000758 0.90 -0.15 -9.87 0.89 hsa-miR-140-3p MIMAT0004597 0.83 -0.27 -17.07 0.74 hsa-miR-140-5p MIMAT0000431 0.34 -1.56 -66.08 0.28 hsa-miR-141-3p MIMAT0000432 0.69 -0.53 -30.74 0.67 hsa-miR-193a-5p MIMAT0004614 0.13 -2.91 -86.70 4.95E-02 hsa-miR-143-3p MIMAT0000435 0.43 -1.22 -57.07 0.23 hsa-miR-144-3p MIMAT0000436 0.20 -2.29 -79.55 0.16 hsa-miR-126-3p MIMAT0000445 0.41 -1.3 -59.39 9.62E-02 hsa-miR-199b-5p MIMAT0000263 0.14 -2.84 -86.03 3.13E-02 hsa-miR-142-3p MIMAT0000434 0.15 -2.7 -84.61 3.36E-02 hsa-miR-424-5p MIMAT0001341 0.16 -2.62 -83.73 4.70E-02 hsa-miR-150-5p MIMAT0000451 0.54 -0.88 -45.66 0.28 hsa-miR-151a-3p MIMAT0000757 0.38 -1.4 -62.11 0.25 hsa-miR-152-3p MIMAT0000438 0.49 -1.03 -51.03 0.45 hsa-miR-1537-3p MIMAT0007399 0.76 -0.39 -23.69 0.54 hsa-miR-154-5p MIMAT0000452 0.56 -0.83 -43.75 0.42 hsa-miR-1972 MIMAT0009447 0.28 -1.84 -72.07 2.84E-02 hsa-miR-361-5p MIMAT0000703 0.16 -2.6 -83.51 9.25E-02 hsa-miR-24-3p MIMAT0000080 0.17 -2.54 -82.81 7.64E-02 hsa-miR-16-5p MIMAT0000069 0.35 -1.53 -65.37 0.13 hsa-miR-181a-2-3p MIMAT0004558 0.98 -0.03 -2.06 0.95 hsa-miR-181a-5p MIMAT0000256 0.33 -1.61 -67.24 0.24 hsa-miR-181c-5p MIMAT0000258 0.75 -0.41 -24.74 0.72hsa-miR-1827 MIMAT0006767 0.97 -0.05 -3.41 0.92 hsa-miR-185-5p MIMAT0000455 0.59 -0.77 -41.36 0.52 hsa-miR-186-5p MIMAT0000456 0.51 -0.96 -48.59 0.45 hsa-miR-187-3p MIMAT0000262 0.81 -0.31 -19.34 0.55 hsa-miR-4455 MIMAT0018977 0.57 -0.8 -42.57 0.17 hsa-miR-190b MIMAT0004929 0.98 -0.03 -2.06 0.95 hsa-miR-191-5p MIMAT0000440 0.26 -1.94 -73.94 0.17 hsa-miR-1910-5p MIMAT0007884 0.44 -1.2 -56.47 0.31 hsa-miR-1915-3p MIMAT0007892 0.47 -1.1 -53.35 0.50 hsa-miR-192-5p MIMAT0000222 0.65 -0.62 -34.93 0.56 hsa-miR-193a-3p MIMAT0000459 0.75 -0.42 -25.26 0.78 hsa-miR-23b-3p MIMAT0000418 0.18 -2.51 -82.44 4.45E-02 hsa-miR-193b-3p MIMAT0002819 0.20 -2.35 -80.39 0.17 hsa-miR-194-5p MIMAT0000460 0.56 -0.83 -43.75 0.55 hsa-miR-195-5p MIMAT0000461 0.25 -2 -75.00 0.23 hsa-miR-505-3p MIMAT0002876 0.19 -2.41 -81.18 5.81E-02 hsa-miR-574-3p MIMAT0003239 0.19 -2.41 -81.18 9.02E-02 hsa-miR-1976 MIMAT0009451 0.88 -0.18 -11.73 0.70 hsa-miR-198 MIMAT0000228 0.90 -0.15 -9.87 0.76 hsa-miR-199a-3p MIMAT0000232 0.40 -1.32 -59.95 0.23 hsa-miR-199a-5p MIMAT0000231 0.49 -1.02 -50.69 0.29 hsa-miR-30e-3p MIMAT0000693 0.20 -2.31 -79.83 7.45E-02 hsa-miR-19a-3p MIMAT0000073 0.29 -1.81 -71.48 0.19 hsa-miR-19b-3p MIMAT0000074 0.30 -1.75 -70.27 0.18 hsa-miR-200a-3p MIMAT0000682 0.50 -1.01 -50.35 0.15 hsa-miR-200b-3p MIMAT0000318 0.57 -0.82 -43.36 0.15 hsa-miR-203a-5p MIMAT0031890 0.86 -0.22 -14.14 0.77 hsa-miR-204-5p MIMAT0000265 0.49 -1.02 -50.69 0.19 hsa-miR-205-5p MIMAT0000266 0.64 -0.64 -35.83 0.58 hsa-miR-2053 MIMAT0009978 0.93 -0.1 -6.70 0.87 hsa-miR-206 MIMAT0000462 0.73 -0.45 -26.80 0.88 hsa-miR-208a-3p MIMAT0000241 0.42 -1.25 -57.96 0.36 hsa-miR-208b-3p MIMAT0004960 0.83 -0.27 -17.07 0.86 hsa-miR-20a-5p MIMAT0000075 0.35 -1.51 -64.89 0.30 hsa-miR-21-5p MIMAT0000076 0.43 -1.21 -56.77 0.22hsa-miR-210-3p MIMAT0000267 0.84 -0.25 -15.91 0.56 hsa-miR-548ar-5p MIMAT0022265 0.65 -0.62 -34.93 0.13 hsa-miR-214-3p MIMAT0000271 0.51 -0.98 -49.30 0.50 hsa-miR-146a-5p MIMAT0000449 0.22 -2.21 -78.39 9.51E-02 hsa-miR-216b-5p MIMAT0004959 0.75 -0.42 -25.26 0.62 hsa-miR-335-5p MIMAT0000765 0.22 -2.18 -77.93 7.86E-02 hsa-miR-22-3p MIMAT0000077 0.36 -1.48 -64.15 0.10 hsa-miR-221-3p MIMAT0000278 0.33 -1.6 -67.01 0.21 hsa-miR-222-3p MIMAT0000279 0.33 -1.61 -67.24 0.15 hsa-miR-223-3p MIMAT0000280 0.45 -1.14 -54.62 0.53 hsa-miR-660-5p MIMAT0003338 0.23 -2.14 -77.31 9.17E-02 hsa-miR-377-3p MIMAT0000730 0.23 -2.1 -76.67 6.02E-02 hsa-miR-145-5p MIMAT0000437 0.24 -2.06 -76.02 5.81E-02 hsa-miR-218-5p MIMAT0000275 0.24 -2.06 -76.02 9.56E-02 hsa-miR-26a-5p MIMAT0000082 0.36 -1.47 -63.90 0.40 hsa-miR-26b-5p MIMAT0000083 0.38 -1.4 -62.11 0.22 hsa-miR-27a-3p MIMAT0000084 0.73 -0.45 -26.80 0.52 hsa-miR-27b-3p MIMAT0000419 0.42 -1.25 -57.96 0.17 hsa-miR-28-3p MIMAT0004502 0.89 -0.17 -11.12 0.86 hsa-miR-28-5p MIMAT0000085 0.63 -0.66 -36.71 0.23 hsa-miR-299-3p MIMAT0000687 0.41 -1.3 -59.39 0.28 hsa-miR-299-5p MIMAT0002890 0.86 -0.21 -13.55 0.74 hsa-miR-29a-3p MIMAT0000086 0.26 -1.97 -74.47 0.13 hsa-miR-495-3p MIMAT0002817 0.24 -2.06 -76.02 1.48E-02 hsa-miR-29c-3p MIMAT0000681 0.44 -1.19 -56.17 0.25 hsa-miR-301a-3p MIMAT0000688 0.77 -0.37 -22.62 0.68 hsa-miR-302b-3p MIMAT0000715 0.63 -0.66 -36.71 0.19 hsa-miR-30a-3p MIMAT0000088 0.31 -1.71 -69.43 0.12 hsa-let-7g-5p MIMAT0000414 0.25 -1.98 -74.65 7.73E-02 hsa-miR-30b-5p MIMAT0000420 0.71 -0.5 -29.29 0.72 hsa-miR-30c-5p MIMAT0000244 0.90 -0.16 -10.50 0.83 hsa-miR-127-3p MIMAT0000446 0.27 -1.89 -73.02 4.66E-02 hsa-miR-4286 MIMAT0016916 0.66 -0.59 -33.57 0.39 hsa-miR-30e-5p MIMAT0000692 0.18 -2.44 -81.57 0.10 hsa-miR-3158-3p MIMAT0015032 0.50 -1 -50.00 0.58hsa-miR-3168 MIMAT0015043 0.93 -0.1 -6.70 0.89 hsa-miR-3180-5p MIMAT0015057 0.93 -0.1 -6.70 0.84 hsa-miR-3195 MIMAT0015079 0.99 -0.02 -1.38 0.97 hsa-miR-32-5p MIMAT0000090 0.72 -0.47 -27.80 0.68 hsa-miR-320a MIMAT0000510 0.97 -0.04 -2.73 0.94 hsa-miR-320e MIMAT0015072 0.66 -0.59 -33.57 0.45 hsa-let-7e-5p MIMAT0000066 0.65 -0.63 -35.38 0.28 hsa-miR-323b-3p MIMAT0015050 0.80 -0.32 -19.89 0.70 hsa-miR-324-5p MIMAT0000761 0.23 -2.14 -77.31 0.13 hsa-miR-325 MIMAT0000771 0.99 -0.01 -0.69 0.99 hsa-miR-148a-3p MIMAT0000243 0.30 -1.75 -70.27 2.90E-02 hsa-miR-337-3p MIMAT0000754 0.99 -0.02 -1.38 0.98 hsa-miR-337-5p MIMAT0004695 0.61 -0.71 -38.87 0.58 hsa-miR-33a-5p MIMAT0000091 0.86 -0.22 -14.14 0.76 hsa-miR-340-5p MIMAT0004692 0.47 -1.1 -53.35 0.23 hsa-miR-342-3p MIMAT0000753 0.43 -1.23 -57.37 0.15 hsa-miR-346 MIMAT0000773 0.96 -0.06 -4.07 0.90 hsa-miR-34a-5p MIMAT0000255 0.44 -1.17 -55.56 0.15 hsa-miR-361-3p MIMAT0004682 0.32 -1.63 -67.69 0.19 hsa-miR-497-5p MIMAT0002820 0.30 -1.73 -69.85 6.24E-02 hsa-miR-362-3p MIMAT0004683 0.73 -0.45 -26.80 0.69 hsa-miR-363-3p MIMAT0000707 0.49 -1.03 -51.03 0.36 hsa-miR-365a-3p MIMAT0000710 0.35 -1.51 -64.89 0.18 hsa-miR-664a-3p MIMAT0005949 0.74 -0.43 -25.77 0.45 hsa-miR-374a-5p MIMAT0000727 0.18 -2.45 -81.70 0.11 hsa-miR-376a-3p MIMAT0000729 0.47 -1.08 -52.70 0.22 hsa-miR-376c-3p MIMAT0000720 0.37 -1.45 -63.40 0.32 hsa-miR-216a-5p MIMAT0000273 0.35 -1.51 -64.89 2.20E-02 hsa-miR-378d MIMAT0018926 0.42 -1.26 -58.25 0.15 hsa-miR-378f MIMAT0018932 0.59 -0.75 -40.54 0.28 hsa-miR-378g MIMAT0018937 0.34 -1.55 -65.85 0.14 hsa-miR-378i MIMAT0019074 0.45 -1.14 -54.62 0.10 hsa-miR-379-5p MIMAT0000733 0.92 -0.12 -7.98 0.80 hsa-miR-381-3p MIMAT0000736 0.78 -0.36 -22.08 0.70 hsa-miR-382-5p MIMAT0000737 0.31 -1.69 -69.01 0.16hsa-miR-421 MIMAT0003339 0.41 -1.27 -58.53 0.28 hsa-miR-423-3p MIMAT0001340 0.39 -1.36 -61.04 0.13 hsa-miR-423-5p MIMAT0004748 0.37 -1.42 -62.63 0.23 hsa-miR-130a-3p MIMAT0000425 0.39 -1.35 -60.77 7.05E-02 hsa-miR-425-5p MIMAT0003393 0.93 -0.11 -7.34 0.90 hsa-miR-190a-5p MIMAT0000458 0.68 -0.56 -32.17 0.31 hsa-miR-2117 MIMAT0011162 0.71 -0.5 -29.29 0.34 hsa-miR-548z MIMAT0018446 0.69 -0.54 -31.22 0.29 hsa-miR-25-3p MIMAT0000081 0.40 -1.34 -60.50 2.77E-02 hsa-miR-1323 MIMAT0005795 0.72 -0.47 -27.80 0.39 hsa-miR-450a-5p MIMAT0001545 0.40 -1.34 -60.50 0.41 hsa-miR-4516 MIMAT0019053 0.86 -0.22 -14.14 0.84 hsa-miR-451a MIMAT0001631 0.68 -0.56 -32.17 0.45 hsa-miR-487a-3p MIMAT0002178 0.83 -0.27 -17.07 0.58 hsa-miR-4532 MIMAT0019071 0.41 -1.3 -59.39 0.41 hsa-miR-455-5p MIMAT0003150 0.47 -1.1 -53.35 0.40 hsa-miR-483-5p MIMAT0004761 0.97 -0.04 -2.73 0.94 hsa-miR-486-3p MIMAT0004762 0.48 -1.07 -52.37 0.30 hsa-miR-4443 MIMAT0018961 0.80 -0.32 -19.89 0.54 hsa-miR-487b-3p MIMAT0003180 0.92 -0.12 -7.98 0.81 hsa-miR-491-5p MIMAT0002807 0.66 -0.6 -34.02 0.54 hsa-miR-543 MIMAT0004954 0.40 -1.32 -59.95 5.04E-02 hsa-miR-496 MIMAT0002818 0.95 -0.07 -4.74 0.91 hsa-let-7f-5p MIMAT0000067 0.73 -0.45 -26.80 0.45 hsa-miR-499a-5p MIMAT0002870 0.60 -0.73 -39.71 0.69 hsa-miR-503-5p MIMAT0002874 0.45 -1.14 -54.62 0.34 hsa-miR-148b-3p MIMAT0000759 0.43 -1.23 -57.37 3.34E-02 hsa-miR-506-3p MIMAT0002878 0.65 -0.62 -34.93 0.52 hsa-miR-509-3p MIMAT0002881 0.33 -1.58 -66.55 0.14 hsa-miR-509-5p MIMAT0004779 0.90 -0.16 -10.50 0.74 hsa-miR-513b-5p MIMAT0005788 0.72 -0.48 -28.30 0.71 hsa-miR-513c-5p MIMAT0005789 0.80 -0.33 -20.45 0.75 hsa-miR-514a-3p MIMAT0002883 0.59 -0.77 -41.36 0.19 hsa-miR-514a-5p MIMAT0022702 0.72 -0.48 -28.30 0.65 hsa-miR-514b-5p MIMAT0015087 0.81 -0.31 -19.34 0.72hsa-miR-518b MIMAT0002844 0.30 -1.75 -70.27 0.24 hsa-miR-5196-3p MIMAT0021129 0.95 -0.08 -5.39 0.87 hsa-miR-520f-3p MIMAT0002830 0.69 -0.53 -30.74 0.70 hsa-miR-521 MIMAT0002854 0.97 -0.04 -2.73 0.93 hsa-miR-526a MIMAT0002845 0.40 -1.34 -60.50 0.11 hsa-miR-548d-5p MIMAT0004812 0.74 -0.43 -25.77 0.41 hsa-miR-532-5p MIMAT0002888 0.96 -0.06 -4.07 0.89 hsa-miR-30a-5p MIMAT0000087 0.45 -1.15 -54.94 8.58E-02 hsa-miR-30d-5p MIMAT0000245 0.49 -1.04 -51.37 5.20E-02 hsa-miR-196a-5p MIMAT0000226 0.55 -0.85 -44.52 8.95E-02 hsa-miR-136-5p MIMAT0000448 0.79 -0.34 -21.00 0.48 hsa-miR-4421 MIMAT0018934 0.94 -0.09 -6.05 0.87 hsa-miR-548m MIMAT0005917 0.76 -0.4 -24.21 0.56 hsa-miR-548n MIMAT0005916 0.61 -0.72 -39.29 0.23 hsa-miR-99b-5p MIMAT0000689 0.85 -0.23 -14.74 0.64 hsa-miR-551b-3p MIMAT0003233 0.22 -2.2 -78.24 0.13 hsa-miR-556-3p MIMAT0004793 0.97 -0.05 -3.41 0.92 hsa-miR-23a-3p MIMAT0000078 0.52 -0.95 -48.24 9.64E-02 hsa-miR-574-5p MIMAT0004795 0.82 -0.28 -17.64 0.81 hsa-miR-575 MIMAT0003240 0.30 -1.75 -70.27 0.20 hsa-miR-578 MIMAT0003243 0.99 -0.01 -0.69 0.99 hsa-miR-584-3p MIMAT0022708 0.93 -0.11 -7.34 0.83 hsa-miR-655-3p MIMAT0003331 0.87 -0.2 -12.94 0.67 hsa-miR-590-5p MIMAT0003258 0.48 -1.06 -52.04 0.44 hsa-miR-593-3p MIMAT0004802 0.73 -0.46 -27.30 0.41 hsa-miR-597-5p MIMAT0003265 0.75 -0.41 -24.74 0.65 hsa-miR-598-3p MIMAT0003266 0.67 -0.57 -32.64 0.60 hsa-miR-601 MIMAT0003269 0.78 -0.35 -21.54 0.74 hsa-miR-607 MIMAT0003275 0.69 -0.53 -30.74 0.42 hsa-miR-616-3p MIMAT0004805 0.61 -0.71 -38.87 0.48 hsa-miR-625-5p MIMAT0003294 0.90 -0.15 -9.87 0.74 hsa-miR-630 MIMAT0003299 0.57 -0.81 -42.96 0.57 hsa-miR-656-3p MIMAT0003332 0.70 -0.52 -30.26 0.57 hsa-miR-663a MIMAT0003326 0.70 -0.51 -29.78 0.72 hsa-miR-7-5p MIMAT0000252 0.65 -0.62 -34.93 0.33hsa-miR-764 MIMAT0010367 0.95 -0.07 -4.74 0.92 hsa-miR-769-5p MIMAT0003886 0.80 -0.32 -19.89 0.73 hsa-miR-873-5p MIMAT0004953 0.92 -0.12 -7.98 0.79 hsa-miR-887-3p MIMAT0004951 0.87 -0.2 -12.94 0.72 hsa-miR-888-5p MIMAT0004916 0.68 -0.56 -32.17 0.46 hsa-miR-93-5p MIMAT0000093 0.37 -1.43 -62.89 0.26 hsa-miR-95-3p MIMAT0000094 0.30 -1.73 -69.85 0.20 Table 2. miRNAs Significantly Depleted using GNA Normal Flow. GNA Resin - Normal Flow miRNA Name Accession # Fold Change Log2 FC Percent Change p-value hsa-let-7a-5p MIMAT0000062 0.02 -5.55 -97.87 4.22E-03 hsa-miR-29b-3p MIMAT0000100 0.06 -4.04 -93.92 1.89E-02 hsa-miR-99a-5p MIMAT0000097 0.08 -3.66 -92.09 9.39E-03 hsa-miR-15b-5p MIMAT0000417 0.11 -3.15 -88.73 2.47E-02 hsa-miR-548aa MIMAT0018447 0.10 -3.32 -89.99 9.74E-03 hsa-miR-4454 MIMAT0018976 0.10 -3.35 -90.19 4.07E-02 hsa-miR-15a-5p MIMAT0000068 0.12 -3.05 -87.93 3.33E-02 hsa-miR-193a-5p MIMAT0004614 0.13 -2.91 -86.70 4.95E-02 hsa-miR-126-3p MIMAT0000445 0.41 -1.3 -59.39 9.62E-02 hsa-miR-199b-5p MIMAT0000263 0.14 -2.84 -86.03 3.13E-02 hsa-miR-142-3p MIMAT0000434 0.15 -2.7 -84.61 3.36E-02 hsa-miR-424-5p MIMAT0001341 0.16 -2.62 -83.73 4.70E-02 hsa-miR-1972 MIMAT0009447 0.28 -1.84 -72.07 2.84E-02 hsa-miR-361-5p MIMAT0000703 0.16 -2.6 -83.51 9.25E-02 hsa-miR-24-3p MIMAT0000080 0.17 -2.54 -82.81 7.64E-02 hsa-miR-23b-3p MIMAT0000418 0.18 -2.51 -82.44 4.45E-02 hsa-miR-505-3p MIMAT0002876 0.19 -2.41 -81.18 5.81E-02 hsa-miR-574-3p MIMAT0003239 0.19 -2.41 -81.18 9.02E-02 hsa-miR-30e-3p MIMAT0000693 0.20 -2.31 -79.83 7.45E-02 hsa-miR-146a-5p MIMAT0000449 0.22 -2.21 -78.39 9.51E-02hsa-miR-335-5p MIMAT0000765 0.22 -2.18 -77.93 7.86E-02 hsa-miR-660-5p MIMAT0003338 0.23 -2.14 -77.31 9.17E-02 hsa-miR-377-3p MIMAT0000730 0.23 -2.1 -76.67 6.02E-02 hsa-miR-145-5p MIMAT0000437 0.24 -2.06 -76.02 5.81E-02 hsa-miR-218-5p MIMAT0000275 0.24 -2.06 -76.02 9.56E-02 hsa-miR-495-3p MIMAT0002817 0.24 -2.06 -76.02 1.48E-02 hsa-let-7g-5p MIMAT0000414 0.25 -1.98 -74.65 7.73E-02 hsa-miR-127-3p MIMAT0000446 0.27 -1.89 -73.02 4.66E-02 hsa-miR-148a-3p MIMAT0000243 0.30 -1.75 -70.27 2.90E-02 hsa-miR-497-5p MIMAT0002820 0.30 -1.73 -69.85 6.24E-02 hsa-miR-216a-5p MIMAT0000273 0.35 -1.51 -64.89 2.20E-02 hsa-miR-130a-3p MIMAT0000425 0.39 -1.35 -60.77 7.05E-02 hsa-miR-25-3p MIMAT0000081 0.40 -1.34 -60.50 2.77E-02 hsa-miR-543 MIMAT0004954 0.40 -1.32 -59.95 5.04E-02 hsa-miR-148b-3p MIMAT0000759 0.43 -1.23 -57.37 3.34E-02 hsa-miR-30a-5p MIMAT0000087 0.45 -1.15 -54.94 8.58E-02 hsa-miR-30d-5p MIMAT0000245 0.49 -1.04 -51.37 5.20E-02 hsa-miR-196a-5p MIMAT0000226 0.55 -0.85 -44.52 8.95E-02 hsa-miR-23a-3p MIMAT0000078 0.52 -0.95 -48.24 9.64E-02 Table 3. miRNAs Depleted using GNA Resin Side Port Flow. GNA Resin - Side Port Flow miRNA Name Accession # Fold Change Log2 FC Percent Change p-value hsa-let-7a-5p MIMAT0000062 0.025 -5.32 -97.50 2.68E-02 hsa-let-7b-5p MIMAT0000063 0.423 -1.24 -57.66 0.27 hsa-let-7c-5p MIMAT0000064 0.291 -1.78 -70.88 0.22 hsa-let-7d-5p MIMAT0000065 0.727 -0.46 -27.30 0.68 hsa-miR-29b-3p MIMAT0000100 0.047 -4.42 -95.33 5.62E-02 hsa-miR-99a-5p MIMAT0000097 0.075 -3.74 -92.52 2.86E-02 hsa-miR-15b-5p MIMAT0000417 0.092 -3.45 -90.85 7.16E-02 hsa-let-7i-5p MIMAT0000415 0.476 -1.07 -52.37 0.28 hsa-miR-1-3p MIMAT0000416 0.590 -0.76 -40.95 0.81hsa-miR-1-5p MIMAT0031892 0.642 -0.64 -35.83 0.25 hsa-miR-548aa MIMAT0018447 0.098 -3.35 -90.19 3.80E-02 hsa-miR-101-3p MIMAT0000099 0.812 -0.3 -18.77 0.26 hsa-miR-103a-3p MIMAT0000101 0.927 -0.11 -7.34 0.62 hsa-miR-106a-5p MIMAT0000103 0.540 -0.89 -46.04 0.61 hsa-miR-106b-5p MIMAT0000680 0.429 -1.22 -57.07 0.30 hsa-miR-10a-5p MIMAT0000253 0.599 -0.74 -40.13 0.44 hsa-miR-10b-5p MIMAT0000254 0.366 -1.45 -63.40 0.18 hsa-miR-1178-3p MIMAT0005823 0.927 -0.11 -7.34 0.62 hsa-miR-1180-3p MIMAT0005825 0.409 -1.29 -59.10 0.36 hsa-miR-1183 MIMAT0005828 0.768 -0.38 -23.16 0.76 hsa-miR-1185-1-3p MIMAT0022838 0.927 -0.11 -7.34 0.62 hsa-miR-1185-2-3p MIMAT0022713 0.847 -0.24 -15.33 0.40 hsa-miR-1193 MIMAT0015049 0.927 -0.11 -7.34 0.62 hsa-miR-1200 MIMAT0005863 0.927 -0.11 -7.34 0.62 hsa-miR-1202 MIMAT0005865 0.927 -0.11 -7.34 0.62 hsa-miR-1203 MIMAT0005866 0.927 -0.11 -7.34 0.62 hsa-miR-1204 MIMAT0005868 0.927 -0.11 -7.34 0.62 hsa-miR-1205 MIMAT0005869 0.927 -0.11 -7.34 0.62 hsa-miR-1206 MIMAT0005870 0.927 -0.11 -7.34 0.62 hsa-miR-122-5p MIMAT0000421 0.979 -0.03 -2.06 0.98 hsa-miR-1226-3p MIMAT0005577 0.927 -0.11 -7.34 0.62 hsa-miR-1228-3p MIMAT0005583 0.847 -0.24 -15.33 0.40 hsa-miR-1233-3p MIMAT0005588 0.927 -0.11 -7.34 0.62 hsa-miR-1234-3p MIMAT0005589 0.927 -0.11 -7.34 0.62 hsa-miR-1236-3p MIMAT0005591 0.927 -0.11 -7.34 0.62 hsa-miR-124-3p MIMAT0000422 0.927 -0.11 -7.34 0.62 hsa-miR-1244 MIMAT0005896 0.927 -0.11 -7.34 0.62 hsa-miR-1245a MIMAT0005897 0.927 -0.11 -7.34 0.62 hsa-miR-1245b-3p MIMAT0019951 0.927 -0.11 -7.34 0.62 hsa-miR-1245b-5p MIMAT0019950 0.927 -0.11 -7.34 0.62 hsa-miR-1246 MIMAT0005898 0.732 -0.45 -26.80 0.38 hsa-miR-1247-5p MIMAT0005899 0.927 -0.11 -7.34 0.62 hsa-miR-1248 MIMAT0005900 0.927 -0.11 -7.34 0.62 hsa-miR-1249-3p MIMAT0005901 0.927 -0.11 -7.34 0.62hsa-miR-1249-5p MIMAT0032029 0.927 -0.11 -7.34 0.62 hsa-miR-1250-5p MIMAT0005902 0.927 -0.11 -7.34 0.62 hsa-miR-1252-5p MIMAT0005944 0.927 -0.11 -7.34 0.62 hsa-miR-1253 MIMAT0005904 0.525 -0.93 -47.51 0.33 hsa-miR-1254 MIMAT0005905 0.927 -0.11 -7.34 0.62 hsa-miR-1255a MIMAT0005906 0.979 -0.03 -2.06 0.98 hsa-miR-1255b-5p MIMAT0005945 0.758 -0.4 -24.21 0.23 hsa-miR-1257 MIMAT0005908 0.908 -0.14 -9.25 0.77 hsa-miR-125a-5p MIMAT0000443 0.712 -0.49 -28.80 0.72 hsa-miR-125b-5p MIMAT0000423 0.426 -1.23 -57.37 0.26 hsa-miR-100-5p MIMAT0000098 0.136 -2.88 -86.42 8.40E-02 hsa-miR-1260a MIMAT0005911 0.927 -0.11 -7.34 0.62 hsa-miR-1260b MIMAT0015041 0.927 -0.11 -7.34 0.62 hsa-miR-1261 MIMAT0005913 0.927 -0.11 -7.34 0.62 hsa-miR-1262 MIMAT0005914 0.927 -0.11 -7.34 0.62 hsa-miR-1264 MIMAT0005791 0.664 -0.59 -33.57 0.12 hsa-miR-1266-5p MIMAT0005920 0.927 -0.11 -7.34 0.62 hsa-miR-548ah-5p MIMAT0018972 0.245 -2.03 -75.51 4.44E-03 hsa-miR-1268b MIMAT0018925 0.927 -0.11 -7.34 0.62 hsa-miR-98-5p MIMAT0000096 0.255 -1.97 -74.47 5.36E-02 hsa-miR-1269b MIMAT0019059 0.927 -0.11 -7.34 0.62 hsa-miR-4454 MIMAT0018976 0.136 -2.88 -86.42 0.16 hsa-miR-127-5p MIMAT0004604 0.927 -0.11 -7.34 0.62 hsa-miR-1270 MIMAT0005924 0.927 -0.11 -7.34 0.62 hsa-miR-1271-3p MIMAT0022712 0.927 -0.11 -7.34 0.62 hsa-miR-1271-5p MIMAT0005796 0.927 -0.11 -7.34 0.62 hsa-miR-1272 MIMAT0005925 0.927 -0.11 -7.34 0.62 hsa-miR-1273c MIMAT0015017 0.927 -0.11 -7.34 0.62 hsa-miR-1275 MIMAT0005929 0.927 -0.11 -7.34 0.62 hsa-miR-1276 MIMAT0005930 0.927 -0.11 -7.34 0.62 hsa-miR-1277-3p MIMAT0005933 0.927 -0.11 -7.34 0.62 hsa-miR-1278 MIMAT0005936 0.927 -0.11 -7.34 0.62 hsa-miR-1279 MIMAT0005937 0.927 -0.11 -7.34 0.62 hsa-miR-128-1-5p MIMAT0026477 0.927 -0.11 -7.34 0.62 hsa-miR-128-2-5p MIMAT0031095 0.927 -0.11 -7.34 0.62hsa-miR-128-3p MIMAT0000424 0.507 -0.98 -49.30 0.37 hsa-miR-1281 MIMAT0005939 0.927 -0.11 -7.34 0.62 hsa-miR-1283 MIMAT0005799 0.927 -0.11 -7.34 0.62 hsa-miR-1285-5p MIMAT0022719 0.655 -0.61 -34.48 0.15 hsa-miR-1287-3p MIMAT0026738 0.927 -0.11 -7.34 0.62 hsa-miR-1287-5p MIMAT0005878 0.758 -0.4 -24.21 0.12 hsa-miR-1288-3p MIMAT0005942 0.927 -0.11 -7.34 0.62 hsa-miR-1289 MIMAT0005879 0.927 -0.11 -7.34 0.62 hsa-miR-129-2-3p MIMAT0004605 0.927 -0.11 -7.34 0.62 hsa-miR-129-5p MIMAT0000242 0.927 -0.11 -7.34 0.62 hsa-miR-1268a MIMAT0005922 0.279 -1.84 -72.07 7.22E-02 hsa-miR-1291 MIMAT0005881 0.927 -0.11 -7.34 0.62 hsa-miR-1293 MIMAT0005883 0.927 -0.11 -7.34 0.62 hsa-miR-1296-5p MIMAT0005794 0.927 -0.11 -7.34 0.62 hsa-miR-1297 MIMAT0005886 0.859 -0.22 -14.14 0.33 hsa-miR-1298-5p MIMAT0005800 0.758 -0.4 -24.21 0.33 hsa-miR-1299 MIMAT0005887 0.871 -0.2 -12.94 0.88 hsa-miR-1301-3p MIMAT0005797 0.927 -0.11 -7.34 0.62 hsa-miR-1302 MIMAT0005890 0.927 -0.11 -7.34 0.62 hsa-miR-1303 MIMAT0005891 0.927 -0.11 -7.34 0.62 hsa-miR-1304-3p MIMAT0022720 0.927 -0.11 -7.34 0.62 hsa-miR-1304-5p MIMAT0005892 0.979 -0.03 -2.06 0.90 hsa-miR-1305 MIMAT0005893 0.877 -0.19 -12.34 0.85 hsa-miR-1306-3p MIMAT0005950 0.927 -0.11 -7.34 0.62 hsa-miR-1306-5p MIMAT0022726 0.646 -0.63 -35.38 0.12 hsa-miR-1290 MIMAT0005880 0.301 -1.73 -69.85 5.08E-02 hsa-miR-15a-5p MIMAT0000068 0.321 -1.64 -67.91 9.03E-02 hsa-miR-130b-3p MIMAT0000691 0.927 -0.11 -7.34 0.62 hsa-miR-132-3p MIMAT0000426 0.480 -1.06 -52.04 0.52 hsa-miR-1322 MIMAT0005953 0.927 -0.11 -7.34 0.62 hsa-miR-323a-3p MIMAT0000755 0.344 -1.54 -65.61 5.50E-03 hsa-miR-133a-5p MIMAT0026478 0.927 -0.11 -7.34 0.62 hsa-miR-133b MIMAT0000770 0.927 -0.11 -7.34 0.62 hsa-miR-134-3p MIMAT0026481 0.927 -0.11 -7.34 0.62 hsa-miR-134-5p MIMAT0000447 0.927 -0.11 -7.34 0.62hsa-miR-135a-5p MIMAT0000428 0.351 -1.51 -64.89 0.48 hsa-miR-135b-5p MIMAT0000758 0.763 -0.39 -23.69hsa-miR-369-3p MIMAT0000721 0.379 -1.4 -62.11hsa-miR-137 MIMAT0000429 0.927 -0.11 -7.34hsa-miR-138-5p MIMAT0000430 0.993 -0.01 -0.69 0.96 hsa-miR-139-3p MIMAT0004552 0.871 -0.2 -12.94 0.52 hsa-miR-139-5p MIMAT0000250 0.927 -0.11 -7.34 0.62 hsa-miR-140-3p MIMAT0004597 0.620 -0.69 -38.01hsa-miR-140-5p MIMAT0000431 0.287 -1.8 -71.28hsa-miR-141-3p MIMAT0000432 0.599 -0.74 -40.13hsa-miR-193a-5p MIMAT0004614 0.390 -1.36 -61.04 9.22E-02 hsa-miR-142-5p MIMAT0000433 0.927 -0.11 -7.34 0.62 hsa-miR-143-3p MIMAT0000435 0.547 -0.87 -45.29 0.47 hsa-miR-144-3p MIMAT0000436 0.521 -0.94 -47.88 0.61 hsa-miR-126-3p MIMAT0000445 0.392 -1.35 -60.77 7.95E-02 hsa-miR-1469 MIMAT0007347 0.927 -0.11 -7.34 0.62 hsa-miR-199b-5p MIMAT0000263 0.293 -1.77 -70.68 0.23 hsa-miR-146b-3p MIMAT0004766 0.927 -0.11 -7.34 0.62 hsa-miR-147a MIMAT0000251 0.927 -0.11 -7.34 0.62 hsa-miR-147b MIMAT0004928 0.927 -0.11 -7.34 0.62 hsa-miR-142-3p MIMAT0000434 0.212 -2.24 -78.83 0.10 hsa-miR-424-5p MIMAT0001341 0.540 -0.89 -46.04 0.27 hsa-miR-149-5p MIMAT0000450 0.927 -0.11 -7.34 0.62 hsa-miR-150-5p MIMAT0000451 0.438 -1.19 -56.17 0.25 hsa-miR-151a-3p MIMAT0000757 0.401 -1.32 -59.95 0.48 hsa-miR-151a-5p MIMAT0004697 0.503 -0.99 -49.65 0.13 hsa-miR-151b MIMAT0010214 0.895 -0.16 -10.50 0.45 hsa-miR-152-3p MIMAT0000438 0.460 -1.12 -53.99 0.50 hsa-miR-152-5p MIMAT0026479 0.927 -0.11 -7.34 0.62 hsa-miR-1537-3p MIMAT0007399 0.633 -0.66 -36.71 0.34 hsa-miR-154-5p MIMAT0000452 0.429 -1.22 -57.07 0.26 hsa-miR-1972 MIMAT0009447 0.403 -1.31 -59.67 2.95E-03 hsa-miR-361-5p MIMAT0000703 0.563 -0.83 -43.75 0.46 hsa-miR-24-3p MIMAT0000080 0.202 -2.31 -79.83 0.26 hsa-miR-16-5p MIMAT0000069 0.457 -1.13 -54.31 0.31hsa-miR-181a-2-3p MIMAT0004558 0.697 -0.52 -30.26 0.15 hsa-miR-181a-5p MIMAT0000256 0.198 -2.34 -80.25 0.29 hsa-miR-181b-2-3p MIMAT0031893 0.678 -0.56 -32.17 0.13 hsa-miR-181b-5p MIMAT0000257 0.742 -0.43 -25.77 0.66 hsa-miR-181c-5p MIMAT0000258 0.790 -0.34 -21.00 0.83 hsa-miR-181d-3p MIMAT0026608 0.927 -0.11 -7.34 0.62 hsa-miR-182-3p MIMAT0000260 0.927 -0.11 -7.34 0.62 hsa-miR-182-5p MIMAT0000259 0.927 -0.11 -7.34 0.62 hsa-miR-1827 MIMAT0006767 0.688 -0.54 -31.22 0.16 hsa-miR-183-5p MIMAT0000261 0.841 -0.25 -15.91 0.84 hsa-miR-184 MIMAT0000454 0.889 -0.17 -11.12 0.45 hsa-miR-186-5p MIMAT0000456 0.953 -0.07 -4.74 0.96 hsa-miR-187-3p MIMAT0000262 0.889 -0.17 -11.12 0.82 hsa-miR-188-3p MIMAT0004613 0.927 -0.11 -7.34 0.62 hsa-miR-18a-5p MIMAT0000072 0.914 -0.13 -8.62 0.52 hsa-miR-18b-5p MIMAT0001412 0.818 -0.29 -18.21 0.26 hsa-miR-1908-3p MIMAT0026916 0.927 -0.11 -7.34 0.62 hsa-miR-1908-5p MIMAT0007881 0.927 -0.11 -7.34 0.62 hsa-miR-1909-3p MIMAT0007883 0.927 -0.11 -7.34 0.62 hsa-miR-190a-3p MIMAT0026482 0.642 -0.64 -35.83 0.25 hsa-miR-4455 MIMAT0018977 0.426 -1.23 -57.37 1.84E-02 hsa-miR-190b MIMAT0004929 0.727 -0.46 -27.30 0.23 hsa-miR-191-5p MIMAT0000440 0.514 -0.96 -48.59 0.44 hsa-miR-1910-3p MIMAT0026917 0.927 -0.11 -7.34 0.62 hsa-miR-1910-5p MIMAT0007884 0.616 -0.7 -38.44 0.69 hsa-miR-1915-3p MIMAT0007892 0.547 -0.87 -45.29 0.65 hsa-miR-193a-3p MIMAT0000459 0.551 -0.86 -44.90 0.58 hsa-miR-23b-3p MIMAT0000418 0.480 -1.06 -52.04 0.31 hsa-miR-193b-3p MIMAT0002819 0.268 -1.9 -73.21 0.37 hsa-miR-194-5p MIMAT0000460 0.268 -1.9 -73.21 0.24 hsa-miR-195-5p MIMAT0000461 0.346 -1.53 -65.37 0.47 hsa-miR-196a-3p MIMAT0004562 0.927 -0.11 -7.34 0.62 hsa-miR-505-3p MIMAT0002876 0.403 -1.31 -59.67 0.46 hsa-miR-196b-5p MIMAT0001080 0.927 -0.11 -7.34 0.62 hsa-miR-574-3p MIMAT0003239 0.291 -1.78 -70.88 0.35hsa-miR-1973 MIMAT0009448 0.812 -0.30.37 hsa-miR-1976 MIMAT0009451 0.953 -0.070.91 hsa-miR-199a-3p MIMAT0000232 0.470 -1.090.53 hsa-miR-199a-5p MIMAT0000231 0.624 -0.680.55 hsa-miR-30e-3p MIMAT0000693 0.291 -1.780.30 hsa-miR-19a-3p MIMAT0000073 0.423 -1.240.50 hsa-miR-19b-3p MIMAT0000074 0.503 -0.990.57 hsa-miR-200a-3p MIMAT0000682 0.603 -0.73 -39.71 0.41 hsa-miR-200b-3p MIMAT0000318 0.555 -0.85 -44.52 0.39 hsa-miR-200c-3p MIMAT0000617 0.847 -0.24 -15.33 0.40 hsa-miR-202-3p MIMAT0002811 0.927 -0.11 -7.34 0.62 hsa-miR-203a-3p MIMAT0000264 0.841 -0.25 -15.91 0.29 hsa-miR-203a-5p MIMAT0031890 0.979 -0.03 -2.06 0.97 hsa-miR-204-5p MIMAT0000265 0.547 -0.87 -45.29 0.40 hsa-miR-205-5p MIMAT0000266 0.582 -0.78 -41.76 0.61 hsa-miR-208b-5p MIMAT0026722 0.927 -0.11 -7.34 0.62 hsa-miR-20a-5p MIMAT0000075 0.651 -0.62 -34.93 0.70 hsa-miR-21-5p MIMAT0000076 0.651 -0.62 -34.93 0.53 hsa-miR-210-5p MIMAT0026475 0.979 -0.03 -2.06 0.96 hsa-miR-211-3p MIMAT0022694 0.927 -0.11 -7.34 0.62 hsa-miR-211-5p MIMAT0000268 0.946 -0.08 -5.39 0.88 hsa-miR-2110 MIMAT0010133 0.927 -0.11 -7.34 0.62 hsa-miR-2113 MIMAT0009206 0.927 -0.11 -7.34 0.62 hsa-miR-2116-5p MIMAT0011160 0.927 -0.11 -7.34 0.62 hsa-miR-548ar-5p MIMAT0022265 0.426 -1.23 -57.37 1.34E-02 hsa-miR-214-3p MIMAT0000271 0.620 -0.69 -38.01 0.65 hsa-miR-215-5p MIMAT0000272 0.732 -0.45 -26.80 0.23 hsa-miR-146a-5p MIMAT0000449 0.586 -0.77 -41.36 0.37 hsa-miR-217 MIMAT0000274 0.927 -0.11 -7.34 0.62 hsa-miR-335-5p MIMAT0000765 0.285 -1.81 -71.48 0.16 hsa-miR-219a-1-3p MIMAT0004567 0.927 -0.11 -7.34 0.62 hsa-miR-219a-2-3p MIMAT0004675 0.774 -0.37 -22.62 0.14 hsa-miR-219a-5p MIMAT0000276 0.927 -0.11 -7.34 0.62 hsa-miR-22-3p MIMAT0000077 0.409 -1.29 -59.10 0.23 hsa-miR-221-3p MIMAT0000278 0.476 -1.07 -52.37 0.48hsa-miR-221-5p MIMAT0004568 0.927 -0.11 -7.34 0.62 hsa-miR-222-3p MIMAT0000279 0.285 -1.81 -71.48 0.36 hsa-miR-223-3p MIMAT0000280 0.423 -1.24 -57.66 0.60 hsa-miR-224-5p MIMAT0000281 0.927 -0.11 -7.34 0.62 hsa-miR-2278 MIMAT0011778 0.927 -0.11 -7.34 0.62 hsa-miR-660-5p MIMAT0003338 0.629 -0.67 -37.15 0.69 hsa-miR-377-3p MIMAT0000730 0.543 -0.88 -45.66 0.37 hsa-miR-23c MIMAT0018000 0.927 -0.11 -7.34 0.62 hsa-miR-145-5p MIMAT0000437 0.321 -1.64 -67.91 0.14 hsa-miR-218-5p MIMAT0000275 0.486 -1.04 -51.37 0.41 hsa-miR-25-5p MIMAT0004498 0.586 -0.77 -41.36 0.28 hsa-miR-26a-5p MIMAT0000082 0.366 -1.45 -63.40 0.42 hsa-miR-26b-5p MIMAT0000083 0.435 -1.2 -56.47 0.34 hsa-miR-27a-3p MIMAT0000084 0.559 -0.84 -44.14 0.23 hsa-miR-27b-3p MIMAT0000419 0.595 -0.75 -40.54 0.49 hsa-miR-28-3p MIMAT0004502 0.616 -0.7 -38.44 0.47 hsa-miR-28-5p MIMAT0000085 0.895 -0.16 -10.50 0.72 hsa-miR-296-3p MIMAT0004679 0.927 -0.11 -7.34 0.62 hsa-miR-296-5p MIMAT0000690 0.927 -0.11 -7.34 0.62 hsa-miR-297 MIMAT0004450 0.927 -0.11 -7.34 0.62 hsa-miR-298 MIMAT0004901 0.927 -0.11 -7.34 0.62 hsa-miR-299-3p MIMAT0000687 0.824 -0.28 -17.64 0.83 hsa-miR-29a-3p MIMAT0000086 0.559 -0.84 -44.14 0.45 hsa-miR-495-3p MIMAT0002817 0.476 -1.07 -52.37 0.20 hsa-miR-29c-3p MIMAT0000681 0.629 -0.67 -37.15 0.58 hsa-miR-300 MIMAT0004903 0.927 -0.11 -7.34 0.62 hsa-miR-301a-3p MIMAT0000688 0.732 -0.45 -26.80 0.69 hsa-miR-301a-5p MIMAT0022696 0.697 -0.52 -30.26 0.64 hsa-miR-301b-3p MIMAT0004958 0.927 -0.11 -7.34 0.62 hsa-miR-301b-5p MIMAT0032026 0.927 -0.11 -7.34 0.62 hsa-miR-302a-3p MIMAT0000684 0.927 -0.11 -7.34 0.62 hsa-miR-302a-5p MIMAT0000683 0.927 -0.11 -7.34 0.62 hsa-miR-302b-3p MIMAT0000715 0.737 -0.44 -26.29 0.55 hsa-miR-302c-3p MIMAT0000717 0.927 -0.11 -7.34 0.62 hsa-miR-302d-3p MIMAT0000718 0.933 -0.1 -6.70 0.70hsa-miR-302e MIMAT0005931 0.927 -0.11 -7.34 0.62 hsa-miR-302f MIMAT0005932 0.927 -0.11 -7.34 0.62 hsa-miR-3065-3p MIMAT0015378 0.927 -0.11 -7.34 0.62 hsa-miR-3065-5p MIMAT0015066 0.927 -0.11 -7.34 0.62 hsa-miR-3074-3p MIMAT0015027 0.812 -0.3 -18.77 0.26 hsa-miR-30a-3p MIMAT0000088 0.486 -1.04 -51.37 0.50 hsa-let-7g-5p MIMAT0000414 0.285 -1.81 -71.48 0.12 hsa-miR-30b-5p MIMAT0000420 0.395 -1.34 -60.50 0.23 hsa-miR-30c-5p MIMAT0000244 0.674 -0.57 -32.64 0.60 hsa-miR-127-3p MIMAT0000446 0.358 -1.48 -64.15 0.28 hsa-miR-4286 MIMAT0016916 0.460 -1.12 -53.99 7.07E-02 hsa-miR-30e-5p MIMAT0000692 0.500 -1 -50.00 0.31 hsa-miR-31-5p MIMAT0000089 0.927 -0.11 -7.34 0.62 hsa-miR-3127-5p MIMAT0014990 0.927 -0.11 -7.34 0.62 hsa-miR-3130-3p MIMAT0014994 0.927 -0.11 -7.34 0.62 hsa-miR-3131 MIMAT0014996 0.927 -0.11 -7.34 0.62 hsa-miR-3136-5p MIMAT0015003 0.927 -0.11 -7.34 0.62 hsa-miR-3140-3p MIMAT0015008 0.927 -0.11 -7.34 0.62 hsa-miR-3140-5p MIMAT0019204 0.927 -0.11 -7.34 0.62 hsa-miR-3144-5p MIMAT0015014 0.927 -0.11 -7.34 0.62 hsa-miR-3147 MIMAT0015019 0.927 -0.11 -7.34 0.62 hsa-miR-3150b-3p MIMAT0018194 0.927 -0.11 -7.34 0.62 hsa-miR-3151-5p MIMAT0015024 0.563 -0.83 -43.75 0.13 hsa-miR-3158-3p MIMAT0015032 0.835 -0.26 -16.49 0.89 hsa-miR-3161 MIMAT0015035 0.927 -0.11 -7.34 0.62 hsa-miR-3164 MIMAT0015038 0.927 -0.11 -7.34 0.62 hsa-miR-3168 MIMAT0015043 0.920 -0.12 -7.98 0.86 hsa-miR-3179 MIMAT0015056 0.927 -0.11 -7.34 0.62 hsa-miR-3180-3p MIMAT0015058 0.927 -0.11 -7.34 0.62 hsa-miR-3180-5p MIMAT0015057 0.693 -0.53 -30.74 0.17 hsa-miR-3185 MIMAT0015065 0.927 -0.11 -7.34 0.62 hsa-miR-3190-3p MIMAT0022839 0.927 -0.11 -7.34 0.62 hsa-miR-3192-5p MIMAT0015076 0.927 -0.11 -7.34 0.62 hsa-miR-3195 MIMAT0015079 0.732 -0.45 -26.80 0.23 hsa-miR-3196 MIMAT0015080 0.927 -0.11 -7.34 0.62hsa-miR-32-5p MIMAT0000090 0.500 -1 -50.00 0.38 hsa-miR-3202 MIMAT0015089 0.927 -0.11 -7.34 0.62 hsa-miR-320a MIMAT0000510 0.722 -0.47 -27.80 0.23 hsa-miR-320b MIMAT0005792 0.927 -0.11 -7.34 0.62 hsa-miR-320c MIMAT0005793 0.927 -0.11 -7.34 0.62 hsa-miR-320d MIMAT0006764 0.785 -0.35 -21.54 0.24 hsa-miR-320e MIMAT0015072 0.940 -0.09 -6.05 0.92 hsa-let-7e-5p MIMAT0000066 0.480 -1.06 -52.04 4.53E-02 hsa-miR-323a-5p MIMAT0004696 0.927 -0.11 -7.34 0.62 hsa-miR-323b-3p MIMAT0015050 0.901 -0.15 -9.87 0.90 hsa-miR-323b-5p MIMAT0001630 0.927 -0.11 -7.34 0.62 hsa-miR-324-3p MIMAT0000762 0.829 -0.27 -17.07 0.28 hsa-miR-324-5p MIMAT0000761 0.384 -1.38 -61.58 0.43 hsa-miR-326 MIMAT0000756 0.927 -0.11 -7.34 0.62 hsa-miR-328-3p MIMAT0000752 0.624 -0.68 -37.58 0.14 hsa-miR-328-5p MIMAT0026486 0.889 -0.17 -11.12 0.45 hsa-miR-329-3p MIMAT0001629 0.829 -0.27 -17.07 0.28 hsa-miR-329-5p MIMAT0026555 0.790 -0.34 -21.00 0.24 hsa-miR-330-3p MIMAT0000751 0.927 -0.11 -7.34 0.62 hsa-miR-330-5p MIMAT0004693 0.927 -0.11 -7.34 0.62 hsa-miR-331-3p MIMAT0000760 0.927 -0.11 -7.34 0.62 hsa-miR-331-5p MIMAT0004700 0.927 -0.11 -7.34 0.62 hsa-miR-148a-3p MIMAT0000243 0.470 -1.09 -53.02 0.23 hsa-miR-337-3p MIMAT0000754 0.607 -0.72 -39.29 0.37 hsa-miR-337-5p MIMAT0004695 0.607 -0.72 -39.29 0.64 hsa-miR-338-5p MIMAT0004701 0.758 -0.4 -24.21 0.33 hsa-miR-339-3p MIMAT0004702 0.927 -0.11 -7.34 0.62 hsa-miR-339-5p MIMAT0000764 0.927 -0.11 -7.34 0.62 hsa-miR-33a-5p MIMAT0000091 0.753 -0.41 -24.74 0.65 hsa-miR-340-5p MIMAT0004692 0.669 -0.58 -33.10 0.41 hsa-miR-342-3p MIMAT0000753 0.500 -1 -50.00 0.31 hsa-miR-342-5p MIMAT0004694 0.927 -0.11 -7.34 0.62 hsa-miR-345-3p MIMAT0022698 0.859 -0.22 -14.14 0.33 hsa-miR-345-5p MIMAT0000772 0.807 -0.31 -19.34 0.20 hsa-miR-34a-5p MIMAT0000255 0.595 -0.75 -40.54 0.45hsa-miR-34b-3p MIMAT0004676 0.927 -0.11 -7.34 0.62 hsa-miR-34c-3p MIMAT0004677 0.927 -0.11 -7.34 0.62 hsa-miR-34c-5p MIMAT0000686 0.927 -0.11 -7.34 0.62 hsa-miR-3605-3p MIMAT0017982 0.927 -0.11 -7.34 0.62 hsa-miR-3605-5p MIMAT0017981 0.927 -0.11 -7.34 0.62 hsa-miR-361-3p MIMAT0004682 0.356 -1.49 -64.40 0.36 hsa-miR-497-5p MIMAT0002820 0.574 -0.8 -42.57 0.43 hsa-miR-3613-3p MIMAT0017991 0.927 -0.11 -7.34 0.62 hsa-miR-3613-5p MIMAT0017990 0.927 -0.11 -7.34 0.62 hsa-miR-3614-3p MIMAT0017993 0.927 -0.11 -7.34 0.62 hsa-miR-3614-5p MIMAT0017992 0.933 -0.1 -6.70 0.90 hsa-miR-3615 MIMAT0017994 0.927 -0.11 -7.34 0.62 hsa-miR-362-3p MIMAT0004683 0.563 -0.83 -43.75 0.48 hsa-miR-362-5p MIMAT0000705 0.895 -0.16 -10.50 0.45 hsa-miR-363-3p MIMAT0000707 0.448 -1.16 -55.25 0.30 hsa-miR-363-5p MIMAT0003385 0.927 -0.11 -7.34 0.62 hsa-miR-365a-3p MIMAT0000710 0.387 -1.37 -61.31 0.19 hsa-miR-365b-5p MIMAT0022833 0.927 -0.11 -7.34 0.62 hsa-miR-367-3p MIMAT0000719 0.841 -0.25 -15.91 0.29 hsa-miR-664a-3p MIMAT0005949 0.500 -1 -50.00 5.89E-02 hsa-miR-369-5p MIMAT0001621 0.927 -0.11 -7.34 0.62 hsa-miR-3690 MIMAT0018119 0.927 -0.11 -7.34 0.62 hsa-miR-370-5p MIMAT0026483 0.927 -0.11 -7.34 0.62 hsa-miR-371a-5p MIMAT0004687 0.927 -0.11 -7.34 0.62 hsa-miR-371b-5p MIMAT0019892 0.927 -0.11 -7.34 0.62 hsa-miR-372-3p MIMAT0000724 0.927 -0.11 -7.34 0.62 hsa-miR-373-3p MIMAT0000726 0.927 -0.11 -7.34 0.62 hsa-miR-374a-3p MIMAT0004688 0.927 -0.11 -7.34 0.62 hsa-miR-374a-5p MIMAT0000727 0.274 -1.87 -72.64 0.36 hsa-miR-374b-5p MIMAT0004955 0.790 -0.34 -21.00 0.64 hsa-miR-374c-5p MIMAT0018443 0.927 -0.11 -7.34 0.62 hsa-miR-375 MIMAT0000728 0.927 -0.11 -7.34 0.62 hsa-miR-376a-3p MIMAT0000729 0.747 -0.42 -25.26 0.68 hsa-miR-376b-3p MIMAT0002172 0.927 -0.11 -7.34 0.62 hsa-miR-376c-3p MIMAT0000720 0.586 -0.77 -41.36 0.64hsa-miR-376c-5p MIMAT0022861 0.927 -0.11 -7.34 0.62 hsa-miR-378b MIMAT0014999 0.812 -0.3 -18.77 0.26 hsa-miR-378c MIMAT0016847 0.927 -0.11 -7.34 0.62 hsa-miR-378d MIMAT0018926 0.470 -1.09 -53.02 0.30 hsa-miR-378f MIMAT0018932 0.563 -0.83 -43.75 0.48 hsa-miR-378g MIMAT0018937 0.801 -0.32 -19.89 0.65 hsa-miR-378h MIMAT0018984 0.812 -0.3 -18.77 0.26 hsa-miR-378i MIMAT0019074 0.529 -0.920.36 hsa-miR-379-5p MIMAT0000733 0.979 -0.030.96 hsa-miR-380-3p MIMAT0000735 0.927 -0.110.62 hsa-miR-381-5p MIMAT0022862 0.927 -0.11 -7.34 0.62 hsa-miR-382-3p MIMAT0022697 0.889 -0.17 -11.12 0.45 hsa-miR-382-5p MIMAT0000737 0.586 -0.77 -41.36 0.55 hsa-miR-383-5p MIMAT0000738 0.927 -0.11 -7.34 0.62 hsa-miR-384 MIMAT0001075 0.927 -0.11 -7.34 0.62 hsa-miR-3916 MIMAT0018190 0.927 -0.11 -7.34 0.62 hsa-miR-3918 MIMAT0018192 0.927 -0.11 -7.34 0.62 hsa-miR-3928-3p MIMAT0018205 0.927 -0.11 -7.34 0.62 hsa-miR-3934-5p MIMAT0018349 0.927 -0.11 -7.34 0.62 hsa-miR-409-3p MIMAT0001639 0.712 -0.49 -28.80 0.24 hsa-miR-409-5p MIMAT0001638 0.927 -0.11 -7.34 0.62 hsa-miR-410-3p MIMAT0002171 0.927 -0.11 -7.34 0.62 hsa-miR-412-3p MIMAT0002170 0.927 -0.11 -7.34 0.62 hsa-miR-422a MIMAT0001339 0.865 -0.21 -13.55 0.35 hsa-miR-423-3p MIMAT0001340 0.732 -0.45 -26.80 0.64 hsa-miR-423-5p MIMAT0004748 0.420 -1.25 -57.96 0.33 hsa-miR-130a-3p MIMAT0000425 0.547 -0.87 -45.29 0.38 hsa-miR-425-5p MIMAT0003393 0.624 -0.68 -37.58 0.40 hsa-miR-4284 MIMAT0016915 0.835 -0.26 -16.49 0.25 hsa-miR-190a-5p MIMAT0000458 0.503 -0.99 -49.65 3.96E-02 hsa-miR-429 MIMAT0001536 0.444 -1.17 -55.56 0.11 hsa-miR-431-5p MIMAT0001625 0.927 -0.11 -7.34 0.62 hsa-miR-432-5p MIMAT0002814 0.790 -0.34 -21.00 0.16 hsa-miR-433-3p MIMAT0001627 0.927 -0.11 -7.34 0.62 hsa-miR-433-5p MIMAT0026554 0.927 -0.11 -7.34 0.62hsa-miR-2117 MIMAT0011162 0.507 -0.98 -49.30 3.29E-02 hsa-miR-4425 MIMAT0018940 0.927 -0.11 -7.34 0.62 hsa-miR-4431 MIMAT0018947 0.927 -0.11 -7.34 0.62 hsa-miR-4435 MIMAT0018951 0.927 -0.11 -7.34 0.62 hsa-miR-548z MIMAT0018446 0.511 -0.97 -48.95 1.97E-02 hsa-miR-4448 MIMAT0018967 0.927 -0.11 -7.34 0.62 hsa-miR-25-3p MIMAT0000081 0.607 -0.72 -39.29 0.31 hsa-miR-1323 MIMAT0005795 0.514 -0.96 -48.59 4.92E-02 hsa-miR-4458 MIMAT0018980 0.927 -0.11 -7.34 0.62 hsa-miR-4461 MIMAT0018983 0.927 -0.11 -7.34 0.62 hsa-miR-4485-3p MIMAT0019019 0.927 -0.11 -7.34 0.62 hsa-miR-449a MIMAT0001541 0.927 -0.11 -7.34 0.62 hsa-miR-449b-5p MIMAT0003327 0.927 -0.11 -7.34 0.62 hsa-miR-449c-5p MIMAT0010251 0.927 -0.11 -7.34 0.62 hsa-miR-450a-1-3p MIMAT0022700 0.859 -0.22 -14.14 0.33 hsa-miR-450b-3p MIMAT0004910 0.927 -0.11 -7.34 0.62 hsa-miR-4516 MIMAT0019053 0.366 -1.45 -63.40 0.15 hsa-miR-451a MIMAT0001631 0.785 -0.35 -21.54 0.73 hsa-miR-487a-3p MIMAT0002178 0.532 -0.91 -46.78 3.77E-02 hsa-miR-4521 MIMAT0019058 0.927 -0.11 -7.34 0.62 hsa-miR-4524a-5p MIMAT0019062 0.927 -0.11 -7.34 0.62 hsa-miR-4532 MIMAT0019071 0.420 -1.25 -57.96 0.46 hsa-miR-4536-3p MIMAT0020959 0.859 -0.22 -14.14 0.33 hsa-miR-454-3p MIMAT0003885 0.779 -0.36 -22.08 0.24 hsa-miR-455-3p MIMAT0004784 0.624 -0.68 -37.58 0.25 hsa-miR-455-5p MIMAT0003150 0.722 -0.47 -27.80 0.74 hsa-miR-4647 MIMAT0019709 0.927 -0.11 -7.34 0.62 hsa-miR-4707-3p MIMAT0019808 0.927 -0.11 -7.34 0.62 hsa-miR-4707-5p MIMAT0019807 0.812 -0.3 -18.77 0.37 hsa-miR-4741 MIMAT0019871 0.927 -0.11 -7.34 0.62 hsa-miR-4787-3p MIMAT0019957 0.927 -0.11 -7.34 0.62 hsa-miR-4792 MIMAT0019964 0.927 -0.11 -7.34 0.62 hsa-miR-483-3p MIMAT0002173 0.774 -0.37 -22.62 0.23 hsa-miR-483-5p MIMAT0004761 0.722 -0.47 -27.80 0.23 hsa-miR-484 MIMAT0002174 0.747 -0.42 -25.26 0.23hsa-miR-485-5p MIMAT0002175 0.927 -0.11 -7.34 0.62 hsa-miR-486-3p MIMAT0004762 0.753 -0.41 -24.74 0.78 hsa-miR-4443 MIMAT0018961 0.540 -0.89 -46.04 5.50E-02 hsa-miR-487b-3p MIMAT0003180 0.655 -0.61 -34.48 0.15 hsa-miR-487b-5p MIMAT0026614 0.927 -0.11 -7.34 0.62 hsa-miR-489-3p MIMAT0002805 0.927 -0.11 -7.34 0.62 hsa-miR-490-3p MIMAT0002806 0.927 -0.11 -7.34 0.62 hsa-miR-490-5p MIMAT0004764 0.927 -0.11 -7.34 0.62 hsa-miR-491-3p MIMAT0004765 0.835 -0.26 -16.49 0.34 hsa-miR-491-5p MIMAT0002807 0.841 -0.25 -15.91 0.84 hsa-miR-492 MIMAT0002812 0.927 -0.11 -7.34 0.62 hsa-miR-493-3p MIMAT0003161 0.927 -0.11 -7.34 0.62 hsa-miR-494-3p MIMAT0002816 0.683 -0.55 -31.70 0.24 hsa-miR-494-5p MIMAT0026607 0.927 -0.11 -7.34 0.62 hsa-miR-543 MIMAT0004954 0.824 -0.28 -17.64 0.43 hsa-miR-496 MIMAT0002818 0.865 -0.21 -13.55 0.81 hsa-let-7f-5p MIMAT0000067 0.543 -0.88 -45.66 9.44E-02 hsa-miR-498 MIMAT0002824 0.927 -0.11 -7.34 0.62 hsa-miR-499a-3p MIMAT0004772 0.927 -0.11 -7.34 0.62 hsa-miR-499a-5p MIMAT0002870 0.940 -0.09 -6.05 0.97 hsa-miR-499b-3p MIMAT0019898 0.927 -0.11 -7.34 0.62 hsa-miR-499b-5p MIMAT0019897 0.927 -0.11 -7.34 0.62 hsa-miR-5001-3p MIMAT0021022 0.927 -0.11 -7.34 0.62 hsa-miR-5001-5p MIMAT0021021 0.927 -0.11 -7.34 0.62 hsa-miR-500a-5p MIMAT0004773 0.835 -0.26 -16.49 0.24 hsa-miR-501-3p MIMAT0004774 0.927 -0.11 -7.34 0.62 hsa-miR-5010-3p MIMAT0021044 0.889 -0.17 -11.12 0.45 hsa-miR-5010-5p MIMAT0021043 0.927 -0.11 -7.34 0.62 hsa-miR-502-3p MIMAT0004775 0.927 -0.11 -7.34 0.62 hsa-miR-502-5p MIMAT0002873 0.927 -0.11 -7.34 0.62 hsa-miR-503-3p MIMAT0022925 0.927 -0.11 -7.34 0.62 hsa-miR-503-5p MIMAT0002874 0.737 -0.44 -26.29 0.66 hsa-miR-504-3p MIMAT0026612 0.927 -0.11 -7.34 0.62 hsa-miR-504-5p MIMAT0002875 0.927 -0.11 -7.34 0.62 hsa-miR-148b-3p MIMAT0000759 0.574 -0.8 -42.57 0.35hsa-miR-506-5p MIMAT0022701 0.927 -0.11 -7.34 0.62 hsa-miR-507 MIMAT0002879 0.927 -0.11 -7.34 0.62 hsa-miR-508-3p MIMAT0002880 0.927 -0.11 -7.34 0.62 hsa-miR-508-5p MIMAT0004778 0.927 -0.11 -7.34 0.62 hsa-miR-509-3-5p MIMAT0004975 0.927 -0.11 -7.34 0.62 hsa-miR-509-3p MIMAT0002881 0.379 -1.4 -62.11 0.34 hsa-miR-509-5p MIMAT0004779 0.664 -0.59 -33.57 0.12 hsa-miR-510-3p MIMAT0026613 0.927 -0.11 -7.34 0.62 hsa-miR-510-5p MIMAT0002882 0.927 -0.11 -7.34 0.62 hsa-miR-511-5p MIMAT0002808 0.758 -0.4 -24.21 0.12 hsa-miR-512-3p MIMAT0002823 0.927 -0.11 -7.34 0.62 hsa-miR-512-5p MIMAT0002822 0.927 -0.11 -7.34 0.62 hsa-miR-513a-5p MIMAT0002877 0.966 -0.05 -3.41 0.90 hsa-miR-513b-5p MIMAT0005788 0.655 -0.61 -34.48 0.65 hsa-miR-513c-3p MIMAT0022728 0.927 -0.11 -7.34 0.62 hsa-miR-513c-5p MIMAT0005789 0.525 -0.93 -47.51 0.20 hsa-miR-514a-3p MIMAT0002883 0.470 -1.09 -53.02 0.16 hsa-miR-514a-5p MIMAT0022702 0.688 -0.54 -31.22 0.70 hsa-miR-514b-3p MIMAT0015088 0.927 -0.11 -7.34 0.62 hsa-miR-514b-5p MIMAT0015087 0.674 -0.57 -32.64 0.66 hsa-miR-515-3p MIMAT0002827 0.927 -0.11 -7.34 0.62 hsa-miR-515-5p MIMAT0002826 0.927 -0.11 -7.34 0.62 hsa-miR-516a-3p MIMAT0006778 0.895 -0.16 -10.50 0.45 hsa-miR-516a-5p MIMAT0004770 0.927 -0.11 -7.34 0.62 hsa-miR-516b-5p MIMAT0002859 0.812 -0.3 -18.77 0.26 hsa-miR-517a-3p MIMAT0002852 0.927 -0.11 -7.34 0.62 hsa-miR-517b-3p MIMAT0002857 0.927 -0.11 -7.34 0.62 hsa-miR-517c-3p MIMAT0002866 0.847 -0.24 -15.33 0.40 hsa-miR-518b MIMAT0002844 0.651 -0.62 -34.93 0.69 hsa-miR-518c-3p MIMAT0002848 0.927 -0.11 -7.34 0.62 hsa-miR-518d-3p MIMAT0002864 0.927 -0.11 -7.34 0.62 hsa-miR-518e-3p MIMAT0002861 0.927 -0.11 -7.34 0.62 hsa-miR-5196-3p MIMAT0021129 0.702 -0.51 -29.78 0.16 hsa-miR-5196-5p MIMAT0021128 0.768 -0.38 -23.16 0.27 hsa-miR-519b-3p MIMAT0002837 0.927 -0.11 -7.34 0.62hsa-miR-519b-5p MIMAT0005454 0.927 -0.11 -7.34 0.62 hsa-miR-519c-3p MIMAT0002832 0.712 -0.49 -28.80 0.18 hsa-miR-519d-3p MIMAT0002853 0.865 -0.21 -13.55 0.67 hsa-miR-519e-3p MIMAT0002829 0.927 -0.11 -7.34 0.62 hsa-miR-520a-3p MIMAT0002834 0.927 -0.11 -7.34 0.62 hsa-miR-520a-5p MIMAT0002833 0.927 -0.11 -7.34 0.62 hsa-miR-520b MIMAT0002843 0.927 -0.11 -7.34 0.62 hsa-miR-520c-3p MIMAT0002846 0.927 -0.11 -7.34 0.62 hsa-miR-520d-3p MIMAT0002856 0.927 -0.11 -7.34 0.62 hsa-miR-520d-5p MIMAT0002855 0.927 -0.11 -7.34 0.62 hsa-miR-520e MIMAT0002825 0.927 -0.11 -7.34 0.62 hsa-miR-520g-3p MIMAT0002858 0.785 -0.35 -21.54 0.32 hsa-miR-520h MIMAT0002867 0.774 -0.37 -22.62 0.21 hsa-miR-522-3p MIMAT0002868 0.927 -0.11 -7.34 0.62 hsa-miR-523-3p MIMAT0002840 0.927 -0.11 -7.34 0.62 hsa-miR-524-3p MIMAT0002850 0.927 -0.11 -7.34 0.62 hsa-miR-525-3p MIMAT0002839 0.678 -0.56 -32.17 0.24 hsa-miR-526a MIMAT0002845 0.463 -1.11 -53.67 0.30 hsa-miR-526b-5p MIMAT0002835 0.927 -0.11 -7.34 0.62 hsa-miR-548d-5p MIMAT0004812 0.551 -0.86 -44.90 5.00E-02 hsa-miR-539-3p MIMAT0022705 0.927 -0.11 -7.34 0.62 hsa-miR-539-5p MIMAT0003163 0.927 -0.11 -7.34 0.62 hsa-miR-541-3p MIMAT0004920 0.927 -0.11 -7.34 0.62 hsa-miR-542-3p MIMAT0003389 0.497 -1.01 -50.35 0.11 hsa-miR-542-5p MIMAT0003340 0.678 -0.56 -32.17 0.24 hsa-miR-30a-5p MIMAT0000087 0.555 -0.85 -44.52 0.29 hsa-miR-544a MIMAT0003164 0.927 -0.11 -7.34 0.62 hsa-miR-545-3p MIMAT0003165 0.807 -0.31 -19.34 0.79 hsa-miR-548a-3p MIMAT0003251 0.927 -0.11 -7.34 0.62 hsa-miR-548a-5p MIMAT0004803 0.927 -0.11 -7.34 0.62 hsa-miR-30d-5p MIMAT0000245 0.611 -0.71 -38.87 0.35 hsa-miR-548ad-3p MIMAT0018946 0.927 -0.11 -7.34 0.62 hsa-miR-196a-5p MIMAT0000226 0.578 -0.79 -42.17 3.36E-02 hsa-miR-548ai MIMAT0018989 0.895 -0.16 -10.50 0.45 hsa-miR-548ak MIMAT0019013 0.927 -0.11 -7.34 0.62hsa-miR-548al MIMAT0019024 0.927 -0.11 -7.34 0.62 hsa-miR-155-5p MIMAT0000646 0.582 -0.78 -41.76 9.93E-02 hsa-miR-136-5p MIMAT0000448 0.586 -0.77 -41.36 3.36E-02 hsa-miR-548b-3p MIMAT0003254 0.927 -0.11 -7.34 0.62 hsa-miR-548c-5p MIMAT0004806 0.927 -0.11 -7.34 0.62 hsa-miR-548d-3p MIMAT0003323 0.927 -0.11 -7.34 0.62 hsa-miR-4421 MIMAT0018934 0.586 -0.77 -41.36 9.25E-02 hsa-miR-548e-3p MIMAT0005874 0.927 -0.11 -7.34 0.62 hsa-miR-548g-3p MIMAT0005912 0.841 -0.25 -15.91 0.29 hsa-miR-548h-5p MIMAT0005928 0.927 -0.11 -7.34 0.62 hsa-miR-548i MIMAT0005935 0.927 -0.11 -7.34 0.62 hsa-miR-548j-5p MIMAT0005875 0.927 -0.11 -7.34 0.62 hsa-miR-548k MIMAT0005882 0.801 -0.32 -19.89 0.25 hsa-miR-548l MIMAT0005889 0.927 -0.11 -7.34 0.62 hsa-miR-548m MIMAT0005917 0.688 -0.54 -31.22 0.53 hsa-miR-548n MIMAT0005916 0.595 -0.75 -40.54 0.20 hsa-miR-548o-3p MIMAT0005919 0.927 -0.11 -7.34 0.62 hsa-miR-548q MIMAT0011163 0.927 -0.11 -7.34 0.62 hsa-miR-532-3p MIMAT0004780 0.611 -0.71 -38.87 9.48E-02 hsa-miR-548y MIMAT0018354 0.933 -0.1 -6.70 0.75 hsa-miR-99b-5p MIMAT0000689 0.633 -0.66 -36.71 8.79E-02 hsa-miR-549a MIMAT0003333 0.753 -0.41 -24.74 0.20 hsa-miR-550a-5p MIMAT0004800 0.927 -0.11 -7.34 0.62 hsa-miR-551a MIMAT0003214 0.927 -0.11 -7.34 0.62 hsa-miR-551b-3p MIMAT0003233 0.702 -0.51 -29.78 0.58 hsa-miR-552-3p MIMAT0003215 0.927 -0.11 -7.34 0.62 hsa-miR-553 MIMAT0003216 0.927 -0.11 -7.34 0.62 hsa-miR-554 MIMAT0003217 0.927 -0.11 -7.34 0.62 hsa-miR-555 MIMAT0003219 0.927 -0.11 -7.34 0.62 hsa-miR-556-3p MIMAT0004793 0.717 -0.48 -28.30 0.24 hsa-miR-556-5p MIMAT0003220 0.807 -0.31 -19.34 0.21 hsa-miR-561-3p MIMAT0003225 0.927 -0.11 -7.34 0.62 hsa-miR-562 MIMAT0003226 0.927 -0.11 -7.34 0.62 hsa-miR-563 MIMAT0003227 0.901 -0.15 -9.87 0.52 hsa-miR-564 MIMAT0003228 0.927 -0.11 -7.34 0.62hsa-miR-566 MIMAT0003230 0.927 -0.11hsa-miR-567 MIMAT0003231 0.927 -0.11hsa-miR-568 MIMAT0003232 0.927 -0.11hsa-miR-570-3p MIMAT0003235 0.841 -0.25hsa-miR-571 MIMAT0003236 0.927 -0.11hsa-miR-573 MIMAT0003238 0.927 -0.11hsa-miR-23a-3p MIMAT0000078 0.633 -0.66 -36.71hsa-miR-574-5p MIMAT0004795 0.376 -1.41 -62.37hsa-miR-575 MIMAT0003240 0.796 -0.33 -20.45hsa-miR-576-3p MIMAT0004796 0.859 -0.22 -14.14hsa-miR-577 MIMAT0003242 0.927 -0.11 -7.34hsa-miR-578 MIMAT0003243 0.737 -0.44 -26.29hsa-miR-579-3p MIMAT0003244 0.927 -0.11 -7.34hsa-miR-579-5p MIMAT0026616 0.889 -0.17 -11.12hsa-miR-580-3p MIMAT0003245 0.927 -0.11 -7.34hsa-miR-582-3p MIMAT0004797 0.927 -0.11 -7.34hsa-miR-582-5p MIMAT0003247 0.812 -0.3 -18.77hsa-miR-584-3p MIMAT0022708 0.688 -0.54 -31.22hsa-miR-585-3p MIMAT0003250 0.712 -0.49 -28.80hsa-miR-655-3p MIMAT0003331 0.646 -0.63 -35.38 8.61E-02 hsa-miR-589-5p MIMAT0004799 0.927 -0.11 -7.34 0.62 hsa-miR-590-3p MIMAT0004801 0.927 -0.11 -7.34 0.62 hsa-miR-590-5p MIMAT0003258 0.323 -1.63 -67.69 0.35 hsa-miR-591 MIMAT0003259 0.927 -0.11 -7.34 0.62 hsa-miR-592 MIMAT0003260 0.790 -0.34 -21.00 0.34 hsa-miR-593-3p MIMAT0004802 0.620 -0.69 -38.01 0.22 hsa-miR-595 MIMAT0003263 0.927 -0.11 -7.34 0.62 hsa-miR-596 MIMAT0003264 0.927 -0.11 -7.34 0.62 hsa-miR-597-5p MIMAT0003265 0.697 -0.52 -30.26 0.52 hsa-miR-599 MIMAT0003267 0.927 -0.11 -7.34 0.62 hsa-miR-600 MIMAT0003268 0.927 -0.11 -7.34 0.62 hsa-miR-601 MIMAT0003269 0.532 -0.91 -46.78 0.36 hsa-miR-604 MIMAT0003272 0.927 -0.11 -7.34 0.62 hsa-miR-605-5p MIMAT0003273 0.927 -0.11 -7.34 0.62 hsa-miR-606 MIMAT0003274 0.927 -0.11 -7.34 0.62hsa-miR-607 MIMAT0003275 0.768 -0.38 -23.16 0.68 hsa-miR-610 MIMAT0003278 0.927 -0.11 -7.34 0.62 hsa-miR-613 MIMAT0003281 0.927 -0.11 -7.34 0.62 hsa-miR-614 MIMAT0003282 0.927 -0.11 -7.34 0.62 hsa-miR-615-3p MIMAT0003283 0.768 -0.38 -23.16 0.33 hsa-miR-615-5p MIMAT0004804 0.927 -0.11 -7.34 0.62 hsa-miR-616-3p MIMAT0004805 0.807 -0.31 -19.34 0.56 hsa-miR-617 MIMAT0003286 0.927 -0.11 -7.34 0.62 hsa-miR-619-3p MIMAT0003288 0.927 -0.11 -7.34 0.62 hsa-miR-620 MIMAT0003289 0.927 -0.11 -7.34 0.62 hsa-miR-624-3p MIMAT0004807 0.927 -0.11 -7.34 0.62 hsa-miR-626 MIMAT0003295 0.927 -0.11 -7.34 0.62 hsa-miR-627-5p MIMAT0003296 0.790 -0.34 -21.00 0.19 hsa-miR-628-3p MIMAT0003297 0.927 -0.11 -7.34 0.62 hsa-miR-628-5p MIMAT0004809 0.927 -0.11 -7.34 0.62 hsa-miR-629-5p MIMAT0004810 0.927 -0.11 -7.34 0.62 hsa-miR-630 MIMAT0003299 0.476 -1.07 -52.37 0.62 hsa-miR-631 MIMAT0003300 0.847 -0.24 -15.33 0.40 hsa-miR-637 MIMAT0003307 0.927 -0.11 -7.34 0.62 hsa-miR-638 MIMAT0003308 0.927 -0.11 -7.34 0.62 hsa-miR-639 MIMAT0003309 0.927 -0.11 -7.34 0.62 hsa-miR-640 MIMAT0003310 0.927 -0.11 -7.34 0.62 hsa-miR-641 MIMAT0003311 0.927 -0.11 -7.34 0.62 hsa-miR-642a-3p MIMAT0020924 0.927 -0.11 -7.34 0.62 hsa-miR-642a-5p MIMAT0003312 0.753 -0.41 -24.74 0.22 hsa-miR-643 MIMAT0003313 0.927 -0.11 -7.34 0.62 hsa-miR-644a MIMAT0003314 0.927 -0.11 -7.34 0.62 hsa-miR-649 MIMAT0003319 0.927 -0.11 -7.34 0.62 hsa-miR-650 MIMAT0003320 0.927 -0.11 -7.34 0.62 hsa-miR-6503-3p MIMAT0025463 0.801 -0.32 -19.89 0.25 hsa-miR-6503-5p MIMAT0025462 0.927 -0.11 -7.34 0.62 hsa-miR-651-3p MIMAT0026624 0.927 -0.11 -7.34 0.62 hsa-miR-651-5p MIMAT0003321 0.727 -0.46 -27.30 0.37 hsa-miR-6511a-3p MIMAT0025479 0.927 -0.11 -7.34 0.62 hsa-miR-6511a-5p MIMAT0025478 0.927 -0.11 -7.34 0.62hsa-miR-652-3p MIMAT0003322 0.927 -0.11 -7.34 0.62 hsa-miR-652-5p MIMAT0022709 0.927 -0.11 -7.34 0.62 hsa-miR-654-3p MIMAT0004814 0.785 -0.35 -21.54 0.24 hsa-miR-654-5p MIMAT0003330 0.841 -0.25 -15.91 0.38 hsa-miR-587 MIMAT0003253 0.660 -0.6 -34.02 9.10E-02 hsa-miR-660-3p MIMAT0022711 0.927 -0.11 -7.34 0.62 hsa-miR-452-5p MIMAT0001635 0.669 -0.58 -33.10 8.73E-02 hsa-miR-661 MIMAT0003324 0.927 -0.11 -7.34 0.62 hsa-miR-663a MIMAT0003326 0.841 -0.25 -15.91 0.88 hsa-miR-548v MIMAT0015020 0.693 -0.53 -30.74 9.24E-02 hsa-miR-664b-3p MIMAT0022272 0.927 -0.11 -7.34 0.62 hsa-miR-664b-5p MIMAT0022271 0.927 -0.11 -7.34 0.62 hsa-miR-665 MIMAT0004952 0.927 -0.11 -7.34 0.62 hsa-miR-671-3p MIMAT0004819 0.927 -0.11 -7.34 0.62 hsa-miR-671-5p MIMAT0003880 0.927 -0.11 -7.34 0.62 hsa-miR-6720-3p MIMAT0025851 0.927 -0.11 -7.34 0.62 hsa-miR-6721-5p MIMAT0025852 0.986 -0.02 -1.38 0.95 hsa-miR-6724-5p MIMAT0025856 0.637 -0.65 -36.27 0.10 hsa-miR-675-5p MIMAT0004284 0.901 -0.15 -9.87 0.52 hsa-miR-7-5p MIMAT0000252 0.473 -1.08 -52.70 0.14 hsa-miR-708-5p MIMAT0004926 0.927 -0.11 -7.34 0.62 hsa-miR-744-5p MIMAT0004945 0.927 -0.11 -7.34 0.62 hsa-miR-758-5p MIMAT0022929 0.927 -0.11 -7.34 0.62 hsa-miR-760 MIMAT0004957 0.927 -0.11 -7.34 0.62 hsa-miR-761 MIMAT0010364 0.927 -0.11 -7.34 0.62 hsa-miR-764 MIMAT0010367 0.920 -0.12 -7.98 0.91 hsa-miR-766-3p MIMAT0003888 0.927 -0.11 -7.34 0.62 hsa-miR-766-5p MIMAT0022714 0.927 -0.11 -7.34 0.62 hsa-miR-767-3p MIMAT0003883 0.927 -0.11 -7.34 0.62 hsa-miR-769-3p MIMAT0003887 0.927 -0.11 -7.34 0.62 hsa-miR-769-5p MIMAT0003886 0.540 -0.89 -46.04 0.43 hsa-miR-770-5p MIMAT0003948 0.927 -0.11 -7.34 0.62 hsa-miR-802 MIMAT0004185 0.927 -0.11 -7.34 0.62 hsa-miR-874-3p MIMAT0004911 0.889 -0.17 -11.12 0.45 hsa-miR-874-5p MIMAT0026718 0.927 -0.11 -7.34 0.62hsa-miR-875-3p MIMAT0004923 0.927 -0.11 -7.34 0.62 hsa-miR-876-3p MIMAT0004925 0.927 -0.11 -7.34 0.62 hsa-miR-876-5p MIMAT0004924 0.927 -0.11 -7.34 0.62 hsa-miR-877-5p MIMAT0004949 0.737 -0.44 -26.29 0.55 hsa-miR-885-3p MIMAT0004948 0.927 -0.11 -7.34 0.62 hsa-miR-885-5p MIMAT0004947 0.927 -0.11 -7.34 0.62 hsa-miR-887-3p MIMAT0004951 0.563 -0.83 -43.75 0.10 hsa-miR-887-5p MIMAT0026720 0.927 -0.11 -7.34 0.62 hsa-miR-888-5p MIMAT0004916 0.511 -0.97 -48.95 0.21 hsa-miR-889-3p MIMAT0004921 0.927 -0.11 -7.34 0.62 hsa-miR-890 MIMAT0004912 0.927 -0.11 -7.34 0.62 hsa-miR-891a-5p MIMAT0004902 0.859 -0.22 -14.14 0.33 hsa-miR-891b MIMAT0004913 0.927 -0.11 -7.34 0.62 hsa-miR-892a MIMAT0004907 0.914 -0.13 -8.62 0.76 hsa-miR-892b MIMAT0004918 0.927 -0.11 -7.34 0.62 hsa-miR-9-5p MIMAT0000441 0.927 -0.11 -7.34 0.62 hsa-miR-922 MIMAT0004972 0.859 -0.22 -14.14 0.33 hsa-miR-924 MIMAT0004974 0.927 -0.11 -7.34 0.62 hsa-miR-92a-1-5p MIMAT0004507 0.927 -0.11 -7.34 0.62 hsa-miR-92a-3p MIMAT0000092 0.785 -0.35 -21.54 0.24 hsa-miR-92b-3p MIMAT0003218 0.927 -0.11 -7.34 0.62 hsa-miR-93-5p MIMAT0000093 0.451 -1.15 -54.94 0.44 hsa-miR-933 MIMAT0004976 0.818 -0.29 -18.21 0.33 hsa-miR-934 MIMAT0004977 0.927 -0.11 -7.34 0.62 hsa-miR-935 MIMAT0004978 0.927 -0.11 -7.34 0.62 hsa-miR-936 MIMAT0004979 0.865 -0.21 -13.55 0.36 hsa-miR-937-3p MIMAT0004980 0.927 -0.11 -7.34 0.62 hsa-miR-940 MIMAT0004983 0.927 -0.11 -7.34 0.62 hsa-miR-941 MIMAT0004984 0.927 -0.11 -7.34 0.62 hsa-miR-942-3p MIMAT0026734 0.927 -0.11 -7.34 0.62 hsa-miR-942-5p MIMAT0004985 0.927 -0.11 -7.34 0.62 hsa-miR-944 MIMAT0004987 0.859 -0.22 -14.14 0.33 hsa-miR-95-3p MIMAT0000094 0.293 -1.77 -70.68 0.31 hsa-miR-96-5p MIMAT0000095 0.785 -0.35 -21.54 0.37 hsa-miR-98-3p MIMAT0022842 0.927 -0.11 -7.34 0.62Table 4. miRNAs Significantly Depleted using GNA Resin Side Port Flow. GNA Resin - Side Port Flow miRNA Name Accession # Fold Change Log2 FC Percent Change p-value hsa-let-7a-5p MIMAT0000062 0.025 -5.32 -97.50 2.68E-02 hsa-miR-29b-3p MIMAT0000100 0.047 -4.42 -95.33 5.62E-02 hsa-miR-99a-5p MIMAT0000097 0.075 -3.74 -92.52 2.86E-02 hsa-miR-15b-5p MIMAT0000417 0.092 -3.45 -90.85 7.16E-02 hsa-miR-548aa MIMAT0018447 0.098 -3.35 -90.19 3.80E-02 hsa-miR-100-5p MIMAT0000098 0.136 -2.88 -86.42 8.40E-02 hsa-miR-548ah-5p MIMAT0018972 0.245 -2.03 -75.51 4.44E-03 hsa-miR-98-5p MIMAT0000096 0.255 -1.97 -74.47 5.36E-02 hsa-miR-1268a MIMAT0005922 0.279 -1.84 -72.07 7.22E-02 hsa-miR-1290 MIMAT0005880 0.301 -1.73 -69.85 5.08E-02 hsa-miR-15a-5p MIMAT0000068 0.321 -1.64 -67.91 9.03E-02 hsa-miR-323a-3p MIMAT0000755 0.344 -1.54 -65.61 5.50E-03 hsa-miR-369-3p MIMAT0000721 0.379 -1.4 -62.11 3.90E-02 hsa-miR-193a-5p MIMAT0004614 0.390 -1.36 -61.04 9.22E-02 hsa-miR-126-3p MIMAT0000445 0.392 -1.35 -60.77 7.95E-02 hsa-miR-1972 MIMAT0009447 0.403 -1.31 -59.67 2.95E-03 hsa-miR-4455 MIMAT0018977 0.426 -1.23 -57.37 1.84E-02 hsa-miR-548ar-5p MIMAT0022265 0.426 -1.23 -57.37 1.34E-02 hsa-miR-4286 MIMAT0016916 0.460 -1.12 -53.99 7.07E-02 hsa-let-7e-5p MIMAT0000066 0.480 -1.06 -52.04 4.53E-02 hsa-miR-664a-3p MIMAT0005949 0.500 -1 -50.00 5.89E-02 hsa-miR-190a-5p MIMAT0000458 0.503 -0.99 -49.65 3.96E-02 hsa-miR-2117 MIMAT0011162 0.507 -0.98 -49.30 3.29E-02 hsa-miR-548z MIMAT0018446 0.511 -0.97 -48.95 1.97E-02 hsa-miR-1323 MIMAT0005795 0.514 -0.96 -48.59 4.92E-02 hsa-miR-487a-3p MIMAT0002178 0.532 -0.91 -46.78 3.77E-02 hsa-miR-4443 MIMAT0018961 0.540 -0.89 -46.04 5.50E-02 hsa-let-7f-5p MIMAT0000067 0.543 -0.88 -45.66 9.44E-02hsa-miR-548d-5p MIMAT0004812 0.551 -0.86 -44.90 5.00E-02 hsa-miR-196a-5p MIMAT0000226 0.578 -0.79 -42.17 3.36E-02 hsa-miR-155-5p MIMAT0000646 0.582 -0.78 -41.76 9.93E-02 hsa-miR-136-5p MIMAT0000448 0.586 -0.77 -41.36 3.36E-02 hsa-miR-4421 MIMAT0018934 0.586 -0.77 -41.36 9.25E-02 hsa-miR-532-3p MIMAT0004780 0.611 -0.71 -38.87 9.48E-02 hsa-miR-99b-5p MIMAT0000689 0.633 -0.66 -36.71 8.79E-02 hsa-miR-655-3p MIMAT0003331 0.646 -0.63 -35.38 8.61E-02 hsa-miR-587 MIMAT0003253 0.660 -0.6 -34.02 9.10E-02 hsa-miR-452-5p MIMAT0001635 0.669 -0.58 -33.10 8.73E-02 hsa-miR-548v MIMAT0015020 0.693 -0.53 -30.74 9.24E-02

[0122] To further confirm the depletion of miRNAs using the devices disclosed herein, a quantitative measurement of 4 miRNAs that were depleted in the kidney perfusates was performed using qPCR. For this method, a cel-miR-39 miRNA marker was spiked into 200μl of kidney perfusates during total RNA isolation using the Plasma / Serum RNA purification Mini Kit (Norgen Biotek Corp, Thorold, Canada).2μl of purified RNA was then reverse transcribed using the Taqman Advanced cDNA Synthesis Kit (Thermofisher) to produce cDNA templates. The miRNA targets of interest were amplified by qPCR on a Quant 3 Studio instrument by mixing one 1ul of cDNA template in a 20μl reaction with the Taqman Fast Advanced Master Mix (Thermofisher) and Taqman Advanced miRNA primers. The reaction conditions included an initial denaturation at 95°C for 2min, and then 40 cycles of denaturing at 95°C for 3s and annealing / extension at 60°C for 30s with target amplification data collected on the Quant 3 Studio instrument. The delta C(T) method was used to normalize the relative level of each miRNA target to the level of the cel-miR-39 spike-in used in each sample. Since the quantity of cel-miR-39 miRNA remained constant in each sample, the relative changes in the abundance of other miRNA targets were attributed to a reduction by treatments using the devices as depicted in FIGS.11-12. As shown in FIG.13, all 4 miRNAs (hsa-miR-let7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p, and hsa-miR-99a-5p) showed a depletion after treatment. The average depletion observed for each miRNA target evaluated inthese treatments was as follows: hsa-let-7a-5p (68±9%), hsa-miR-142-3p (70±37%), hsa-miR- 29b-3p (40±18%), and / or hsa-miR-99a-5p (57±29%). Examples 7: Removal of chemokines, cytokines and proteins from kidney perfusate

[0123] This example describes methods of removal of chemokines, cytokines and proteins from a kidney perfusate and can be used in addition to performing examples disclosed herein or individually.

[0124] For this example, discarded kidneys were perfused using normothermic ex vivo machine perfusion. Then 250 milliliters of kidney perfusate was put into a circuit (FIG.11 or FIG.12) containing a full-scale Hemopurifier®, filled with 40 grams of GNA affinity resin. The perfusate was circulated at 200 milliliters per minute for a total of 24 total volume passes. 500 microliters of pre- and post-treated kidney perfusate were then submitted for analysis. Immune protein levels were quantified using bead panels; Human Cytokine / Chemokine 96- Plex Discovery Assay, Human Complement 13-Plex Discovery Assay, and Human Supplemental Biomarker 10-Plex Discovery Assay Chemokine (Eve Technologies, Calgary, Canada) according to the manufacturer’s protocol. The data was loaded into the R statistical environment (v4.3.1). Statistical analysis of experimental data was performed using R programing language (v4.3.2) and the integrated development environment RStudio. R and RStudio were used for data preprocessing, exploratory data analysis, hypothesis testing, and data visualization. A list of chemokines, cytokines and proteins depleted using devices as depicted in FIG.11 or FIG.12 are shown in Tables 5-8. Table 5 shows a list of chemokines, cytokines and proteins depleted using a normal flow device as depicted in FIG. 11. Table 6 shows a list of chemokines, cytokines and proteins depleted using a normal flow device as depicted in FIG.11 with a p <0.1. Table 7 shows a list of chemokines and cytokines depleted using a side port flow device as depicted in FIG. 11. Table 8 shows a list of chemokines, cytokines and proteins depleted using a side port flow device as depicted in FIG. 11 with p <0.1.Table 5. Chemokine and Cytokine Depleted using GNA Resin Normal flow direction. GNA Resin - Normal Flow Protein Gene ID Fold Change Log2 Fold Change Percent Change p-value Complement C2 C2 0.23 -2.12 -77% 1.56E-03 Complement C4b C4B 0.17 -2.59 -83% 1.02E-03 Complement C5 C5 0.73 -0.46 -27% 0.24 Mannose Binding LecƟn LMAN1 0.46 -1.13 -54% 0.18 Complement C1q C1QBP 0.32 -1.63 -68% 1.42E-02 BDNF BDNF 0.52 -0.93 -48% 5.69E-03 Cathepsin D CTSD 0.25 -1.99 -75% 0.17 NCAM NCAM 0.94 -0.09 -6% 0.87 PAI-1 (Total) SERPINE1 0.61 -0.72 -39% 0.50 PDGF-AA PDGFA 0.83 -0.27 -17% 0.37 PDGF-AB / BB PDGFB 0.55 -0.85 -45% 2.19E-03 RANTES CCL5 0.23 -2.13 -77% 2.10E-03 sICAM-1 ICAM1 0.83 -0.27 -17% 0.53 sVCAM-1 VCAM1 0.52 -0.94 -48% 6.55E-02 FGF-2 FGF2 0.55 -0.87 -45% 0.28 Fractalkine CX3CL1 0.13 -2.99 -87% 1.56E-02 GROɲ CXCL1 0.85 -0.23 -15% 0.81 IFNɲ2 IFNA2 0.03 -4.89 -97% 5.95E-02 IL-1RA IL1RN 0.92 -0.12 -8% 0.81 IL-2 IL2 0.22 -2.21 -78% 0.35 IL-3 IL3 0.07 -3.87 -93% 0.35 IL-4 IL4 0.85 -0.23 -15% 0.67 IL-8 CXCL8 0.97 -0.05 -3% 0.96 IL-9 IL9 0.61 -0.72 -39% 1.94E-03 IL-10 IL10 0.96 -0.06 -4% 0.93 IL-12p40 IL12B 0.00 -10.97 -100% 9.52E-02 IL-12p70 IL12 0.75 -0.41 -25% 0.12 IL-13 IL13 0.57 -0.80 -43% 0.38 IL-15 IL15 0.58 -0.79 -42% 6.45E-02 IP-10 CXCL10 0.82 -0.29 -18% 0.80 MCP-1 CCL2 0.71 -0.49 -29% 0.53MCP-3 CCL7 0.38 -1.38 -62% 0.21 MDC CCL22 0.32 -1.64 -68% 0.16 MIP-1ɴ CCL4 0.00 -13.79 -100% 3.66E-07 PDGF-AA PDGFA 0.64 -0.64 -36% 0.42 RANTES CCL5 0.29 -1.80 -71% 3.03E-03 sCD40L CD40LG 0.91 -0.13 -9% 0.91 TNFɲ TNF 0.81 -0.31 -19% 0.60 TNFɴ LTA 0.03 -5.25 -97% 0.14 6CKine CCL21 0.00 -16.87 -100% 1.26E-08 APRIL TNFSF13 0.01 -6.27 -99% 5.72E-03 BCA-1 CXCL13 0.06 -4.03 -94% 2.82E-02 CCL28 CCL28 0.56 -0.83 -44% 0.45 CTACK CCL27 0.00 -11.21 -100% 2.31E-02 CXCL16 CXCL16 0.96 -0.07 -4% 0.80 ENA-78 CXCL5 0.15 -2.78 -85% 1.17E-07 Eotaxin-2 CCL24 0.75 -0.42 -25% 0.72 Eotaxin-3 CCL26 0.00 -12.07 -100% 8.26E-03 GCP-2 TUBGCP2 0.26 -1.93 -74% 1.37E-02 Granzyme A GZMA 0.23 -2.14 -77% 0.16 Granzyme B GZMB 0.39 -1.34 -61% 0.33 HMGB1 HMGB1 0.45 -1.16 -55% 0.29 I-TAC CXCL11 0.61 -0.72 -39% 0.32 IFNɴ IFNB1 0.00 -7.68 -100% 3.15E-02 IFNʘ IFNW1 0.04 -4.76 -96% 0.35 IL-11 IL11 0.00 -7.75 -100% 0.15 IL-16 IL16 0.23 -2.13 -77% 9.66E-04 IL-20 IL20 0.17 -2.58 -83% 6.63E-03 IL-24 IL24 0.35 -1.53 -65% 0.23 IL-31 IL31 0.18 -2.48 -82% 1.45E-03 IL-33 IL33 0.18 -2.51 -82% 4.38E-02 IL-34 IL34 0.35 -1.53 -65% 8.07E-03 IL-35 IL12A 0.60 -0.73 -40% 0.31 LIF LIF 0.52 -0.95 -48% 0.37 MCP-2 CCL8 0.39 -1.37 -61% 8.73E-02 MCP-4 CCL13 0.40 -1.32 -60% 0.11MIP 1ɷ CCL15 0.76 -0.40 -24% 0.12 MIP-3ɲ CCL20 0.11 -3.21 -89% 7.97E-02 MIP-3ɴ CCL19 0.03 -5.18 -97% 2.19E-02 MPIF-1 CCL23 0.65 -0.62 -35% 0.24 Perforin PRF1 0.19 -2.40 -81% 5.06E-02 sCD137 TNFRSF9 0.91 -0.13 -9% 0.72 SDF-1 CXCL12 0.13 -2.91 -87% 5.47E-05 sFas FAS 0.71 -0.50 -29% 0.35 sFasL FASLG 0.96 -0.06 -4% 0.86 TARC CCL17 0.23 -2.15 -77% 7.47E-02 TPO TPO 0.07 -3.90 -93% 1.41E-02 TRAIL TNFSF10 0.99 -0.01 -1% 0.99 Table 6. Chemokine / Cytokines Significantly Depleted using GNA Resin Normal flow direction. GNA Resin - Normal Flow Protein Gene ID Fold Change Log2 Fold Change Percent Change p-value Complement C2 C2 0.23 -2.12 -77% 1.56E-03 Complement C4b C4B 0.17 -2.59 -83% 1.02E-03 Complement C1q C1QBP 0.32 -1.63 -68% 1.42E-02 BDNF BDNF 0.52 -0.93 -48% 5.69E-03 PDGF-AB / BB PDGFB 0.55 -0.85 -45% 2.19E-03 RANTES CCL5 0.23 -2.13 -77% 2.10E-03 sVCAM-1 VCAM1 0.52 -0.94 -48% 6.55E-02 Fractalkine CX3CL1 0.13 -2.99 -87% 1.56E-02 IFNɲ2 IFNA2 0.03 -4.89 -97% 5.95E-02 IL-9 IL9 0.61 -0.72 -39% 1.94E-03 IL-12p40 IL12B 0.00 -10.97 -100% 9.52E-02 IL-15 IL15 0.58 -0.79 -42% 6.45E-02 MIP-1ɴ CCL4 0.00 -13.79 -100% 3.66E-07 RANTES CCL5 0.29 -1.80 -71% 3.03E-03 6CKine CCL21 0.00 -16.87 -100% 1.26E-08 APRIL TNFSF13 0.01 -6.27 -99% 5.72E-03BCA-1 CXCL13 0.06 -4.03 -94% 2.82E-02 CTACK CCL27 0.00 -11.21 -100% 2.31E-02 ENA-78 CXCL5 0.15 -2.78 -85% 1.17E-07 Eotaxin-3 CCL26 0.00 -12.07 -100% 8.26E-03 GCP-2 TUBGCP2 0.26 -1.93 -74% 1.37E-02 IFNɴ IFNB1 0.00 -7.68 -100% 3.15E-02 IL-16 IL16 0.23 -2.13 -77% 9.66E-04 IL-20 IL20 0.17 -2.58 -83% 6.63E-03 IL-31 IL31 0.18 -2.48 -82% 1.45E-03 IL-33 IL33 0.18 -2.51 -82% 4.38E-02 IL-34 IL34 0.35 -1.53 -65% 8.07E-03 MCP-2 CCL8 0.39 -1.37 -61% 8.73E-02 MIP-3ɲ CCL20 0.11 -3.21 -89% 7.97E-02 MIP-3ɴ CCL19 0.03 -5.18 -97% 2.19E-02 Perforin PRF1 0.19 -2.40 -81% 5.06E-02 SDF-1 CXCL12 0.13 -2.91 -87% 5.47E-05 TARC CCL17 0.23 -2.15 -77% 7.47E-02 TPO TPO 0.07 -3.90 -93% 1.41E-02 Table 7. Chemokine / Cytokines Depleted using GNA Resin Side Port Flow Direction GNA Resin - Side Port Flow Protein Gene ID Fold Change Log2 Fold Change Percent Change p-value Complement C2 C2 0.41 -1.29 -59% 4.26E-02 Complement C4b C4B 0.11 -3.18 -89% 2.68E-06 Complement C5 C5 0.70 -0.51 -30% 0.23 Mannose Binding LecƟn LMAN1 0.43 -1.22 -57% 0.16 Complement C1q C1QBP 0.20 -2.30 -80% 8.95E-04 Complement C4 C4A 0.93 -0.10 -7% 0.49 BDNF BDNF 0.47 -1.10 -53% 4.50E-03 Cathepsin D CTSD 0.26 -1.92 -74% 0.18 Myeloperoxidase (MPO) MPO 0.97 -0.05 -3% 0.94 NCAM NCAM 0.99 -0.01 -1% 0.98PAI-1 (Total) SERPINE1 0.61 -0.72 -39% 0.49 PDGF-AA PDGFA 0.76 -0.39 -24% 0.19 PDGF-AB / BB PDGFB 0.44 -1.20 -56% 2.86E-04 RANTES CCL5 0.27 -1.90 -73% 2.84E-03 sICAM-1 ICAM1 0.84 -0.26 -16% 0.56 sVCAM-1 VCAM1 0.53 -0.93 -47% 5.42E-02 Eotaxin CCL11 0.93 -0.11 -7% 0.59 FGF-2 FGF2 0.49 -1.02 -51% 0.21 Fractalkine CX3CL1 0.13 -2.89 -87% 1.47E-02 GROɲ CXCL1 0.78 -0.35 -22% 0.71 IFNɲ2 IFNA2 0.00 -9.08 -100% 5.33E-02 IFNɶ IFNG 0.06 -3.97 -94% 0.17 IL-1ɲ IL1A 0.82 -0.29 -18% 0.59 IL-1RA IL1RN 0.75 -0.41 -25% 0.36 IL-2 IL2 0.22 -2.21 -78% 0.35 IL-3 IL3 0.07 -3.87 -93% 0.35 IL-4 IL4 0.71 -0.48 -29% 0.43 IL-6 IL6 0.99 -0.01 -1% 0.99 IL-8 CXCL8 0.94 -0.09 -6% 0.93 IL-9 IL9 0.53 -0.92 -47% 1.80E-02 IL-10 IL10 0.98 -0.03 -2% 0.96 IL-12p40 IL12B 0.95 -0.07 -5% 0.96 IL-13 IL13 0.36 -1.46 -64% 0.21 IL-15 IL15 0.62 -0.69 -38% 0.14 IP-10 CXCL10 0.64 -0.64 -36% 0.56 MCP-1 CCL2 0.68 -0.56 -32% 0.46 MCP-3 CCL7 0.00 -11.01 -100% 1.27E-03 MDC CCL22 0.27 -1.88 -73% 0.12 MIP-1ɴ CCL4 0.00 -13.79 -100% 3.66E-07 PDGF-AA PDGFA 0.54 -0.89 -46% 0.30 RANTES CCL5 0.30 -1.76 -70% 2.91E-03 sCD40L CD40LG 0.98 -0.04 -2% 0.98 TNFɲ TNF 0.78 -0.36 -22% 0.53 TNFɴ LTA 0.03 -5.25 -97% 0.14 6CKine CCL21 0.11 -3.18 -89% 2.35E-03APRIL TNFSF13 0.01 -6.56 -99% 5.65E-03 BAFF TNFSF13B 1.00 -0.01 0% 0.99 BCA-1 CXCL13 0.07 -3.84 -93% 2.92E-02 CCL28 CCL28 0.19 -2.39 -81% 6.96E-02 CTACK CCL27 0.00 -11.21 -100% 2.31E-02 ENA-78 CXCL5 0.16 -2.66 -84% 5.17E-07 Eotaxin-2 CCL24 0.70 -0.51 -30% 0.68 Eotaxin-3 CCL26 0.00 -12.07 -100% 8.26E-03 GCP-2 TUBGCP2 0.25 -2.00 -75% 1.09E-02 Granzyme A GZMA 0.26 -1.96 -74% 0.18 Granzyme B GZMB 0.36 -1.47 -64% 0.30 HMGB1 HMGB1 0.31 -1.69 -69% 0.15 I-309 CCL1 0.60 -0.74 -40% 0.16 I-TAC CXCL11 0.40 -1.33 -60% 0.11 IFNɴ IFNB1 0.00 -7.68 -100% 3.15E-02 IFNʘ IFNW1 0.04 -4.76 -96% 0.35 IL-11 IL11 0.14 -2.87 -86% 0.21 IL-16 IL16 0.30 -1.75 -70% 1.86E-03 IL-20 IL20 0.22 -2.18 -78% 9.46E-03 IL-24 IL24 0.20 -2.30 -80% 8.71E-02 IL-31 IL31 0.08 -3.69 -92% 6.64E-04 IL-33 IL33 0.19 -2.39 -81% 4.71E-02 IL-34 IL34 0.39 -1.34 -61% 9.45E-02 IL-35 IL12A 0.56 -0.84 -44% 0.27 LIF LIF 0.45 -1.14 -55% 0.31 MCP-2 CCL8 0.37 -1.43 -63% 5.95E-02 MCP-4 CCL13 0.35 -1.52 -65% 6.76E-02 MIP 1ɷ CCL15 0.74 -0.43 -26% 0.10 MIP-3ɲ CCL20 0.09 -3.47 -91% 7.37E-02 MIP-3ɴ CCL19 0.02 -5.57 -98% 2.13E-02 MPIF-1 CCL23 0.66 -0.59 -34% 0.27 Perforin PRF1 0.17 -2.54 -83% 4.57E-02 sCD137 TNFRSF9 0.97 -0.05 -3% 0.90 SDF-1 CXCL12 0.14 -2.79 -86% 9.57E-05 sFas FAS 0.68 -0.55 -32% 0.27sFasL FASLG 0.92 -0.11 -8% 0.76 TARC CCL17 0.20 -2.34 -80% 6.46E-02 TPO TPO 0.11 -3.14 -89% 1.76E-02 TRAIL TNFSF10 0.95 -0.08 -5% 0.90 Table 8. Chemokine / Cytokines Significantly Depleted using GNA Resin Side Port Flow Direction. GNA Resin - Side Port Flow Protein Gene ID Fold Change Log2 Fold Change Percent Change p-value Complement C2 C2 0.41 -1.29 -59% 4.26E-02 Complement C4b C4B 0.11 -3.18 -89% 2.68E-06 Complement C1q C1QBP 0.20 -2.30 -80% 8.95E-04 BDNF BDNF 0.47 -1.10 -53% 4.50E-03 PDGF-AB / BB PDGFB 0.44 -1.20 -56% 2.86E-04 RANTES CCL5 0.27 -1.90 -73% 2.84E-03 sVCAM-1 VCAM1 0.53 -0.93 -47% 5.42E-02 Fractalkine CX3CL1 0.13 -2.89 -87% 1.47E-02 IFNɲ2 IFNA2 0.00 -9.08 -100% 5.33E-02 IL-9 IL9 0.53 -0.92 -47% 1.80E-02 MCP-3 CCL7 0.00 -11.01 -100% 1.27E-03 MIP-1ɴ CCL4 0.00 -13.79 -100% 3.66E-07 RANTES CCL5 0.30 -1.76 -70% 2.91E-03 6CKine CCL21 0.11 -3.18 -89% 2.35E-03 APRIL TNFSF13 0.01 -6.56 -99% 5.65E-03 BCA-1 CXCL13 0.07 -3.84 -93% 2.92E-02 CCL28 CCL28 0.19 -2.39 -81% 6.96E-02 CTACK CCL27 0.00 -11.21 -100% 2.31E-02 ENA-78 CXCL5 0.16 -2.66 -84% 5.17E-07 Eotaxin-3 CCL26 0.00 -12.07 -100% 8.26E-03 GCP-2 TUBGCP2 0.25 -2.00 -75% 1.09E-02 IFNɴ IFNB1 0.00 -7.68 -100% 3.15E-02 IL-16 IL16 0.30 -1.75 -70% 1.86E-03IL-20 IL20 0.22 -2.18 -78% 9.46E-03 IL-24 IL24 0.20 -2.30 -80% 8.71E-02 IL-31 IL31 0.08 -3.69 -92% 6.64E-04 IL-33 IL33 0.19 -2.39 -81% 4.71E-02 IL-34 IL34 0.39 -1.34 -61% 9.45E-02 MCP-2 CCL8 0.37 -1.43 -63% 5.95E-02 MCP-4 CCL13 0.35 -1.52 -65% 6.76E-02 MIP-3ɲ CCL20 0.09 -3.47 -91% 7.37E-02 MIP-3ɴ CCL19 0.02 -5.57 -98% 2.13E-02 Perforin PRF1 0.17 -2.54 -83% 4.57E-02 SDF-1 CXCL12 0.14 -2.79 -86% 9.57E-05 TARC CCL17 0.20 -2.34 -80% 6.46E-02 TPO TPO 0.11 -3.14 -89% 1.76E-02 Examples 8: Analysis of DNA from kidney perfusate after treatment with exemplary devices disclosed herein

[0125] This example describes methods for analysis of DNA from a kidney perfusate and can be used in addition to performing examples disclosed herein or individually.

[0126] To analyze the DNA content of the kidney perfusates after treatment with the exemplary devices, quantitative measurement of nucleic DNA marker (RNAseP) and mitochondrial DNA marker (7s) in the kidney perfusates was performed using qPCR. For this method, DNA was purified from the control and kidney perfusate solutions passed for 24 times through the device as depicted in FIG. 10 using the QIAamp DNA Blood mini kit (Qiagen) according to the instructions provided by the manufacturer. In brief, 200ul of kidney perfusate solution or control was lysed, heated at 56°C for 10min, loaded onto a spin column, washed, and then and eluted into 50ul of the kit’s AE elution buffer. DNA purity and concentrations were assessed using the Nanodrop A260. The DNA isolated from the control and kidney perfusate solutions was analyzed using the Quant Studio 3 instrument to evaluate differences in the levels of several markers of interest between perfusates and after HP treatments. A multiplex assay was used to simultaneously amplify both nucleic and mitochondrial DNA in each sample with the Taqman Fast Advanced Master Mix (Thermofisher). Nucleic DNA was amplified using the RNAseP Taqman primers (Thermofisher) while mitochondrial DNA wasamplified with the Taqman human 7s primers (Thermofisher). qPCR was conducted in a 20μl total volume containing 2ul of the purified perfusate DNA as a template and the following conditions: initial denaturation at 95°C for 2min, and then 40 cycles of denaturing at 95°C for 3s and annealing / extension at 60°C for 30s. The delta C(T) method was used to quantify relative changes in the content of nucleic...

Claims

WHAT IS CLAIMED IS:

1. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject, wherein said subject is an organ, cell, or tissue donor, the method comprising: a) introducing a sample from said subject prior to removal of an organ, population of cells, or tissue into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody preferably, the support in the vessel, such as in an extracorporeal device; c) reintroducing the sample obtained after b) into said subject, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicles associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, cell, or tissue transplantation, which removes the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associatedDNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood or plasma, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof.

2. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in a subject, wherein said subject is an organ, cell, or tissue transplant recipient, the method comprising: a) introducing a sample from said subject prior to or after organ, cell, or tissue transplantation into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such asGalanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody and, preferably, the support in the vessel, such as in an extracorporeal device; c) reintroducing the sample obtained after b) into said subject, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample of said subject prior to b); and d) optionally, selecting said subject for receiving an extracorporeal therapy accompanying organ, cell, or tissue transplantation, which viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said subject, such as blood or plasma, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / orf) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said subject prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof.

3. A method for removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, population of cells, or tissue, the method comprising: a) introducing a sample from said organ, organ perfusate, population of cells, or tissue, preferably, a perfused organ or organ perfusate, isolated from a donor, preferably a deceased donor e.g., a donation after circulatory death (DCD) or a donation after brain death (DBD), into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support; b) contacting the sample with the support, lectin and / or antibody and, preferably, the support in the vessel, such as in an extracorporeal device; c) reintroducing the sample obtained after b) into said organ, population of cells, or tissue, wherein the sample obtained after b) has a reduced amount of the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the sample prior to b); andd) optionally, selecting said organ, organ perfusate, population of cells, or tissue for receiving an extracorporeal therapy, which removes the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof prior to (a) and / or e) optionally, screening for the presence of, e.g., detecting or identifying, the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, in a sample from said organ, such as blood, plasma or organ perfusion fluid, prior to (a) or after (b) or both accompanying organ, cell, or tissue transplantation; and / or f) optionally, analyzing the glycan profile of extracellular vesicles, such as exosomes, ectosomes, or fragments thereof, from a sample from said organ or organ perfusate, prior to a) or after b) or both e.g., determining the ability of said extracellular vesicles, such as exosomes, ectosomes, or fragments thereof to bind to said lectin, such as GNA, or said antibody or said support or any combination thereof.

4. A method of organ, cell, or tissue transplantation comprising performing the method of any one of claims 1-3 accompanying an organ, cell, or tissue transplantation procedure, preferably wherein organ, cell, or tissue viability, such as tissue functionality including, e.g., production of urine when the organ is a kidney, engraftment, and / or survival of the transplant and / or recipient is increased or improved as compared to the organ, cell, or tissue viability, engraftment, and / or survival of the transplant or recipient after transplantation in theabsence of the methods of any one of claims 1-3 or, wherein the presence of molecules or compositions from the organ perfusate and / or organ, which are associated with tissue rejection, organ failure, necrosis, or poor patient outcome after transplantation, are reduced as compared to the organ perfusate and / or organ prior to performing the method of any one of claims 1-3.

5. The method of any one of claims 1-4, further comprising repeating steps b) and c) to further reduce the amount of the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof in the sample.

6. The method of any one of claims 1-5, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma- associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV-D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof.

7. The method of any one of claims 1-6, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof.

8. The method of any one of claims 1-7, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M.genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum.

9. The method of any of claims 1-8, wherein the miRNAs comprise miR23a, miR 374b-5p, miR28-5p and / or miR24-3p.

10. The method of any one of claims 1-9, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed.

11. The method of any one of claims 1-10, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR-29b-3p, hsa- miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa-miR- 106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR-122- 5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa- miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa-miR- 1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR-126-3p, hsa- miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa- miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa-miR- 24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa-miR- 1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR-191-5p, hsa- miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b-3p, hsa- miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR- 199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR- 200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205-5p, hsa-miR- 20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa-miR-335- 5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa- miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa-miR- 29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195, hsa- miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa- miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa-miR- 363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa-miR- 376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa- miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa-miR- 190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa- miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR- 486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa- miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p.

12. The method of any one of claims 1-11, wherein the miRNAs comprise any one or more of : hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR- 548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR- 196a-5p.

13. The method of any one of claims 1-12, wherein the miRNAs comprise any one or more of hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p.

14. The method of any one of claims 1-13, wherein the biomarker or mediator for tissue damage comprise Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA,PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL- 11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL.

15. The method of any one of claims 1-14, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO.

16. The method of any one of claims 1-15, wherein the biomarker or mediator of tissue damage comprises any one or more of BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1.

17. The method of any one of claims 1 -16, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, cell, or tissue donor before the organ, cell, or tissue is harvested from the donor.

18. The method of any one of claims 1 -17, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, abiomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, organ perfusate, population of cells, or tissue after the organ, population of cells, or tissue is harvested from the donor and before the organ, population of cells, or tissue is transplanted into the recipient.

19. The method of any one of claims 1-18, wherein the pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed from the organ, organ perfusate, population of cells, or tissue after the organ, population of cells, or tissue is harvested from the donor and prior to transplantation into the recipient.

20. The method of any one of claims 1-19, wherein the organ is a solid organ or the organ perfusate is from a solid organ.

21. The method of claim 20, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas.

22. The method of any one of claims 1-21, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells.

23. The method of any one of claims 1-22, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.

24. The method of any one of claims 1-23, wherein the sample is selected from peripheral blood, serum, plasma, organ perfusion fluid or organ perfusate, such as near normothermic organ perfusion fluid or near normothermic organ perfusate or hypothermic organ perfusion fluid or hypothermic organ perfusate, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, Cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, umbilical cord blood, ascites fluid, cell culture, such as CAR T cell culture, stem cell culture, or pancreatic islet culture.

25. The method of claim 24, wherein the biological sample is mammalian, such as human or porcine.

26. The method of claim 25, wherein the biological sample is human.

27. The method of any one of claims 1-26, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon.

28. The method of any one of claims 1-27, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker.

29. Use of a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support to improve, enhance, or increase organ, cell, or tissue viability, engraftment, and / or survival of a transplant or to remove viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteinsand / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue ex vivo, as compared to organ, cell, or tissue viability, engraftment, and / or survival of the transplant or the organ perfusate in the absence of said lectin and / or antibody affinity isolation or capture.

30. The use of claim 29, wherein said organ is a solid organ, preferably selected from kidney, liver, intestines, heart, lung, or pancreas or, wherein the cell population is selected from chimeric antigen receptor T cells (CAR T cells), bone marrow cells, stem cells, or pancreatic islet cells.

31. A device for use in removing a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue ex vivo, wherein said device comprises a support, such as diatomaceous earth or an ion exchange resin, and optionally a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support.

32. The device for use as set forth in claim 31, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV- D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneousretroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof.

33. The device for use as set forth in claim 31 or 32, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof.

34. The device for use as set forth in any one of claims 31-33, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum.

35. The device for use as set forth in any one of claims 31-34, wherein the miRNA comprises any one or more of: hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b- 5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR-196a-5p.

36. The device for use as set forth in any one of claims 31-35, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa- miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR- 106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR- 1183, hsa-miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa- miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR- 15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR- 140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144- 3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa- miR-361-5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa- miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR- 190b, hsa-miR-191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b- 3p, hsa-miR-193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p,hsa-miR-1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa- miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa- miR-205-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR- 146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223- 3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa- miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR- 302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa- miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa- miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR- 362-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR- 376a-3p, hsa-miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa- miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR- 425-5p, hsa-miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa- miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483- 5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa- miR-496, hsa-let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509- 3p, hsa-miR-509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a- 5p, hsa-miR-514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa- miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR- 23a-3p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa- miR-590-5p, hsa-miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888-5p, hsa-miR-93-5p and / or hsa-miR-95-3p.

37. The device for use as set forth in any one of claims 31-36, wherein the miRNAs comprise any one or more of: hsa-miR1285-5p, hsa-miR-575, hsa-miR-223-3p, hsa-miR-127- 3p, hsa-miR-29b-3p, hsa-miR-3144-3p, hsa-miR-28-5p and / or hsa-miR-1286.

38. The device for use as set forth in any one of claims 31-37, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa- miR-99a-5p .

39. The device for use as set forth in any one of claims 31-38, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2 ,Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL- 34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF- 1, sFas, sFasL, TARC, TPO, and / or TRAIL.

40. The device for use as set forth in any one of claims 31-39, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO.

41. The device for use as set forth in any one of claims 31-40, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1..

42. The device for use as set forth in any one of claims 31-41, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are removed.

43. The device for use as set forth in any one of claims 31-42, wherein the organ is a solid organ or the organ perfusate is from a solid organ.

44. The device for use as set forth in claim 43, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas.

45. The device for use as set forth in any one of claims 31-44, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells.

46. The device for use as set forth in any one of claims 31-45, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.

47. The device for use as set forth in any one of claims 31-46, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon.

48. The device for use as set forth in any one of claims 31-47, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker.

49. A device comprising a support, such as diatomaceous earth or an ion exchange resin, and optionally a lectin, such as Galanthus nivalis lectin (GNA), or an antibody, preferably, wherein the lectin or antibody or both are immobilized on the support, wherein the support, lectin and / or antibody is joined to a pathogen, viral particles, virus-like particles(VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof from an organ, organ perfusate, cell population, or tissue 50. The device as set forth in claim 49, wherein the viral particles or fragments thereof are from Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis B (HBV), Hepatitis D virus (HDV); herpes family viruses such as HTLV-1, HSV1 / 2, varicella zoster virus (VZV), Human herpesvirus (HHV)-6, HHV-7, HHV-8, EBV, Kaposi's sarcoma- associated herpesvirus (KSHV), cytomegalovirus (CMV); Human papilloma virus (HPV), picornaviruses including coronaviruses such as SARS-CoV2, SARS-CoV2 Spike protein and variants thereof, SARS, MERS, OC43, 229E, NL63, HKU1 porcine epidemic diarrhea virus (PEDV), Transmissible gastroenteritis virus (TGEV), enteroviruses, such as EV-D68, A71, Coxsackie A / B, echoviruses, polioviruses; rhinoviruses, noroviruses, porcine cytomegalovirus (pCMV), porcine reseolovirus, porcine Retroviruses, porcine endogeneous retroviruses (PERVs) A, B, C, porcine lymphotrophic herpesviruses (pLHV), or porcine circovirus or any combination thereof.

51. The device as set forth in claim 49 or 50, wherein the lectin binds to a viral coat or envelope protein or a fragment thereof.

52. The device as set forth in any one of claims 49-51, wherein the pathogen is Mycoplasma or Ureaplasma, such as M. amphoriforme, M. buccale, M. faucium, M. fermentans, M. genitalium, M. hominis, M. incognitus, M. lipophilum, M. orale, M. penetrans, M. pirum, M. pneumoniae, M. primatum, M. salivarium, M. spermatophilum, or Ureaplasma urealyticum.

53. The device as set forth in any one of claims 49-52, wherein the miRNA comprises any one or more of: hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR-196a-5p.

54. The device as set forth in any one of claims 49-53, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa- miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR- 106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR- 1183, hsa-miR-122-5p, hsa-miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR-548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa- miR-1285-5p, hsa-miR-1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR- 15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR- 140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144- 3p, hsa-miR-126-3p, hsa-miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa- miR-361-5p, hsa-miR-24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa- miR-181c-5p, hsa-miR-1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR- 190b, hsa-miR-191-5p, hsa-miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b- 3p, hsa-miR-193b-3p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa- miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa- miR-205-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR- 146a-5p, hsa-miR-335-5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223- 3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa- miR-299-3p, hsa-miR-29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR- 302b-3p, hsa-miR-30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa- miR-3195, hsa-miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa- miR-340-5p, hsa-miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR- 362-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa-miR-376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa- miR-379-5p, hsa-miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR- 425-5p, hsa-miR-190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa- miR-4516, hsa-miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483- 5p, hsa-miR-486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa- miR-496, hsa-let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509- 3p, hsa-miR-509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a- 5p, hsa-miR-514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa- miR-548m, hsa-miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR- 23a-3p, hsa-miR-574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa- miR-590-5p, hsa-miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630, hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888-5p, hsa-miR-93-5p and / or hsa-miR-95-3p.

55. The device as set forth in any one of claims 49-54, wherein the miRNAs comprise any one or more of: hsa-miR1285-5p, hsa-miR-575, hsa-miR-223-3p, hsa-miR-127- 3p, hsa-miR-29b-3p, hsa-miR-3144-3p, hsa-miR-28-5p and / or hsa-miR-1286.

56. The device as set forth in any one of claims 49-55, wherein the miRNAs comprise any one or more of hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR- 99a-5p.

57. The device as set forth in any one of claims 49-56, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2 ,Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL- 15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF,MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL.

58. The device as set forth in any one of claims 49-57, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL-34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO.

59. The device as set forth in any one of claims 49-58, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1, NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1.

60. The device as set forth in any one of claims 49-59, wherein inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are joined to the support, lectin and / or antibody.

61. The device as set forth in any one of claims 49-60, wherein the organ is a solid organ or the organ perfusate is from a solid organ.

62. The device as set forth in claim 61, wherein the solid organ is selected from kidney, liver, intestines, heart, lung, or pancreas.

63. The device as set forth in any one of claims 49-62, wherein the population of cells are chimeric antigen receptor T cells (CAR T cells), immune cells, bone marrow cells, stem cells, or pancreatic islet cells.

64. The device as set forth in any one of claims 49-63, wherein the lectin immobilized on the support is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.

65. The device as set forth in any one of claims 49-64, wherein the support comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon.

66. The device as set forth in any one of claims 49-65, wherein the vessel is a plate, such as a multi-well plate, a column, a cartridge, a tube, a flask, or a beaker.

67. A method of preparing a kidney, which has been removed from a donor, for transplantation, preferably a kidney obtained from a deceased donor e.g., a donation after circulatory death (DCD) or a donation after brain death (DBD) , the method comprising: a) collecting a biological sample from the kidney; b) detecting the presence or amount of at least one or more pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof; c) comparing the detected one or more pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteinsand / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof to a reference level; and d) upon determining that the detected one or more pathogens, viral particles, virus- like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof are present or altered in the sample as compared to the reference level, providing a therapy to the kidney, wherein the therapy comprises: i. introducing perfusate from the kidney into a vessel, such as an extracorporeal device, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody preferably, wherein the lectin or antibody or both are immobilized on the support; ii. contacting the perfusate with the support, lectin and / or antibody in the vessel; and iii. reintroducing the perfusate obtained after ii) into the kidney, wherein the perfusate obtained after ii) has a reduced amount of pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator for tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof, as compared to the perfusate prior to ii).

68. The method of claim 67, wherein the presence or amount of at least one or more of the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids,such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof is detected using Western blot, enzyme-linked immunosorbent assay (ELISA), Northern blotting, quantitative polymerase chain reaction (qPCR) protein microarray, DNA microarray, gene expression analysis or RNA- seq.

69. A method of any one of claims 67-68, wherein kidney viability, engraftment, and / or survival of the transplant and / or recipient is increased or improved as compared to the kidney viability, engraftment, and / or survival of the transplant or recipient after transplantation in the absence of the methods of any one of claims 67-68.

70. The method of any one of claims 67-69, further comprising repeating steps (i)- (iii) to further reduce the amount of amount of the pathogens, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans, or fragments thereof.

71. The method of any one of claims 67-70, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-miR-29b-3p, hsa-miR- 99a-5p, hsa-miR-15b-5p, hsa-miR-1-3p, hsa-miR-548aa, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1180-3p, hsa-miR-1183, hsa-miR-122-5p, hsa- miR-1246, hsa-miR-1253, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-100-5p, hsa-miR- 548ah-5p, hsa-miR-98-5p, hsa-miR-4454, hsa-miR-128-3p, hsa-miR-1285-5p, hsa-miR- 1268a, hsa-miR-1299, hsa-miR-1306-5p, hsa-miR-1290, hsa-miR-15a-5p, hsa-miR-132-3p, hsa-miR-323a-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-140-3p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-193a-5p, hsa-miR-143-3p, hsa-miR-144-3p, hsa-miR-126-3p, hsa- miR-199b-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-150-5p, hsa-miR-151a-3p, hsa-miR-152-3p, hsa-miR-1537-3p, hsa-miR-154-5p, hsa-miR-1972, hsa-miR-361-5p, hsa-miR- 24-3p, hsa-miR-16-5p, hsa-miR-181a-2-3p, hsa-miR-181a-5p, hsa-miR-181c-5p, hsa-miR- 1827, hsa-miR-186-5p, hsa-miR-187-3p, hsa-miR-4455, hsa-miR-190b, hsa-miR-191-5p, hsa- miR-1910-5p, hsa-miR-1915-3p, hsa-miR-193a-3p, hsa-miR-23b-3p, hsa-miR-193b-3p, hsa- miR-194-5p, hsa-miR-195-5p, hsa-miR-505-3p, hsa-miR-574-3p, hsa-miR-1976, hsa-miR- 199a-3p, hsa-miR-199a-5p, hsa-miR-30e-3p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR- 200a-3p, hsa-miR-200b-3p, hsa-miR-203a-5p, hsa-miR-204-5p, hsa-miR-205-5p, hsa-miR- 20a-5p, hsa-miR-21-5p, hsa-miR-548ar-5p, hsa-miR-214-3p, hsa-miR-146a-5p, hsa-miR-335- 5p, hsa-miR-22-3p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR-660-5p, hsa-miR-377-3p, hsa-miR-145-5p, hsa-miR-218-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa- miR-27a-3p, hsa-miR-27b-3p, hsa-miR-28-3p, hsa-miR-28-5p, hsa-miR-299-3p, hsa-miR- 29a-3p, hsa-miR-495-3p, hsa-miR-29c-3p, hsa-miR-301a-3p, hsa-miR-302b-3p, hsa-miR- 30a-3p, hsa-let-7g-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-127-3p, hsa-miR-4286, hsa-miR-30e-5p, hsa-miR-3158-3p, hsa-miR-3168, hsa-miR-3180-5p, hsa-miR-3195, hsa- miR-32-5p, hsa-miR-320a, hsa-miR-320e, hsa-let-7e-5p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-148a-3p, hsa-miR-337-3p, hsa-miR-337-5p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa- miR-342-3p, hsa-miR-34a-5p, hsa-miR-361-3p, hsa-miR-497-5p, hsa-miR-362-3p, hsa-miR- 363-3p, hsa-miR-365a-3p, hsa-miR-664a-3p, hsa-miR-374a-5p, hsa-miR-376a-3p, hsa-miR- 376c-3p, hsa-miR-378d, hsa-miR-378f, hsa-miR-378g, hsa-miR-378i, hsa-miR-379-5p, hsa- miR-382-5p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-130a-3p, hsa-miR-425-5p, hsa-miR- 190a-5p, hsa-miR-2117, hsa-miR-548z, hsa-miR-25-3p, hsa-miR-1323, hsa-miR-4516, hsa- miR-451a, hsa-miR-487a-3p, hsa-miR-4532, hsa-miR-455-5p, hsa-miR-483-5p, hsa-miR- 486-3p, hsa-miR-4443, hsa-miR-487b-3p, hsa-miR-491-5p, hsa-miR-543, hsa-miR-496, hsa- let-7f-5p, hsa-miR-499a-5p, hsa-miR-503-5p, hsa-miR-148b-3p, hsa-miR-509-3p, hsa-miR- 509-5p, hsa-miR-513b-5p, hsa-miR-513c-5p, hsa-miR-514a-3p, hsa-miR-514a-5p, hsa-miR- 514b-5p, hsa-miR-518b, hsa-miR-5196-3p, hsa-miR-526a, hsa-miR-548d-5p, hsa-miR-30a- 5p, hsa-miR-30d-5p, hsa-miR-196a-5p, hsa-miR-136-5p, hsa-miR-4421, hsa-miR-548m, hsa- miR-548n, hsa-miR-99b-5p, hsa-miR-551b-3p, hsa-miR-556-3p, hsa-miR-23a-3p, hsa-miR- 574-5p, hsa-miR-575, hsa-miR-578, hsa-miR-584-3p, hsa-miR-655-3p, hsa-miR-590-5p, hsa- miR-593-3p, hsa-miR-597-5p, hsa-miR-601, hsa-miR-607, hsa-miR-616-3p, hsa-miR-630,hsa-miR-663a, hsa-miR-7-5p, hsa-miR-764, hsa-miR-769-5p, hsa-miR-887-3p, hsa-miR-888- 5p, hsa-miR-93-5p and / or hsa-miR-95-3p.

72. The method of any one of claims 67-71, wherein the miRNAs comprise any one or more of; hsa-let-7a-5p, hsa-miR-29b-3p, hsa-miR-99a-5p, hsa-miR-15b-5p, hsa-miR-548aa, hsa-miR-15a-5p, hsa-miR-193a-5p, hsa-miR-126-3p, hsa-miR-1972 and / or hsa-miR-196a-5p.

73. The method of any one of claims 67-72, wherein the miRNAs comprise any one or more of: hsa-let-7a-5p, hsa-miR-142-3p, hsa-miR-29b-3p and / or hsa-miR-99a-5p.

74. The method of any one of claims 67-73, wherein the biomarker or mediator of tissue damage comprise any one or more of: Complement C2, Complement C4b, Complement C5, Mannose Binding Lectin, Complement C1q, BDNF, Cathepsin D, NCAM, PAI-1 (Total), PDGF-AA, PDGF-AB / BB, RANTES, sICAM-1, sVCAM-1, FGF-2, Fractalkine, GROĮ, IFNĮ2, IL-1RA, IL-2, IL-3, IL-4, IL-8, IL-9, IL-10, IL-12p40, IL-13, IL-15, IP-10, MCP-1, MCP-3, MDC, MIP-1ȕ, sCD40L, TNFĮ, TNFȕ, 6CKine, APRIL, BCA-1, CCL28, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, GCP-2, Granzyme A, Granzyme B, HMGB1, I-TAC, IFNȕ, IFN^,IL-11, IL-16, IL-20 ,IL-24, IL-31, IL-33, IL-34, IL-35, LIF, MCP-2, MCP-4, MIP 1į, MIP-3Į, MIP-3ȕ, MPIF-1, Perforin, sCD137, SDF-1, sFas, sFasL, TARC, TPO and / or TRAIL.

75. The method of any one of claims 67-74, wherein the biomarker or mediator of tissue damage comprises any one or more of: Complement C2, Complement C4b, Complement C1q, BDNF, PDGF-AB / BB, RANTES, sVCAM-1, Fractalkine, IFNĮ2, IL-9, MIP-1ȕ, 6CKine, APRIL, BCA-1, CTACK, ENA-78, Eotaxin-3, GCP-2, IFNȕ, IL-16, IL-20, IL-31, IL-33, IL- 34, MCP-2, MIP-3Į, MIP-3ȕ, Perforin, SDF-1, TARC and / or TPO.

76. The method of any one of claims 67-75, wherein the biomarker or mediator of tissue damage comprises any one or more of: BDNF, C1QBP, C2, C4B, C5, CCL13, CCL15, CCL17, CCL19, CCL20, CCL22, CCL23, CCL26, CCL27, CCL3,CCL4, CCL5-2, CCL5, CCL8, CTSD, CX3CL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL5, FASLG, FGF2, GZMA, GZMB, HMGB1, ICAM1, IFNA2, IL16, IL1RN, IL20, IL33, IL34, IL9, LMAN1,NCAM, PDGFA, PDGFB, PRF1, SERPINE1, TNFRSF9, TNFSF13, TNFSF13B, TPO, TUBGCP2 and / or VCAM1.

77. The method of any one of claims 67-76, wherein the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.

78. The method of any one of claims 67-77, wherein the kidney is mammalian, such as human or porcine.

79. The method of claim 78, wherein the kidney is human.

80. The method of any one of claims 67-79, wherein the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon.

81. The method of any one of claims 67-80, wherein the vessel is a plate, such as a multi-well plate, a column, tube, flask, or beaker.

82. A method for connecting an organ to a circuit, configured to remove a pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans from said organ comprising: attaching the organ, such as a kidney, liver, intestines, heart, lung, or pancreas to a vessel, such as an extracorporeal column, comprising a support, such as diatomaceous earth or an ion exchange resin, a lectin, such as Galanthus nivalis lectin (GNA), and / or an antibody preferably, wherein the lectin or antibody or both are immobilized on the support, such thatwhen the organ is perfused with a perfusion solution, the perfusion solution exits the organ and is passed into the vessel comprising the support and when the perfusion solution exits the vessel comprising the support it is, optionally passed back through the organ, and preferably has a reduced amount of pathogen, viral particles, virus-like particles (VLPs), extracellular vesicles, such as exosomes or ectosomes, miRNAs, a biomarker or mediator of tissue damage, nucleic acids, such as DNA or RNA, circulating extracellular DNA (ceDNA), extracellular vesicle associated DNA, Neutrophil extracellular traps (NETs) and their components including DNA, histones, neutrophil granule proteins and / or oxidant enzymes, inflammatory or immunomodulatory glycoproteins, glycolipids or lipoglycans than the perfusion solution had after exiting the organ prior to entering the vessel comprising the support.

83. The method of claim 82, wherein the lectin is selected from the group consisting of Galanthus nivalis lectin (GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL), and concanavalin A.

84. The method of any one of claims 82 or 83, wherein the organ is a kidney and the kidney is mammalian, such as human or porcine.

85. The method of claim 84, wherein the kidney is human.

86. The method of any one of claims 82-85, wherein the lectin is immobilized on a support that comprises a material selected from the group consisting of Sepharose, agarose, latex, glass, thermoplastic polymers, polystyrene, polyethylene beads, polyvinyl, diatomaceous earth, nitrocellulose and silicon.

87. The method of any one of claims 82-86, wherein the vessel is a plate, such as a multi-well plate, a column, tube, flask, or beaker.

Images